Secondary Logo

Journal Logo

Miscellaneous

Subject Index

Journal of Clinical Psychopharmacology: December 2012 - Volume 32 - Issue 6 - p 849-882
doi: 10.1097/01.jcp.0000423118.53283.20
  • Free

A

α-aminobutyric acid (GABA)

 High-dose baclofen for treatment-resistant alcohol dependence (brief report), April, 266

 The psychopharmacology of aggressive behavior: A translational approach (review article), Feb, 83, April, 237

α-receptors

 Peripheral edema associated with risperidone oral solution: A case report and a review of the literature (letter), Feb, 128

ABCB1

 Association study of 27 annotated genes for clozapine pharmacogenetics: Validation of preexisting studies and identification of a new candidate gene, ABCB1, for treatment response, Aug, 441

Abdominal obesity

 The relationship between serum uric acid concentration and metabolic syndrome in patients with schizophrenia or schizoaffective disorder, Oct, 585

Abdominal pain

 Recurrence of panic attacks after brucellosis treatment-highly probable citalopram and rifampin drug interaction (letter), Dec, 842

Aberrant Behavior Checklist-Community

 Effects of large doses of arachidonic acid added to docosahexaenoic acid on social impairment in individuals with autism spectrum disorders: A double-blind, placebo-controlled, randomized trial, April, 200

Abnormal Involuntary Movement Scale (AIMS)

 Asenapine as adjunctive treatment for acute mania associated with bipolar disorder: Results of a 12-week core study and 40-week extension, Feb, 46

 Dyskinesia symptoms during treatment with olanzapine or haloperidol (letter), June, 420

 Parkinsonism in elderly users of haloperidol (brief report), Oct, 688

 Tetrabenazine augmentation in treatment-resistant schizophrenia: A 12-week, double-blind, placebo-controlled trial (brief report), Feb, 95

 Two 6-week, randomized, double-blind, placebo-controlled studies of ziprasidone in outpatients with bipolar I depression, Aug, 470

Absolute neutrophil count (ANC)

 A case of quetiapine XR and divalproex-associated neutropenia followed by successful use of ziprasidone, June, 417

Abuse potential

 Human abuse potential and cognitive effects of taranabant, a cannabinoid 1 receptor inverse agonist, Aug, 492

Academic sites

 Comparison of academic and nonacademic sites in multi-center clinical trials, Feb, 65

Acamprosate

 A randomized controlled pilot study of acamprosate added to escitalopram in adults with major depressive disorder and alcohol use disorder, Dec, 787

 The impact of acamprosate on cue reactivity in alcohol dependent individuals: A functional magnetic resonance imaging study, Oct, 661

Accreditation Council for Graduate Medical Education (ACGME)

 US psychiatric residents’ treatment of patients with bipolar disorder, April, 231

Acetylcholinesterase inhibitors

 Do local meteorological conditions influence skin irritation caused by transdermal rivastigmine? A retroprospective, pilot study (brief report), June, 412

Acetylcysteine

 N-acetylcysteine add-on treatment in refractory obsessive-compulsive disorder: A randomized, double-blind, placebo-controlled trial, Dec, 797

Actigraphy

 Actigraphic measurements in opioid detoxification with methadone or buprenorphine, Feb, 75

Activities of daily living (ADL) index

 Treatment of late-life major depressive disorder with selective serotonin reuptake inhibitors improves the multidimensional prognostic index (letter), Oct, 726

Acute angle-closure glaucoma (AACG)

 Short-term exposure to antidepressant drugs and risk of acute angle-closure glaucoma among older adults (brief report), June, 403

Acute extrapyramidal symptoms

 Tetrabenazine augmentation in treatment-resistant schizophrenia: A 12-week, double-blind, placebo-controlled trial (brief report), Feb, 95

Acute laryngeal dystonia

 Acute laryngeal dystonia associated with aripiprazole (letter), Dec, 837

Acute myocardial infarction

 Treatment with duloxetine in adults and the incidence of cardiovascular events, Feb, 23

Acute renal failure (ARF)

 Acute renal failure after paliperidone overdose: A case report (letter), Feb, 128

Add-on treatment

 Add-on treatment of quetiapine for fibromyalgia (brief report), Oct, 684

Addenbrooke’s Cognitive Examination (ACE)

 Effects of drug burden index on cognitive function in older men (brief report), April, 273

Addiction

 From disordered eating to addiction: The “food drug” in bulimia nervosa (review article), June, 376

 The anticonvulsant levetiracetam potentiates alcohol consumption in non-treatment seeking alcohol abusers (brief report), April, 269

Addiction Research Center Inventory

 Human abuse potential and cognitive effects of taranabant, a cannabinoid 1 receptor inverse agonist, Aug, 492

Adenosine triphosphate (ATP)

 Association study of 27 annotated genes for clozapine pharmacogenetics: Validation of preexisting studies and identification of a new candidate gene, ABCB1, for treatment response, Aug, 441

ADHD.SeeAttention-deficit/hyperactivity disorder (ADHD)

ADHD Rating Scale

 Does atomoxetine improve executive function, inhibitory control, and hyperactivity?: Results from a placebo-controlled trial using quantitative measurement technology, Oct, 653

Adherence

 Case manager- and patient-rated alliance as a predictor of medication adherence in first-episode psychosis, Aug, 465

 Prevalence of concomitant oral antipsychotic drug use among patients treated with long-acting, intramuscular, antipsychotic medications, June, 323

Adiponectin

 Dysregulation of adipocytokines related to second-generation antipsychotics in normal fasting glucose patients with schizophrenia (brief report), June, 390

Adolescence

 Adverse effects of second-generation antipsychotics in children and adolescents: A Bayesian meta-analysis, June, 309

 Electroconvulsive therapy and clozapine in adolescents with schizophrenia spectrum disorders: Is it a safe and effective combination?, Dec, 756

Adverse childhood experiences (ACE)

 Caudate gray matter volume in obsessive-compulsive disorder is influenced by adverse childhood experiences and ongoing drug treatment (brief report), Aug, 544

Adverse drug reaction (ADR)

 Does the medication pattern reflect the CYP2D6 genotype in patients with diagnoses within the schizophrenic spectrum?, Feb, 100

 Drugs associated with restless legs syndrome: A case/noncase study in the French pharmacovigilance database (brief report), Dec, 824

 Evidence-based medicine versus personalized medicine: Are they enemies? (guest editorial), April, 153

 Identifying potential adverse effects by patients’ ratings: A proof-of-concept study of a novel approach (brief report), Dec, 828

Adverse Drug Reaction Probability Scale (ADRPS)

 Identifying potential adverse effects by patients’ ratings: A proof-of-concept study of a novel approach (brief report), Dec, 828

Adverse events (AEs)

 A randomized, naturalistic, parallel-group study for the long-term treatment of panic disorder with clonazepam or paroxetine (brief report), Feb, 120

 Adverse effects of second-generation antipsychotics in children and adolescents: A Bayesian meta-analysis, June, 309

 Adverse events in healthy subjects exposed to single and multiple doses of LY2140023 monohydrate: pooled results from 10 phase 1 studies, June, 408

 Behavioral adverse effects of antiepileptic drugs in epilepsy (review article), June, 362

 Do local meteorological conditions influence skin irritation caused by transdermal rivastigmine? A retroprospective, pilot study (brief report), June, 412

 Does the medication pattern reflect the CYP2D6 genotype in patients with diagnoses within the schizophrenic spectrum?, Feb, 100

 Early switch strategy in patients with major depressive disorder, Aug, 479

 Effectiveness and cost of atypical versus typical antipsychotic treatment in a nationwide cohort of patients with schizophrenia in Germany, Oct, 602

 Efficacy and safety of levetiracetam for the prevention of alcohol relapse in recently detoxified alcohol-dependent patients (brief report), Aug, 558

 Functional polymorphism of the dopamine a-hydroxylase gene is associated with increased risk of disulfiram-induced of disulfiram-induced adverse effects in alcohol-dependent patients (letter), Aug, 578

 Human abuse potential and cognitive effects of taranabant, a cannabinoid 1 receptor inverse agonist, Aug, 492

 Identifying potential adverse effects by patients’ ratings: A proof-of-concept study of a novel approach (brief report), Dec, 828

 Impact of switching or initiating antipsychotic treatment on body weight during a 6-month follow-up in a cohort of patients with schizophrenia (brief report), Oct, 672

 Randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder (brief report), Aug, 551

 Two 6-week, randomized, double-blind, placebo-controlled studies of ziprasidone in outpatients with bipolar I depression, Aug, 470

 Unwanted interactions among psychotropic drugs and other treatments for autism spectrum disorders (guest editorial), Aug, 437

Age

 Sedative load among community-dwelling people aged 75 years or older: Association with balance and mobility, April, 218

Aggression

 Modulation of central serotonin affects emotional information processing in impulsive aggressive personality disorder, June, 329

 The psychopharmacology of aggressive behavior: A translational approach (review article), Feb, 83, April, 237

Agitation

 A naturalistic study of intramuscular haloperidol versus intramuscular olanzapine for the management of acute agitation, June, 317

Agomelatine

 Agomelatine may improve REM sleep behavior disorder symptoms (letter), Oct, 732

 Agomelatine versus venlafaxine XR in the treatment of anhedonia in major depressive disorder, Aug, 487

Agoraphobia

 An exploratory, open trial of fluoxetine treatment of juvenile fibromyalgia (letter), April, 293

Agouti-related protein (AGRP)

 Trajectories of agouti-related protein and leptin levels during antipsychotic-associated weight gain in patients with schizophrenia, Dec, 767

AIMS.seeAbnormal Involuntary Movement Scale (AIMS)

Akathisia

 Akathisia and suicidal ideation in first-episode schizophrenia (brief report), Oct, 694

 Two 6-week, randomized, double-blind, placebo-controlled studies of ziprasidone in outpatients with bipolar I depression, Aug, 470

Alcohol

 Efficacy and safety of levetiracetam for the prevention of alcohol relapse in recently detoxified alcohol-dependent patients (brief report), Aug, 558

 Selective serotonin reuptake inhibitors and the risk of acute pancreatitis: A Swedish population-based case-control study, June, 336

Alcohol dependence

 High-dose baclofen for treatment-resistant alcohol dependence (brief report), April, 266

 The impact of acamprosate on cue reactivity in alcohol dependent individuals: A functional magnetic resonance imaging study, Oct, 661

Alcohol dependent patients

 Functional polymorphism of the dopamine a-hydroxylase gene is associated with increased risk of disulfiram-induced of disulfiram-induced adverse effects in alcohol-dependent patients (letter), Aug, 578

Alcohol use disorder (AUD)

 A randomized controlled pilot study of acamprosate added to escitalopram in adults with major depressive disorder and alcohol use disorder, Dec, 787

Alcohol Use Disorders Identification Test (AUDIT)

 The anticonvulsant levetiracetam potentiates alcohol consumption in non-treatment seeking alcohol abusers (brief report), April, 269

Alcohol withdrawal syndrome

 Mephenesin dependence (letter), Oct, 736

Alcoholism

 Functional polymorphism of the dopamine a-hydroxylase gene is associated with increased risk of disulfiram-induced of disulfiram-induced adverse effects in alcohol-dependent patients (letter), Aug, 578

 The anticonvulsant levetiracetam potentiates alcohol consumption in non-treatment seeking alcohol abusers (brief report), April, 269

Algorithm

 Predictors of clozapine response in patients with treatment-refractory schizophrenia (brief report), Oct, 678

Alleles

 Association study of 27 annotated genes for clozapine pharmacogenetics: Validation of preexisting studies and identification of a new candidate gene, ABCB1, for treatment response, Aug, 441

Alzheimer disease (AD)

 Do local meteorological conditions influence skin irritation caused by transdermal rivastigmine? A retroprospective, pilot study (brief report), June, 412

 Mianserin for the treatment of sleep disorders in patients with dementia (letter), Aug, 576

Amantadine

 Short-term treatment of catatonia with amantadine in schizophrenia and schizoaffective disorder (letter), Aug, 569

Amenorrhea

 Long-term effect of haloperidol, olanzapine, and risperidone on plasma prolactin levels in patients with first-episode psychosis (brief report), Dec, 804

American Psychiatric Association (APA)

 Reporting bias in industry-supported medication trials presented at the American Psychiatric Association meeting (letter), June, 435

Amisulpride

 Cognitive effects of a single dose of atypical antipsychotics in healthy volunteers compared with placebo or haloperidol, Dec, 778

 Comment on “a multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia” by Kinon et al (letter), April, 291

 Metabolic effects of paliperidone extended release versus oral olanzapine in patients with schizophrenia: A prospective, randomized, controlled trial, Aug, 449

Amoxapine

 Olanzapine-related life-threatening hyperosmolar hyperglycemic syndrome: A case report (letter), Feb, 130

Amphetamine

 Predictive factors for more than 3 years’ duration of central stimulant treatment in adult attention-deficit/hyperactivity disorder: A retrospective, naturalistic study, Oct, 645

Amylase

 Selective serotonin reuptake inhibitors and the risk of acute pancreatitis: A Swedish population-based case-control study, June, 336

Anabolic androgenic steroids (AASs)

 Mania related to mesterolone in a previously mentally healthy person (letter), Oct, 734

Analysis of covariance (ANCOVA)

 A randomized, double-blind study of 30 versus 20 mg dexmethylphenidate extended-release in children with attention-deficit/hyperactivity disorder: Late-day symptom control, Oct, 637

 Two 6-week, randomized, double-blind, placebo-controlled studies of ziprasidone in outpatients with bipolar I depression, Aug, 470

Analysis of Functional NeuroImages (AFNI)

 The impact of acamprosate on cue reactivity in alcohol dependent individuals: A functional magnetic resonance imaging study, Oct, 661

Anatomical Therapeutic Chemical (ATC)

 Effectiveness and cost of atypical versus typical antipsychotic treatment in a nationwide cohort of patients with schizophrenia in Germany, Oct, 602

Anger Irritability Assault Questionnaire

 The psychopharmacology of aggressive behavior: A translational approach (review article), April, 237

Anhedonia

 Agomelatine versus venlafaxine XR in the treatment of anhedonia in major depressive disorder, Aug, 487

Anorexia nervosa (AN)

 Trajectories of agouti-related protein and leptin levels during antipsychotic-associated weight gain in patients with schizophrenia, Dec, 767

Anthropometrical measurements

 The relationship between serum uric acid concentration and metabolic syndrome in patients with schizophrenia or schizoaffective disorder, Oct, 585

Antianxiety agents

 Omega-3 fatty acid treatment, with or without cytidine, fails to show therapeutic properties in bipolar disorder (brief report), Oct, 699

Antiarrhythmic effects

 Eicosapentaenoic acid interventions in schizophrenia: Meta-analysis of randomized, placebo-controlled studies, April, 179

Anticholinergic affinity

 Augmenting clozapine with sertindole: Double-blind, randomized, placebo-controlled study, April, 173

Anticholinergic Drug Scale (ADS)

 Short-term exposure to antidepressant drugs and risk of acute angle-closure glaucoma among older adults (brief report), June, 403

Anticholinergic drugs

 A randomized, double-blind, placebo-controlled trial of fluvoxamine in patients with schizophrenia, Oct, 593

 All-cause mortality and medication risk factors in schizophrenia: A prospective cohort study, Feb, 31

 Management of a risperidone-induced tardive Pisa syndrome: A case report, June, 418

Anticonvulsants

 Neonatal complications after maternal concomitant use of SSRI and other central nervous system active drugs during the second or third trimester of pregnancy, Oct, 608

 The anticonvulsant levetiracetam potentiates alcohol consumption in non-treatment seeking alcohol abusers (brief report), April, 269

 The psychopharmacology of aggressive behavior: A translational approach (review article), April, 237

Anticraving drug acamprosate

 The impact of acamprosate on cue reactivity in alcohol dependent individuals: A functional magnetic resonance imaging study, Oct, 661

Antidepressant switch

 Early switch strategy in patients with major depressive disorder, Aug, 479

Antidepressants (ADs)

 All-cause mortality and medication risk factors in schizophrenia: A prospective cohort study, Feb, 31

 Antidepressant agents and suicide death among US department of veterans affairs patients in depression treatment, June, 346

 Antidepressant use and the risk of upper gastrointestinal bleeding in psychiatric patients, Aug, 518

 Delayed, fatal cardiotoxicity associated with bupropion and citalopram overdose (letter), June, 431

 Pregnancy outcome after exposure to antidepressants and the role of maternal depression: results from the Norwegian mother and child cohort study, April, 186

 Randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder (brief report), Aug, 551

 Unwanted interactions among psychotropic drugs and other treatments for autism spectrum disorders (guest editorial), Aug, 437

 Combination of antidepressants in the treatment of major depressive disorder: A systematic review and meta-analysis (brief report), April, 278

 Omega-3 fatty acid augmentation of citalopram treatment for patients with major depressive disorder, Feb, 61

 Randomized trials published in Chinese or Western journals: Comparative empirical analysis, June, 354

 Short-term exposure to antidepressant drugs and risk of acute angle-closure glaucoma among older adults (brief report), June, 403

 Symptomatic treatment of interferon-a-induced depression in hepatitis C: A systematic review (review article), Aug, 531

 Tranylcypromine and bupropion combination therapy in treatment-resistant major depression (letter), Aug, 572

Antiepileptic drugs (AEDs)

 Behavioral adverse effects of antiepileptic drugs in epilepsy (review article), June, 362

 Efficacy and safety of levetiracetam for the prevention of alcohol relapse in recently detoxified alcohol-dependent patients (brief report), Aug, 558

 The psychopharmacology of aggressive behavior: A translational approach (review article), April, 237

Antiobsessive medication

 Caudate gray matter volume in obsessive-compulsive disorder is influenced by adverse childhood experiences and ongoing drug treatment (brief report), Aug, 544

Antioxidant protection

 The relationship between serum uric acid concentration and metabolic syndrome in patients with schizophrenia or schizoaffective disorder, Oct, 585

Antiplatelet medications

 Antidepressant use and the risk of upper gastrointestinal bleeding in psychiatric patients, Aug, 518

Antipsychotic drugs (APD)

 A case of quetiapine XR and divalproex-associated neutropenia followed by successful use of ziprasidone, June, 417

 A randomized, double-blind, placebo-controlled trial of fluvoxamine in patients with schizophrenia: A preliminary study, Oct, 593

 Add-on treatment of quetiapine for fibromyalgia (brief report), Oct, 684

 Association between HTR2C polymorphisms and obessity in patients without antipsychotic drugs (letter), Oct, 715

 Association study of 27 annotated genes for clozapine pharmacogenetics: Validation of preexisting studies and identification of a new candidate gene, ABCB1, for treatment response, Aug, 441

 Augmenting clozapine with sertindole: Double-blind, randomized, placebo-controlled study, April, 173

 Cognitive impairment in patients clinically recovered from central nervous system depressant drug overdose, Aug, 503

 Common use of antipsychotic polypharmacy in older Asian patients with schizophrenia (2001–2009) (brief report), Dec, 809

 Does the medication pattern reflect the CYP2D6 genotype in patients with diagnoses within the schizophrenic spectrum?, Feb, 100

 Dopaminergic genes influence early response to atypical antipsychotics in patients with first presentation of psychosis (letter), Aug, 566

 Effectiveness and cost of atypical versus typical antipsychotic treatment in a nationwide cohort of patients with schizophrenia in Germany, Oct, 602

 Eicosapentaenoic acid interventions in schizophrenia: Meta-analysis of randomized, placebo-controlled studies, April, 179

 Electroconvulsive therapy and clozapine in adolescents with schizophrenia spectrum disorders: Is it a safe and effective combination?, Dec, 756

 Excessive insulin secretion in Japanese schizophrenic patients treated with antipsychotics despite normal fasting glucose levels, Dec, 750

 Impact of switching or initiating antipsychotic treatment on body weight during a 6-month follow-up in a cohort of patients with schizophrenia (brief report), Oct, 672

 Improvement in intractable tardive dystonia in bipolar disorder after aripiprazole treatment: A case report (letter), Aug, 563

 Long-term effect of haloperidol, olanzapine, and risperidone on plasma prolactin levels in patients with first-episode psychosis (brief report), Dec, 804

 Management of a risperidone-induced tardive Pisa syndrome: A case report, June, 418

 Medicare part D’s impact on antipsychotic drug use and costs among elderly patients without prior drug insurance, Feb, 3

 Metabolic effects of paliperidone extended release versus oral olanzapine in patients with schizophrenia: A prospective, randomized, controlled trial, Aug, 449

 Neonatal complications after maternal concomitant use of SSRI and other central nervous system active drugs during the second or third trimester of pregnancy, Oct, 608

 Neutropenia associated with the comedication of quetiapine and valproate in 2 elderly patients (letter), June, 416

 Parkinsonism in elderly users of haloperidol (brief report), Oct, 688

 Peripheral edema associated with risperidone oral solution: A case report and a review of the literature (letter), Feb, 128

 Predictors of clozapine response in patients with treatment-refractory schizophrenia (brief report), Oct, 678

 Prevalence of concomitant oral antipsychotic drug use among patients treated with long-acting, intramuscular, antipsychotic medications, June, 323

 Risk factors associated with metabolic syndrome in bipolar and schizophrenia subjects treated with antipsychotics: The role of folate pharmacogenetics (brief report), April, 261

 The psychopharmacology of aggressive behavior: A translational approach (review article), April, 237

 The relationship between serum uric acid concentration and metabolic syndrome in patients with schizophrenia or schizoaffective disorder, Oct, 585

 Unwanted interactions among psychotropic drugs and other treatments for autism spectrum disorders (guest editorial), Aug, 437

 US psychiatric residents’ treatment of patients with bipolar disorder, April, 231

 Variation in antipsychotic treatment choice across US nursing homes, Feb, 11

Antisocial personality disorder

 Predictive factors for more than 3 years’ duration of central stimulant treatment in adult attention-deficit/hyperactivity disorder: A retrospective, naturalistic study, Oct, 645

Anxiety

 Agomelatine versus venlafaxine XR in the treatment of anhedonia in major depressive disorder, Aug, 487

 Antidepressant use and the risk of upper gastrointestinal bleeding in psychiatric patients, Aug, 518

 Aripiprazole for the treatment of Tourette syndrome: A case series of 100 patients (brief report), Aug, 548

 Bupropion xl for the sustained treatment of trichotillomania (letter), April, 298

 Computational prediction of state anxiety in Asian patients with cancer susceptible to chemotherapy-induced nausea and vomiting, April, 207

 Pregabalin misuse-related issues; intake of large dosages, drug-smoking allegations, and possible association with myositis two case reports (letter), Dec, 839

Anxiolytics

 Effectiveness and cost of atypical versus typical antipsychotic treatment in a nationwide cohort of patients with schizophrenia in Germany, Oct, 602

 Multicenter study on the clinical effectiveness, pharmacokinetics, and pharmacogenetics of mirtazapine in depression, Oct, 622

Apoptosis

 Different impacts of aquaporin 4 and MAOA allele variation among olanzapine, risperidone, and paliperidone in schizophrenia (brief report), June, 394

Appetite

 Trajectories of agouti-related protein and leptin levels during antipsychotic-associated weight gain in patients with schizophrenia, Dec, 767

AQ indicates Aggression Questionnaire

 The psychopharmacology of aggressive behavior: A translational approach (review article), April, 237

Aquaporin 4

 Different impacts of aquaporin 4 and MAOA allele variation among olanzapine, risperidone, and paliperidone in schizophrenia (brief report), June, 394

Arachidonic acid (ARA)

 Effects of large doses of arachidonic acid added to docosahexaenoic acid on social impairment in individuals with autism spectrum disorders: A double-blind, placebo-controlled, randomized trial, April, 200

Area under the concentration-time curve (AUC)

 Optimizing the early prediction model for symptomatic remission with short-term treatment for schizophrenia, Dec, 773

 Reduced methadone clearance during aromatase inhibition, Aug, 511

Aripiprazole (ARP)

 A naturalistic study of intramuscular haloperidol versus intramuscular olanzapine for the management of acute agitation, June, 317

 A randomized, placebo-controlled study of zonisamide to prevent olanzapine-associated weight gain, April, 165

 Acute laryngeal dystonia associated with aripiprazole (letter), Dec, 837

 Adverse effects of second-generation antipsychotics in children and adolescents: A Bayesian meta-analysis, June, 309

 Aripiprazole for the treatment of Tourette syndrome: A case series of 100 patients (brief report), Aug, 548

 Cognitive effects of a single dose of atypical antipsychotics in healthy volunteers compared with placebo or haloperidol, Dec, 778

 Comparison of academic and nonacademic sites in multi-center clinical trials, Feb, 65

 Effects of aripiprazole and the Taq1A polymorphism in the dopamine D2 receptor gene on the clinical response and plasma monoamine metabolites level during the acute phase of schizophrenia (brief report), Feb, 106

 Hypomania associated with adjunctive aripiprazole in an elder female with recurrent major depressive disorder: Dose-related phenomenon? (letter), Dec, 836

 Impact of switching or initiating antipsychotic treatment on body weight during a 6-month follow-up in a cohort of patients with schizophrenia (brief report), Oct, 672

 Improvement in intractable tardive dystonia in bipolar disorder after aripiprazole treatment: A case report (letter), Aug, 563

 Tardive laryngeal dystonia associated with aripiprazole monotherapy (letter), April, 297

 The effectiveness and safety of adjunctive aripiprazole in Taiwanese patients with antidepressant-refractory major depressive disorder: A prospective, open-label trial, Feb, 56

 The sustained effects of aripiprazole-augmented clozapine treatment on the psychotic symptoms and metabolic profiles of patients with refractory schizophrenia (letter), April, 282

 Unwanted interactions among psychotropic drugs and other treatments for autism spectrum disorders (guest editorial), Aug, 437

Aromatase

 Reduced methadone clearance during aromatase inhibition, Aug, 511

Arrhythmia

 Treatment with duloxetine in adults and the incidence of cardiovascular events, Feb, 23

Ascertainment bias

 Follow-up study of a pharmacovigilance signal: No evidence of increased risk with risperidone of pituitary tumor with mass effect, Dec, 743

ASD.SeeAutism spectrum disorders (ASD)

Asenapine

 Asenapine as adjunctive treatment for acute mania associated with bipolar disorder: Results of a 12-week core study and 40-week extension, Feb, 46

 Asenapine versus olanzapine in people with persistent negative symptoms of schizophrenia, Feb, 36

Aspirin

 Too good to be true? Aspirin and schizophrenia (editorial), Oct, 583

Asthon Withdrawal Symptoms Rating Scale

 A randomized, naturalistic, parallel-group study for the long-term treatment of panic disorder with clonazepam or paroxetine (brief report), Feb, 120

Atherosclerosis

 The relationship between serum uric acid concentration and metabolic syndrome in patients with schizophrenia or schizoaffective disorder, Oct, 585

Atomoxetine

 Does atomoxetine improve executive function, inhibitory control, and hyperactivity?: Results from a placebo-controlled trial using quantitative measurement technology, Oct, 653

Attention-deficit/hyperactivity disorder (ADHD)

 A case of severe hyperthermia after administration of methylphenidate (letter), April, 299

 A randomized, double-blind study of 30 versus 20 mg dexmethylphenidate extended-release in children with attention-deficit/hyperactivity disorder: Late-day symptom control, Oct, 637

 Atomoxetine for encopresis in 2 children with attention-deficit/hyperactivity disorder (letter), April, 302

 Does atomoxetine improve executive function, inhibitory control, and hyperactivity?: Results from a placebo-controlled trial using quantitative measurement technology, Oct, 653

 No significant association between genetic variants in 7 candidate genes and response to ethylphenidate treatment in adult patients with ADHD (brief report), Dec, 820

 Predictive factors for more than 3 years’ duration of central stimulant treatment in adult attention-deficit/hyperactivity disorder: A retrospective, naturalistic study, Oct, 645

 Sapophagia (compulsive soap eating) and attention-deficit/ hyperactivity disorder in a child responsive to clonidine (letter), April, 291

 Status epilepticus associated with the administration of long-acting methylphenidate in a 7-year-old girl (letter), April, 300

Attrition

 Effectiveness of a cognitive behavioral weight management intervention in obese patients with psychotic disorders compared to patients with nonpsychotic disorders or no psychiatric disorders, Aug, 458

Atypical antipsychotic (AAPs)

 Effectiveness and cost of atypical versus typical antipsychotic treatment in a nationwide cohort of patients with schizophrenia in Germany, Oct, 602

 Risk factors associated with metabolic syndrome in bipolar and schizophrenia subjects treated with antipsychotics: The role of folate pharmacogenetics (brief report), April, 261

 Two 6-week, randomized, double-blind, placebo-controlled studies of ziprasidone in outpatients with bipolar I depression, Aug, 470

 Follow-up study of a pharmacovigilance signal: No evidence of increased risk with risperidone of pituitary tumor with mass effect, Dec, 743

Augmentation

 Augmenting clozapine with sertindole: Double-blind, randomized, placebo-controlled study, April, 173

 Early switch strategy in patients with major depressive disorder, Aug, 479

 Tetrabenazine augmentation in treatment-resistant schizophrenia: A 12-week, double-blind, placebo-controlled trial (brief report), Feb, 95

 The effectiveness and safety of adjunctive aripiprazole in Taiwanese patients with antidepressant-refractory major depressive disorder: A prospective, open-label trial, Feb, 56

Autism spectrum disorders (ASDs)

 Effects of large doses of arachidonic acid added to docosahexaenoic acid on social impairment in individuals with autism spectrum disorders: A double-blind, placebo-controlled, randomized trial, April, 200

 Unwanted interactions among psychotropic drugs and other treatments for autism spectrum disorders (guest editorial), Aug, 437

Average wholesale price (AWP)

 Medicare part D’s impact on antipsychotic drug use and costs among elderly patients without prior drug insurance, Feb, 3

B

β-cell function

 Olanzapine-related life-threatening hyperosmolar hyperglycemic syndrome: A case report (letter), Feb, 130

Baclofen

 High-dose baclofen for treatment-resistant alcohol dependence (brief report), Balter Award April, 266

Mitchell B. Balter Award Selection for 2011 (announcement), June, 328

Barnes Akathisia Rating Scale (BARS)

 Asenapine as adjunctive treatment for acute mania associated with bipolar disorder: Results of a 12-week core study and 40-week extension, Feb, 46

 Cognitive effects of a single dose of atypical antipsychotics in healthy volunteers compared with placebo or haloperidol, Dec, 778

 Open-label treatment with olanzapine for patients with borderline personality disorder (brief report), June, 398

 Tetrabenazine augmentation in treatment-resistant schizophrenia: A 12-week, double-blind, placebo-controlled trial (brief report), Feb, 95

 Two 6-week, randomized, double-blind, placebo-controlled studies of ziprasidone in outpatients with bipolar I depression, Aug, 470

Barratt Impulsivity Scale (BIS)

 The psychopharmacology of aggressive behavior: A translational approach (review article), April, 237

Baseline

 Early switch strategy in patients with major depressive disorder, Aug, 479

 Functional polymorphism of the dopamine a-hydroxylase gene is associated with increased risk of disulfiram-induced of disulfiram-induced adverse effects in alcohol-dependent patients (letter), Aug, 578

Bcrp

 Ketoconazole-associated preferential increase in dopamine D2 receptor occupancy in striatum compared to pituitary in vivo: Role for drug transporters? (brief report), Feb, 110

Beck Anxiety Inventory (BAI)

 Computational prediction of state anxiety in Asian patients with cancer susceptible to chemotherapy-induced nausea and vomiting, April, 207

Beck Depression Inventory (BDI)

 Effectiveness of a cognitive behavioral weight management intervention in obese patients with psychotic disorders compared to patients with nonpsychotic disorders or no psychiatric disorders, Aug, 458

Bed-days

 Effectiveness and cost of atypical versus typical antipsychotic treatment in a nationwide cohort of patients with schizophrenia in Germany, Oct, 602

 Predictors of clozapine response in patients with treatment-refractory schizophrenia (brief report), Oct, 678

Behavior Rating Scale (BRS)

 The psychopharmacology of aggressive behavior: A translational approach (review article), April, 237

Benzamides

 Symptomatic treatment of interferon-a-induced depression in hepatitis C: A systematic review (review article), Aug, 531

Benzodiazepines

 A naturalistic study of intramuscular haloperidol versus intramuscular olanzapine for the management of acute agitation, June, 317

 All-cause mortality and medication risk factors in schizophrenia: A prospective cohort study, Feb, 31

 Cognitive impairment in patients clinically recovered from central nervous system depressant drug overdose, Aug, 503

 Early switch strategy in patients with major depressive disorder, Aug, 479

 Electroconvulsive therapy and clozapine in adolescents with schizophrenia spectrum disorders: Is it a safe and effective combination?, Dec, 756

 Management of a risperidone-induced tardive Pisa syndrome: A case report, June, 418

 Mianserin for the treatment of sleep disorders in patients with dementia (letter), Aug, 576

 Neonatal complications after maternal concomitant use of SSRI and other central nervous system active drugs during the second or third trimester of pregnancy, Oct, 608

 The case for basic research on the psychopharmacology of aggression (guest editorial), Feb, 1

 The psychopharmacology of aggressive behavior: A translational approach (review article), April, 237

 Treatment with mirtazapine and venlafaxine increases noradrenaline excretion in depressed patients (letter), Aug, 574

 US psychiatric residents’ treatment of patients with bipolar disorder, April, 231

Berg Balance Scale (BBS)

 Sedative load among community-dwelling people aged 75 years or older: Association with balance and mobility, April, 218

Beta human chorionic gonadotropin (b-hCG)

 Human abuse potential and cognitive effects of taranabant, a cannabinoid 1 receptor inverse agonist, Aug, 492

Binge Eating Scale (BES)

 A randomized, placebo-controlled study of zonisamide to prevent olanzapine-associated weight gain, April, 165

Biochemical analysis

 The relationship between serum uric acid concentration and metabolic syndrome in patients with schizophrenia or schizoaffective disorder, Oct, 585

Bipolar depression (BPD)

 Two 6-week, randomized, double-blind, placebo-controlled studies of ziprasidone in outpatients with bipolar I depression, Aug, 470

Bipolar disorder (BD)

 An exploratory, open trial of fluoxetine treatment of juvenile fibromyalgia (letter), April, 293

 Asenapine as adjunctive treatment for acute mania associated with bipolar disorder: Results of a 12-week core study and 40-week extension, Feb, 46

 Enhanced ziprasidone combination therapy effectiveness in obese compared to nonobese patients with bipolar disorder, Dec, 814

 Omega-3 fatty acid treatment, with or without cytidine, fails to show therapeutic properties in bipolar disorder (brief report), Oct, 699

 Purinergic system in the treatment of bipolar disorder (letter), Oct, 735

 Risk factors associated with metabolic syndrome in bipolar and schizophrenia subjects treated with antipsychotics: The role of folate pharmacogenetics (brief report), April, 261

 Two 6-week, randomized, double-blind, placebo-controlled studies of ziprasidone in outpatients with bipolar I depression, Aug, 470

 US psychiatric residents’ treatment of patients with bipolar disorder, April, 231

Birth defects

 Pregnancy outcome after exposure to antidepressants and the role of maternal depression: results from the Norwegian mother and child cohort study, April, 186

Blood pressure

 Tetrabenazine augmentation in treatment-resistant schizophrenia: A 12-week, double-blind, placebo-controlled trial (brief report), Feb, 95

Blood samples for brain-derived neurotrophic factor (BDNF)

 Randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder (brief report), Aug, 551

Blood-brain barrier (BBB)

 Ketoconazole-associated preferential increase in dopamine D2 receptor occupancy in striatum compared to pituitary in vivo: Role for drug transporters? (brief report), Feb, 110

Blunted affect

 Tetrabenazine augmentation in treatment-resistant schizophrenia: A 12-week, double-blind, placebo-controlled trial (brief report), Feb, 95

Body mass index (BMI)

 Effectiveness of a cognitive behavioral weight management intervention in obese patients with psychotic disorders compared to patients with nonpsychotic disorders or no psychiatric disorders, Aug, 458

 Enhanced ziprasidone combination therapy effectiveness in obese compared to nonobese patients with bipolar disorder, Dec, 814

 From disordered eating to addiction: The “food drug” in bulimia nervosa (review article), June, 376

 Impact of switching or initiating antipsychotic treatment on body weight during a 6-month follow-up in a cohort of patients with schizophrenia (brief report), Oct, 672

 Metabolic effects of paliperidone extended release versus oral olanzapine in patients with schizophrenia: A prospective, randomized, controlled trial, Aug, 449

 The relationship between serum uric acid concentration and metabolic syndrome in patients with schizophrenia or schizoaffective disorder, Oct, 585

 Trajectories of agouti-related protein and leptin levels during antipsychotic-associated weight gain in patients with schizophrenia, Dec, 767

Body weight

 Metabolic effects of paliperidone extended release versus oral olanzapine in patients with schizophrenia: A prospective, randomized, controlled trial, Aug, 449

Books received, Dec, 844

Borderline personality disorder (BPD)

 Open-label treatment with olanzapine for patients with borderline personality disorder (brief report), June, 398

 The psychopharmacology of aggressive behavior: A translational approach (review article), Feb, 83

Bradykinesia

 Parkinsonism in elderly users of haloperidol (brief report), Oct, 688

Brain derived neurotrophic factor (BDNF)

 DRD3, but not BDNF, genotype affects treatment response to paroxetine in major depressive disorder (letter), Oct, 724

 The case for basic research on the psychopharmacology of aggression (guest editorial), Feb, 1

Breast cancer resistance protein (BCRP)

 Ketoconazole-associated preferential increase in dopamine D2 receptor occupancy in striatum compared to pituitary in vivo: Role for drug transporters? (brief report), Feb, 110

Brief Psychiatric Rating Scale (BPRS)

 Application of external review for subject selection in a schizophrenia trial (letter), April, 285

 Catatonia and encephalopathy associated with paliperidone palmitate (letter), April, 284

 Dyskinesia symptoms during treatment with olanzapine or haloperidol (letter), June, 420

 Eicosapentaenoic acid interventions in schizophrenia: Meta-analysis of randomized, placebo-controlled studies, April, 179

 Optimizing the early prediction model for symptomatic remission with short-term treatment for schizophrenia, Dec, 773

 Tetrabenazine augmentation in treatment-resistant schizophrenia: A 12-week, double-blind, placebo-controlled trial (brief report), Feb, 95

 The psychopharmacology of aggressive behavior: A translational approach (review article), April, 237

 The sustained effects of aripiprazole-augmented clozapine treatment on the psychotic symptoms and metabolic profiles of patients with refractory schizophrenia (letter), April, 282

Bromazepam

 Olanzapine-related life-threatening hyperosmolar hyperglycemic syndrome: A case report (letter), Feb, 130

Brucellosis infection

 Recurrence of panic attacks after brucellosis treatment-highly probable citalopram and rifampin drug interaction (letter), Dec, 842

Bulimia nervosa

 From disordered eating to addiction: The “food drug” in bulimia nervosa (review article), June, 376

Buprenorphine

 Actigraphic measurements in opioid detoxification with methadone or buprenorphine, Feb, 75

 Reduced methadone clearance during aromatase inhibition, Aug, 511

Bupropion

 Antidepressant agents and suicide death among US department of veterans affairs patients in depression treatment, June, 346

 Symptomatic treatment of interferon-a-induced depression in hepatitis C: A systematic review (review article), Aug, 531

Bush-Francis Catatonia Rating Scale (BFCRS)

 Short-term treatment of catatonia with amantadine in schizophrenia and schizoaffective disorder (letter), Aug, 569

Buss-Durkee Hostility Inventory

 The psychopharmacology of aggressive behavior: A translational approach (review article), April, 237

C

C-(N-methyl)-erythromycin breath test (ERMBT)

 The cytochrome P-450 2C9/2C19 but not the ABCB1 genetic polymorphism may be associated with the liver cytochrome 3A4 induction by phenytoin (letter), June, 429

C-6 glioma cells

 Cognitive effects of a single dose of atypical antipsychotics in healthy volunteers compared with placebo or haloperidol, Dec, 778

Caffeine

 Clozapine levels might be affected by excessive cola consumption (letter), Oct, 717

 Human abuse potential and cognitive effects of taranabant, a cannabinoid 1 receptor inverse agonist, Aug, 492

Calgary Depression Scale for Schizophrenia (CDSS)

 Asenapine versus olanzapine in people with persistent negative symptoms of schizophrenia, Feb, 36

Cambridge Neuropsychological Test Automated Battery (CANTAB)

 A randomized, double-blind, placebo-controlled trial of fluvoxamine in patients with schizophrenia: A preliminary study, Oct, 593

 Cognitive impairment in patients clinically recovered from central nervous system depressant drug overdose, Aug, 503

Cancer

 Effectiveness of a cognitive behavioral weight management intervention in obese patients with psychotic disorders compared to patients with nonpsychotic disorders or no psychiatric disorders, Aug, 458

Cannabinoid 1 receptors (CB1Rs)

 Human abuse potential and cognitive effects of taranabant, a cannabinoid 1 receptor inverse agonist, Aug, 492

Cannabis

 An exploratory, open trial of fluoxetine treatment of juvenile fibromyalgia (letter), April, 293

 Predictive factors for more than 3 years’ duration of central stimulant treatment in adult attention-deficit/hyperactivity disorder: A retrospective, naturalistic study, Oct, 645

Carbamazepine (CBZ)

 Behavioral adverse effects of antiepileptic drugs in epilepsy (review article), June, 362

 Evidence-based medicine versus personalized medicine: Are they enemies? (guest editorial), April, 153

 The psychopharmacology of aggressive behavior: A translational approach (review article), April, 237

 Valproic acid treatment is associated with altered leukocyte subset development (brief report), Dec, 832

Carbon monoxide verification

 Effects of naltrexone on smoking cessation outcomes and weight gain in nicotine-dependent men and women, Oct, 630

Cardiac rhythm

 Human abuse potential and cognitive effects of taranabant, a cannabinoid 1 receptor inverse agonist, Aug, 492

Cardiovascular events

 Treatment with duloxetine in adults and the incidence of cardiovascular events, Feb, 23

Cardiovascular malformations

 Pregnancy outcome after exposure to antidepressants and the role of maternal depression: results from the Norwegian mother and child cohort study, April, 186

Case manager (CM)

 Case manager- and patient-rated alliance as a predictor of medication adherence in first-episode psychosis, Aug, 465

Catatonia

 Short-term treatment of catatonia with amantadine in schizophrenia and schizoaffective disorder (letter), Aug, 569

Catechol-O-methyl transferase (COMT)

 Dopaminergic genes influence early response to atypical antipsychotics in patients with first presentation of psychosis (letter), Aug, 566

 Risk factors associated with metabolic syndrome in bipolar and schizophrenia subjects treated with antipsychotics: The role of folate pharmacogenetics (brief report), April, 261

 The psychopharmacology of aggressive behavior: A translational approach (review article), Feb, 83

Cathinones

 Suspected and confirmed fatalities associated with mephedrone (4-methylmethcathinone, “meow meow”) in the United Kingdom (brief report), Oct, 710

Caudate nucleus

 Caudate gray matter volume in obsessive-compulsive disorder is influenced by adverse childhood experiences and ongoing drug treatment (brief report), Aug, 544

cb-CPT

 Does atomoxetine improve executive function, inhibitory control, and hyperactivity?: Results from a placebo-controlled trial using quantitative measurement technology, Oct, 653

CEDIA immunoassays

 Actigraphic measurements in opioid detoxification with methadone or buprenorphine, Feb, 75

Cellular metabolic rate

 Normobaric hyperoxia treatment of schizophrenia, Aug, 525

Central nervous system (CNS)

 Cognitive impairment in patients clinically recovered from central nervous system depressant drug overdose, Aug, 503

 Effects of drug burden index on cognitive function in older men (brief report), April, 273

 Enhanced ziprasidone combination therapy effectiveness in obese compared to nonobese patients with bipolar disorder, Dec, 814

 Neonatal complications after maternal concomitant use of SSRI and other central nervous system active drugs during the second or third trimester of pregnancy, Oct, 608

 Symptomatic treatment of interferon-a-induced depression in hepatitis C: A systematic review (review article), Aug, 531

Central Nervous Systems (CNS) Vital Signs scale

 Asenapine as adjunctive treatment for acute mania associated with bipolar disorder: Results of a 12-week core study and 40-week extension, Feb, 46

Central stimulant treatment

 Predictive factors for more than 3 years’ duration of central stimulant treatment in adult attention-deficit/hyperactivity disorder: A retrospective, naturalistic study, Oct, 645

Cerebrospinal fluid (CSF)

 Interindividual variation in olanzapine concentration influenced by UGT1A4 L48V polymorphism in serum and upstream FMO polymorphisms in cerebrospinal fluid (letter), April, 287

 The psychopharmacology of aggressive behavior: A translational approach (review article), Feb, 83

CGI.SeeClinical Global Impression (CGI)

CGI-Improvement (CGI-I) scales

 A randomized, naturalistic, parallel-group study for the long-term treatment of panic disorder with clonazepam or paroxetine (brief report), Feb, 120

 Asenapine versus olanzapine in people with persistent negative symptoms of schizophrenia, Feb, 36

Characteristic curve

 Optimizing the early prediction model for symptomatic remission with short-term treatment for schizophrenia, Dec, 773

Chemotherapy-induced nausea and vomiting (CINV)

 Computational prediction of state anxiety in Asian patients with cancer susceptible to chemotherapy-induced nausea and vomiting, April, 207

Childhood

 Adverse effects of second-generation antipsychotics in children and adolescents: A Bayesian meta-analysis, June, 309

Childhood trauma

 Caudate gray matter volume in obsessive-compulsive disorder is influenced by adverse childhood experiences and ongoing drug treatment (brief report), Aug, 544

Children

 A randomized, double-blind study of 30 versus 20 mg dexmethylphenidate extended-release in children with attention-deficit/hyperactivity disorder: Late-day symptom control, Oct, 637

Children’s Psychiatric Rating Scale (CPRS)

 The psychopharmacology of aggressive behavior: A translational approach (review article), April, 237

Chlordiazepoxide

 The case for basic research on the psychopharmacology of aggression (guest editorial), Feb, 1

Chlorpromazine

 Excessive insulin secretion in Japanese schizophrenic patients treated with antipsychotics despite normal fasting glucose levels, Dec, 750

Chlorpromazine equivalents (CPZEq)

 Does the medication pattern reflect the CYP2D6 genotype in patients with diagnoses within the schizophrenic spectrum?, Feb, 100

Cholesterol

 Metabolic effects of paliperidone extended release versus oral olanzapine in patients with schizophrenia: A prospective, randomized, controlled trial, Aug, 449

 The sustained effects of aripiprazole-augmented clozapine treatment on the psychotic symptoms and metabolic profiles of patients with refractory schizophrenia (letter), April, 282

Chronic pain

 Add-on treatment of quetiapine for fibromyalgia (brief report), Oct, 684

Chronic psychotic illness

 Metabolic effects of paliperidone extended release versus oral olanzapine in patients with schizophrenia: A prospective, randomized, controlled trial, Aug, 449

Citalopram

 Antidepressant agents and suicide death among US department of veterans affairs patients in depression treatment, June, 346

 Delayed, fatal cardiotoxicity associated with bupropion and citalopram overdose (letter), June, 431

 Recurrence of panic attacks after brucellosis treatment-highly probable citalopram and rifampin drug interaction (letter), Dec, 842

Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE)

 Metabolic effects of paliperidone extended release versus oral olanzapine in patients with schizophrenia: A prospective, randomized, controlled tria, Aug, 449

Clinical CINV end points

 Computational prediction of state anxiety in Asian patients with cancer susceptible to chemotherapy-induced nausea and vomiting, April, 207

Clinical Global Impression (CGI) Scale

 Effects of aripiprazole and the Taq1A polymorphism in the dopamine D2 receptor gene on the clinical response and plasma monoamine metabolites level during the acute phase of schizophrenia (brief report), Feb, 106

 Multicenter study on the clinical effectiveness, pharmacokinetics, and pharmacogenetics of mirtazapine in depression, Oct, 622

 Omega-3 fatty acid augmentation of citalopram treatment for patients with major depressive disorder, Feb, 61

 Randomized trials published in Chinese or Western journals: Comparative empirical analysis, June, 354

 Tetrabenazine augmentation in treatment-resistant schizophrenia: A 12-week, double-blind, placebo-controlled trial (brief report), Feb, 95

 The psychopharmacology of aggressive behavior: A translational approach (review article), April, 237

 Two 6-week, randomized, double-blind, placebo-controlled studies of ziprasidone in outpatients with bipolar I depression, Aug, 470

Clinical Global Impression Improvement (CGI-I) scale

 Aripiprazole for the treatment of Tourette syndrome: A case series of 100 patients (brief report), Aug, 548

 Association study of 27 annotated genes for clozapine pharmacogenetics: Validation of preexisting studies and identification of a new candidate gene, ABCB1, for treatment response, Aug, 441

 Escitalopram for treatment of night eating syndrome: A 12-week, randomized, placebo-controlled trial, June, 341

 N-acetylcysteine add-on treatment in refractory obsessive-compulsive disorder: A randomized, double-blind, placebo-controlled trial, Dec, 797

 No significant association between genetic variants in 7 candidate genes and response to ethylphenidate treatment in adult patients with ADHD (brief report), Dec, 820

 The psychopharmacology of aggressive behavior: A translational approach (review article), April, 237

Clinical Global Impression-Severity (CGI-S) scale

 A randomized, naturalistic, parallel-group study for the long-term treatment of panic disorder with clonazepam or paroxetine (brief report), Feb, 120

 Add-on treatment of quetiapine for fibromyalgia (brief report), Oct, 684

 Application of external review for subject selection in a schizophrenia trial (letter), April, 285

Clinical Global Impression-Severity of Illness (CGI-S) scores

 Enhanced ziprasidone combination therapy effectiveness in obese compared to nonobese patients with bipolar disorder, Dec, 814

Clinical Global Improvement(CGI) scale

 A randomized, placebo-controlled study of zonisamide to prevent olanzapine-associated weight gain, April, 165

 Comparison of academic and nonacademic sites in multi-center clinical trials, Feb, 65

Clinical trial methodology

 Comparison of academic and nonacademic sites in multi-center clinical trials, Feb, 65

 Identifying potential adverse effects by patients’ ratings: A proof-of-concept study of a novel approach (brief report), Dec, 828

Clinical Trials Network and Institute (CTNI)

 Comparison of academic and nonacademic sites in multi-center clinical trials, Feb, 65

Clinical Validation Inventory for Study Admission (C-VISA)

 Application of external review for subject selection in a schizophrenia trial (letter), April, 285

Clonazepam

 A case of quetiapine XR and divalproex-associated neutropenia followed by successful use of ziprasidone, June, 417

 A randomized, naturalistic, parallel-group study for the long-term treatment of panic disorder with clonazepam or paroxetine (brief report), Feb, 120

Clostridium difficile

 Clozapine-associated colitis: Case report and review of the literature (letter), Aug, 564

Clozapine

 Adverse effects of second-generation antipsychotics in children and adolescents: A Bayesian meta-analysis, June, 309

 Association study of 27 annotated genes for clozapine pharmacogenetics: Validation of preexisting studies and identification of a new candidate gene, ABCB1, for treatment response, Aug, 441

 Augmenting clozapine with sertindole: Double-blind, randomized, placebo-controlled study, April, 173

 Clozapine levels might be affected by excessive cola consumption (letter), Oct, 717

 Clozapine-associated colitis: Case report and review of the literature (letter), Aug, 564

 Does the medication pattern reflect the CYP2D6 genotype in patients with diagnoses within the schizophrenic spectrum?, Feb, 100

 Dyskinesia symptoms during treatment with olanzapine or haloperidol (letter), June, 420

 Dysregulation of adipocytokines related to second-generation antipsychotics in normal fasting glucose patients with schizophrenia (brief report), June, 390

 Electroconvulsive therapy and clozapine in adolescents with schizophrenia spectrum disorders: Is it a safe and effective combination?, Dec, 756

 Impact of switching or initiating antipsychotic treatment on body weight during a 6-month follow-up in a cohort of patients with schizophrenia (brief report), Oct, 672

 Is psychiatry ignoring suicide? The case for clozapine (guest editorial), June, 307

 Metabolic effects of paliperidone extended release versus oral olanzapine in patients with schizophrenia: A prospective, randomized, controlled trial, Aug, 449

 Neutropenia associated with the comedication of quetiapine and valproate in 2 elderly patients (letter), June, 416

 Normobaric hyperoxia treatment of schizophrenia, Aug, 525

 Predictors of clozapine response in patients with treatment-refractory schizophrenia (brief report), Oct, 678

 Pregabalin-associated increase of clozapine serum levels (letter), Feb, 127

 Tardive laryngeal dystonia associated with aripiprazole monotherapy (letter), April, 297

 Tetrabenazine augmentation in treatment-resistant schizophrenia: A 12-week, double-blind, placebo-controlled trial (brief report), Feb, 95

 The relationship between serum uric acid concentration and metabolic syndrome in patients with schizophrenia or schizoaffective disorder, Oct, 585

 The sustained effects of aripiprazole-augmented clozapine treatment on the psychotic symptoms and metabolic profiles of patients with refractory schizophrenia (letter), April, 282

 Too good to be true? Aspirin and schizophrenia (editorial), Oct, 583

CNS.SeeCentral nervous system (CNS)

CNS depressants

 Cognitive impairment in patients clinically recovered from central nervous system depressant drug overdose, Aug, 503

CNS pathologic abnormalities

 Neonatal complications after maternal concomitant use of SSRI and other central nervous system active drugs during the second or third trimester of pregnancy, Oct, 608

CNS-active drugs

 Neonatal complications after maternal concomitant use of SSRI and other central nervous system active drugs during the second or third trimester of pregnancy, Oct, 608

Cocaine

 Reduced methadone clearance during aromatase inhibition, Aug, 511

 Symptomatic treatment of interferon-a-induced depression in hepatitis C: A systematic review (review article), Aug, 531

Cognitive disturbance

 Open-label treatment with olanzapine for patients with borderline personality disorder (brief report), June, 398

Cognitive function

 Cognitive effects of a single dose of atypical antipsychotics in healthy volunteers compared with placebo or haloperidol, Dec, 778

 Effects of drug burden index on cognitive function in older men (brief report), April, 273

Cognitive impairment

 A randomized, double-blind, placebo-controlled trial of fluvoxamine in patients with schizophrenia: A preliminary study, Oct, 593

 Cognitive impairment in patients clinically recovered from central nervous system depressant drug overdose, Aug, 503

Cohort Studies

 All-cause mortality and medication risk factors in schizophrenia: A prospective cohort study, Feb, 31

 Effectiveness and cost of atypical versus typical antipsychotic treatment in a nationwide cohort of patients with schizophrenia in Germany, Oct, 602

Cola consumption

 Clozapine levels might be affected by excessive cola consumption (letter), Oct, 717

Combination drug therapy

 Combination of antidepressants in the treatment of major depressive disorder: A systematic review and meta-analysis (brief report), April, 278

Comorbid antisocial personality disorder

 Predictive factors for more than 3 years’ duration of central stimulant treatment in adult attention-deficit/hyperactivity disorder: A retrospective, naturalistic study, Oct, 645

Composite Benzodiazepine Discontinuation Symptom Scale

 A randomized, naturalistic, parallel-group study for the long-term treatment of panic disorder with clonazepam or paroxetine (brief report), Feb, 120

Comprehensive geriatric assessment (CGA)

 Treatment of late-life major depressive disorder with selective serotonin reuptake inhibitors improves the multidimensional prognostic index (letter), Oct, 726

Computerized Neurocognitive Test (CNT)

 Cognitive effects of a single dose of atypical antipsychotics in healthy volunteers compared with placebo or haloperidol, Dec, 778

COMT

 No significant association between genetic variants in 7 candidate genes and response to ethylphenidate treatment in adult patients with ADHD (brief report), Dec, 820

Confidence intervals (CIs)

 Combination of antidepressants in the treatment of major depressive disorder: A systematic review and meta-analysis (brief report), April, 278

 Effects of drug burden index on cognitive function in older men (brief report), April, 273

 Follow-up study of a pharmacovigilance signal: No evidence of increased risk with risperidone of pituitary tumor with mass effect, Dec, 743

 Selective serotonin reuptake inhibitors and the risk of acute pancreatitis: A Swedish population-based case-control study, June, 336

 Short-term exposure to antidepressant drugs and risk of acute angle-closure glaucoma among older adults (brief report), June, 403

 Treatment with duloxetine in adults and the incidence of cardiovascular events, Feb, 23

Confirmatory factor analysis (CFA)

 Satisfaction with methadone as a medication: Psychometric properties of the Spanish version of the treatment satisfaction questionnaire for medication, Feb, 69

Congenital malformation

 Neonatal complications after maternal concomitant use of SSRI and other central nervous system active drugs during the second or third trimester of pregnancy, Oct, 608

Conners parent rating scale

 Behavioral adverse effects of antiepileptic drugs in epilepsy (review article), June, 362

Conners Teacher Questionnaire (CTQ)

 The psychopharmacology of aggressive behavior: A translational approach (review article), April, 237

Continuous performance test (CPT)

 Cognitive effects of a single dose of atypical antipsychotics in healthy volunteers compared with placebo or haloperidol, Dec, 778

 Does atomoxetine improve executive function, inhibitory control, and hyperactivity?: Results from a placebo-controlled trial using quantitative measurement technology, Oct, 653

Continuous Tracking Test (CTT)

 A method to assess the dissipation of the effects of residual hypnotics (brief report), Oct, 704

Coronary heart disease (CHD)

 Effectiveness of a cognitive behavioral weight management intervention in obese patients with psychotic disorders compared to patients with nonpsychotic disorders or no psychiatric disorders, Aug, 458

Coronary revascularization

 Treatment with duloxetine in adults and the incidence of cardiovascular events, Feb, 23

Corticotropin releasing factor (CRF) R1 antagonists

 The case for basic research on the psychopharmacology of aggression (guest editorial), Feb, 1

Cost and effectiveness

 Effectiveness and cost of atypical versus typical antipsychotic treatment in a nationwide cohort of patients with schizophrenia in Germany, Oct, 602

Cox regression model

 Effectiveness of a cognitive behavioral weight management intervention in obese patients with psychotic disorders compared to patients with nonpsychotic disorders or no psychiatric disorders, Aug, 458

 Predictors of clozapine response in patients with treatment-refractory schizophrenia (brief report), Oct, 678

Craving

 Efficacy and safety of levetiracetam for the prevention of alcohol relapse in recently detoxified alcohol-dependent patients (brief report), Aug, 558

Critical Flicker Fusion

 A method to assess the dissipation of the effects of residual hypnotics (brief report), Oct, 704

Cue reactivity

 The impact of acamprosate on cue reactivity in alcohol dependent individuals: A functional magnetic resonance imaging study, Oct, 661

CYP1A2

 Interindividual variation in olanzapine concentration influenced by UGT1A4 L48V polymorphism in serum and upstream FMO polymorphisms in cerebrospinal fluid (letter), April, 287

 Multicenter study on the clinical effectiveness, pharmacokinetics, and pharmacogenetics of mirtazapine in depression, Oct, 622

CYP2B6

 Multicenter study on the clinical effectiveness, pharmacokinetics, and pharmacogenetics of mirtazapine in depression, Oct, 622

 Reduced methadone clearance during aromatase inhibition, Aug, 511

CYP2C

 The cytochrome P-450 2C9/2C19 but not the ABCB1 genetic polymorphism may be associated with the liver cytochrome 3A4 induction by phenytoin (letter), June, 429

CYP2C19

 Delayed, fatal cardiotoxicity associated with bupropion and citalopram overdose (letter), June, 431

 High venlafaxine serum levels after prior fluoxetine medication (letter), April, 295

 Recurrence of panic attacks after brucellosis treatment-highly probable citalopram and rifampin drug interaction (letter), Dec, 842

 The cytochrome P-450 2C9/2C19 but not the ABCB1 genetic polymorphism may be associated with the liver cytochrome 3A4 induction by phenytoin (letter), June, 429

CYP2D6

 Association study of 27 annotated genes for clozapine pharmacogenetics: Validation of preexisting studies and identification of a new candidate gene, ABCB1, for treatment response, Aug, 441

 Does the medication pattern reflect the CYP2D6 genotype in patients with diagnoses within the schizophrenic spectrum?, Feb, 100

 Evidence-based medicine versus personalized medicine: Are they enemies? (guest editorial), April, 153

 High venlafaxine serum levels after prior fluoxetine medication (letter), April, 295

 Interindividual variation in olanzapine concentration influenced by UGT1A4 L48V polymorphism in serum and upstream FMO polymorphisms in cerebrospinal fluid (letter), April, 287

 Ketoconazole-associated preferential increase in dopamine D2 receptor occupancy in striatum compared to pituitary in vivo: Role for drug transporters? (brief report), Feb, 110

CYP2D6*10

 Hypomania associated with adjunctive aripiprazole in an elder female with recurrent major depressive disorder: Dose-related phenomenon? (letter), Dec, 836

CYP3A activity

 Pharmacokinetic-pharmacodynamic modeling of mood and withdrawal symptoms in relation to plasma concentrations of methadone in patients undergoing methadone maintenance treatment, Oct, 666

CYP3A4

 Delayed, fatal cardiotoxicity associated with bupropion and citalopram overdose (letter), June, 431

 High venlafaxine serum levels after prior fluoxetine medication (letter), April, 295

 Recurrence of panic attacks after brucellosis treatment-highly probable citalopram and rifampin drug interaction (letter), Dec, 842

 The cytochrome P-450 2C9/2C19 but not the ABCB1 genetic polymorphism may be associated with the liver cytochrome 3A4 induction by phenytoin (letter), June, 429

Cytidine (CYT)

 Omega-3 fatty acid treatment, with or without cytidine, fails to show therapeutic properties in bipolar disorder (brief report), Oct, 699

Cytochrome P450 (CYP)

 Evidence-based medicine versus personalized medicine: Are they enemies? (guest editorial), April, 153

 Multicenter study on the clinical effectiveness, pharmacokinetics, and pharmacogenetics of mirtazapine in depression, Oct, 622

 The cytochrome P-450 2C9/2C19 but not the ABCB1 genetic polymorphism may be associated with the liver cytochrome 3A4 induction by phenytoin (letter), June, 429

Cytochrome P450 2D6 enzyme (CYP2D6)

 Does the medication pattern reflect the CYP2D6 genotype in patients with diagnoses within the schizophrenic spectrum?, Feb, 100

D

D-fenfluramine

 A randomized, placebo-controlled study of zonisamide to prevent olanzapine-associated weight gain, April, 165

D2-receptor

 Aripiprazole for the treatment of Tourette syndrome: A case series of 100 patients (brief report), Aug, 548

 Dopaminergic genes influence early response to atypical antipsychotics in patients with first presentation of psychosis (letter), Aug, 566

 Hypomania associated with adjunctive aripiprazole in an elder female with recurrent major depressive disorder: Dose-related phenomenon? (letter), Dec, 836

D2L receptor

 Cognitive effects of a single dose of atypical antipsychotics in healthy volunteers compared with placebo or haloperidol, Dec, 778

Debrisoquine

 Evidence-based medicine versus personalized medicine: Are they enemies? (guest editorial), April, 153

Decreased appetite

 A randomized, double-blind study of 30 versus 20 mg dexmethylphenidate extended-release in children with attention-deficit/hyperactivity disorder: Late-day symptom control, Oct, 637

Defined daily doses (DDD)

 Antidepressant use and the risk of upper gastrointestinal bleeding in psychiatric patients, Aug, 518

 Cognitive impairment in patients clinically recovered from central nervous system depressant drug overdose, Aug, 503

Delirium

 Mianserin for the treatment of sleep disorders in patients with dementia (letter), Aug, 576

Delusional disorder

 Two 6-week, randomized, double-blind, placebo-controlled studies of ziprasidone in outpatients with bipolar I depression, Aug, 470

Dementia

 Effects of drug burden index on cognitive function in older men (brief report), April, 273

Depression

 A randomized controlled pilot study of acamprosate added to escitalopram in adults with major depressive disorder and alcohol use disorder, Dec, 787

 Agomelatine versus venlafaxine XR in the treatment of anhedonia in major depressive disorder, Aug, 487

 Antidepressant agents and suicide death among US department of veterans affairs patients in depression treatment, June, 346

 Combination of antidepressants in the treatment of major depressive disorder: A systematic review and meta-analysis (brief report), April, 278

 Comparison of academic and nonacademic sites in multi-center clinical trials, Feb, 65

 Multicenter study on the clinical effectiveness, pharmacokinetics, and pharmacogenetics of mirtazapine in depression, Oct, 622

 Neonatal outcomes after late-gestation exposure to selective serotonin reuptake inhibitors, Oct, 615

 Olanzapine-related life-threatening hyperosmolar hyperglycemic syndrome: A case report (letter), Feb, 130

 Randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder (brief report), Aug, 551

 Selective serotonin reuptake inhibitors and the risk of acute pancreatitis: A Swedish population-based case-control study, June, 336

 Serotonin-norepinephrine euptake inhibitor treatment for tinnitus and depression (letter), Oct, 729

 Symptomatic treatment of interferon-a-induced depression in hepatitis C: A systematic review (review article), Aug, 531

 Tetrabenazine augmentation in treatment-resistant schizophrenia: A 12-week, double-blind, placebo-controlled trial (brief report), Feb, 95

Depressive disorders

 Antidepressant use and the risk of upper gastrointestinal bleeding in psychiatric patients, Aug, 518

 Hypomania associated with adjunctive aripiprazole in an elder female with recurrent major depressive disorder: Dose-related phenomenon? (letter), Dec, 836

Depressive symptoms

 Effects of naltrexone on smoking cessation outcomes and weight gain in nicotine-dependent men and women, Oct, 630

Desmethyldiazepam

 Reduced methadone clearance during aromatase inhibition, Aug, 511

Dexamethasone suppression test (DST)

 Evidence-based medicine versus personalized medicine: Are they enemies? (guest editorial), April, 153

Dexmethylphenidate (d-MPH)

 A randomized, double-blind study of 30 versus 20 mg dexmethylphenidate extended-release in children with attention-deficit/hyperactivity disorder: Late-day symptom control, Oct, 637

Dextromethorphan (CYP2D6)

 Multicenter study on the clinical effectiveness, pharmacokinetics, and pharmacogenetics of mirtazapine in depression, Oct, 622

Dextropropoxyphene

 Neonatal complications after maternal concomitant use of SSRI and other central nervous system active drugs during the second or third trimester of pregnancy, Oct, 608

Diabetes mellitus (DM)

 Effectiveness of a cognitive behavioral weight management intervention in obese patients with psychotic disorders compared to patients with nonpsychotic disorders or no psychiatric disorders, Aug, 458

 Excessive insulin secretion in Japanese schizophrenic patients treated with antipsychotics despite normal fasting glucose levels, Dec, 750

 Status epilepticus associated with the administration of long-acting methylphenidate in a 7-year-old girl (letter), April, 300

Diabetic ketoacidosis

 Olanzapine-related life-threatening hyperosmolar hyperglycemic syndrome: A case report (letter), Feb, 130

DIEPSS.SeeDrug-Induced Extrapyramidal Symptoms Scale (DIEPSS)

Digit Symbol Substitution Test (DSST)

 A method to assess the dissipation of the effects of residual hypnotics (brief report), Oct, 704

 Cognitive effects of a single dose of atypical antipsychotics in healthy volunteers compared with placebo or haloperidol, Dec, 778

Disorientation

 Tetrabenazine augmentation in treatment-resistant schizophrenia: A 12-week, double-blind, placebo-controlled trial (brief report), Feb, 95

Docosahexaenoic acid (DHA)

 Effects of large doses of arachidonic acid added to docosahexaenoic acid on social impairment in individuals with autism spectrum disorders: A double-blind, placebo-controlled, randomized trial, April, 200

Donepezil

 Do local meteorological conditions influence skin irritation caused by transdermal rivastigmine? A retroprospective, pilot study (brief report), June, 412

Dopamine (DA)

 Atypical antipsychotics and pituitary tumors (guest editorial), Dec, 741

 Bupropion xl for the sustained treatment of trichotillomania (letter), April, 298

 Delayed, fatal cardiotoxicity associated with bupropion and citalopram overdose (letter), June, 431

 From disordered eating to addiction: The “food drug” in bulimia nervosa (review article), June, 376

 No significant association between genetic variants in 7 candidate genes and response to ethylphenidate treatment in adult patients with ADHD (brief report), Dec, 820

 Tetrabenazine augmentation in treatment-resistant schizophrenia: A 12-week, double-blind, placebo-controlled trial (brief report), Feb, 95

 The anticonvulsant levetiracetam potentiates alcohol consumption in non-treatment seeking alcohol abusers (brief report), April, 269

 The psychopharmacology of aggressive behavior: A translational approach (review article), Feb, 83, April, 237

Dopamine A-hydroxylase (DBH)

 Functional polymorphism of the dopamine a-hydroxylase gene is associated with increased risk of disulfiram-induced of disulfiram-induced adverse effects in alcohol-dependent patients (letter), Aug, 578

Dopamine D2 receptor

 Augmenting clozapine with sertindole: Double-blind, randomized, placebo-controlled study, April, 173

 Comment on “a multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia” by Kinon et al (letter), April, 291

 Follow-up study of a pharmacovigilance signal: No evidence of increased risk with risperidone of pituitary tumor with mass effect, Dec, 743

 Peripheral edema associated with risperidone oral solution: A case report and a review of the literature (letter), Feb, 128

Dopamine D3 receptor (DRD3)

 DRD3, but not BDNF, genotype affects treatment response to paroxetine in major depressive disorder (letter), Oct, 724

Dopamine dysregulation syndrome (DDS)

 Dopamine dysregulation syndrome including mania related to coadministration of droxidopa (letter), June, 428

Dopamine replacement therapies (DRTs)

 Finasteride attenuates pathological gambling in patients with Parkinson disease (letter), June, 424

Doxycycline

 Recurrence of panic attacks after brucellosis treatment-highly probable citalopram and rifampin drug interaction (letter), Dec, 842

Dronabinol

 Human abuse potential and cognitive effects of taranabant, a cannabinoid 1 receptor inverse agonist, Aug, 492

Drug Burden Index (DBI)

 Effects of drug burden index on cognitive function in older men (brief report), April, 273

Drug insurance

 Medicare part D’s impact on antipsychotic drug use and costs among elderly patients without prior drug insurance, Feb, 3

Drug metabolism

 Reduced methadone clearance during aromatase inhibition, Aug, 511

Drug misuse

 Suspected and confirmed fatalities associated with mephedrone (4-methylmethcathinone, “meow meow”) in the United Kingdom (brief report), Oct, 710

Drug overdose

 Cognitive impairment in patients clinically recovered from central nervous system depressant drug overdose, Aug, 503

Drug related deaths

 Suspected and confirmed fatalities associated with mephedrone (4-methylmethcathinone, “meow meow”) in the United Kingdom (brief report), Oct, 710

Drug Use Screening Inventory (DUSI)

 The anticonvulsant levetiracetam potentiates alcohol consumption in non-treatment seeking alcohol abusers (brief report), April, 269

Drug utilization

 Medicare part D’s impact on antipsychotic drug use and costs among elderly patients without prior drug insurance, Feb, 3

 Sedative load among community-dwelling people aged 75 years or older: Association with balance and mobility, April, 218

Drug-drug interaction

 Ketoconazole-associated preferential increase in dopamine D2 receptor occupancy in striatum compared to pituitary in vivo: Role for drug transporters? (brief report), Feb, 110

Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS)

 A randomized, double-blind, placebo-controlled trial of fluvoxamine in patients with schizophrenia: A preliminary study, Oct, 593

 Effects of aripiprazole and the Taq1A polymorphism in the dopamine D2 receptor gene on the clinical response and plasma monoamine metabolites level during the acute phase of schizophrenia (brief report), Feb, 106

 The sustained effects of aripiprazole-augmented clozapine treatment on the psychotic symptoms and metabolic profiles of patients with refractory schizophrenia (letter), April, 282

Drug-induced movement disorders

 Drugs associated with restless legs syndrome: A case/noncase study in the French pharmacovigilance database (brief report), Dec, 824

Drug-related long QT syndrome

 Increased risk of antipsychotic-related qt prolongation during nighttime: A 24-hour Holter electrocardiogram recording study, Feb, 18

Duloxetine

 Add-on treatment of quetiapine for fibromyalgia (brief report), Oct, 684

 Duloxetine-Associated Tardive dyskinesia resolved with fluvoxamine (letter), Oct, 723

 Serotonin-norepinephrine euptake inhibitor treatment for tinnitus and depression (letter), Oct, 729

 Treatment with duloxetine in adults and the incidence of cardiovascular events, Feb, 23

Dysgeusia

 A method to assess the dissipation of the effects of residual hypnotics (brief report), Oct, 704

Dysmenorrhea

 An exploratory, open trial of fluoxetine treatment of juvenile fibromyalgia (letter), April, 293

Dyspepsia

 Recurrence of panic attacks after brucellosis treatment-highly probable citalopram and rifampin drug interaction (letter), Dec, 842

Dysphoria

 Human abuse potential and cognitive effects of taranabant, a cannabinoid 1 receptor inverse agonist, Aug, 492

Dystonia

 Aripiprazole for the treatment of Tourette syndrome: A case series of 100 patients (brief report), Aug, 548

 Management of a risperidone-induced tardive Pisa syndrome: A case report, June, 418

E

Early switch strategy

 Early switch strategy in patients with major depressive disorder, Aug, 479

Eating disorders (EDs)

 Effectiveness of a cognitive behavioral weight management intervention in obese patients with psychotic disorders compared to patients with nonpsychotic disorders or no psychiatric disorders, Aug, 458

 Escitalopram for treatment of night eating syndrome: A 12-week, randomized, placebo-controlled trial, June, 341

 From disordered eating to addiction: The “food drug” in bulimia nervosa (review article), June, 376

 Polymorphisms in serotonergic genes and psychopathological traits in eating disorders (letter), June, 426

Efficacy

 A randomized, double-blind study of 30 versus 20 mg dexmethylphenidate extended-release in children with attention-deficit/hyperactivity disorder: Late-day symptom control, Oct, 637

 Add-on treatment of quetiapine for fibromyalgia (brief report), Oct, 684

 Does atomoxetine improve executive function, inhibitory control, and hyperactivity?: Results from a placebo-controlled trial using quantitative measurement technology, Oct, 653

 Effects of naltrexone on smoking cessation outcomes and weight gain in nicotine-dependent men and women, Oct, 630

 Multicenter study on the clinical effectiveness, pharmacokinetics, and pharmacogenetics of mirtazapine in depression, Oct, 622

 Predictors of clozapine response in patients with treatment-refractory schizophrenia (brief report), Oct, 678

Eicosapentaenoic acid (EPA)

 Effects of large doses of arachidonic acid added to docosahexaenoic acid on social impairment in individuals with autism spectrum disorders: A double-blind, placebo-controlled, randomized trial, April, 200

 Eicosapentaenoic acid interventions in schizophrenia: Meta-analysis of randomized, placebo-controlled studies, April, 179

Elderly

 Medicare part D’s impact on antipsychotic drug use and costs among elderly patients without prior drug insurance, Feb, 3

 Parkinsonism in elderly users of haloperidol (brief report), Oct, 688

Electrocardiograms (ECGs)

 A randomized, double-blind study of 30 versus 20 mg dexmethylphenidate extended-release in children with attention-deficit/hyperactivity disorder: Late-day symptom control, Oct, 637

 A randomized, double-blind, placebo-controlled trial of fluvoxamine in patients with schizophrenia: A preliminary study, Oct, 593

 Delayed, fatal cardiotoxicity associated with bupropion and citalopram overdose (letter), June, 431

 Increased risk of antipsychotic-related qt prolongation during nighttime: A 24-hour Holter electrocardiogram recording study, Feb, 18

Electrocardiography

 A case of quetiapine XR and divalproex-associated neutropenia followed by successful use of ziprasidone, June, 417

 Acute renal failure after paliperidone overdose: A case report (letter), Feb, 128

 Tranylcypromine and bupropion combination therapy in treatment-resistant major depression (letter), Aug, 572

Electroconvulsive therapy (ECT)

 Catatonia and encephalopathy associated with paliperidone palmitate (letter), April, 284

 Electroconvulsive therapy and clozapine in adolescents with schizophrenia spectrum disorders: Is it a safe and effective combination?, Dec, 756

 Short-term treatment of catatonia with amantadine in schizophrenia and schizoaffective disorder (letter), Aug, 569

 Symptomatic treatment of interferon-a-induced depression in hepatitis C: A systematic review (review article), Aug, 531

 Tranylcypromine and bupropion combination therapy in treatment-resistant major depression (letter), Aug, 572

Electroencephalographic (EEG)

 Electroconvulsive therapy and clozapine in adolescents with schizophrenia spectrum disorders: Is it a safe and effective combination?, Dec, 756

Emotions

 Modulation of central serotonin affects emotional information processing in impulsive aggressive personality disorder, June, 329

Enantiomers

 Multicenter study on the clinical effectiveness, pharmacokinetics, and pharmacogenetics of mirtazapine in depression, Oct, 622

 Pharmacokinetic-pharmacodynamic modeling of mood and withdrawal symptoms in relation to plasma concentrations of methadone in patients undergoing methadone maintenance treatment, Oct, 666

Encopresis

 Atomoxetine for encopresis in 2 children with attention-deficit/hyperactivity disorder (letter), April, 302

Endogenous opioid system

 Effects of naltrexone on smoking cessation outcomes and weight gain in nicotine-dependent men and women, Oct, 630

Enuretic symptoms

 Atomoxetine for encopresis in 2 children with attention-deficit/hyperactivity disorder (letter), April, 302

Epidemiology

 All-cause mortality and medication risk factors in schizophrenia: A prospective cohort study, Feb, 31

Epilepsy

 Behavioral adverse effects of antiepileptic drugs in epilepsy (review article), June, 362

 Pregabalin misuse-related issues; intake of large dosages, drug-smoking allegations, and possible association with myositis two case reports (letter), Dec, 839

 Successful treatment of musical hallucinations with the acetylcholinesterase inhibitor donepezil, June, 422

Epileptic seizures

 Efficacy and safety of levetiracetam for the prevention of alcohol relapse in recently detoxified alcohol-dependent patients (brief report), Aug, 558

Erratum, 185, 206, 766, 803

Escitalopram

 A randomized controlled pilot study of acamprosate added to escitalopram in adults with major depressive disorder and alcohol use disorder, Dec, 787

 Escitalopram for treatment of night eating syndrome: A 12-week, randomized, placebo-controlled trial, June, 341

 Ramelteon dose escalation in a patient with substance misuse (letter), Oct, 738

 Restoration of functionality in postpartum depressed mothers (letter), Oct, 729

 Symptomatic treatment of interferon-a-induced depression in hepatitis C: A systematic review (review article), Aug, 531

Eszopiclone

 A method to assess the dissipation of the effects of residual hypnotics (brief report), Oct, 704

Ethosuximide

 Behavioral adverse effects of antiepileptic drugs in epilepsy (review article), June, 362

Euphoria

 Human abuse potential and cognitive effects of taranabant, a cannabinoid 1 receptor inverse agonist, Aug, 492

Evaluation bias

 Case manager- and patient-rated alliance as a predictor of medication adherence in first-episode psychosis, Aug, 465

Evidence-based medicine (EBM)

 Evidence-based medicine versus personalized medicine: Are they enemies? (guest editorial), April, 153

Executive functions

 Cognitive impairment in patients clinically recovered from central nervous system depressant drug overdose, Aug, 503

 Does atomoxetine improve executive function, inhibitory control, and hyperactivity?: Results from a placebo-controlled trial using quantitative measurement technology, Oct, 653

Extended release (ER)

 Metabolic effects of paliperidone extended release versus oral olanzapine in patients with schizophrenia: A prospective, randomized, controlled trial, Aug, 449

 Predictive factors for more than 3 years’ duration of central stimulant treatment in adult attention-deficit/hyperactivity disorder: A retrospective, naturalistic study, Oct, 645

Extrapyramidal adverse effects (EPS)

 Common use of antipsychotic polypharmacy in older Asian patients with schizophrenia (2001–2009) (brief report), Dec, 809

Extrapyramidal symptoms (EPS)

 A naturalistic study of intramuscular haloperidol versus intramuscular olanzapine for the management of acute agitation, June, 317

 Cognitive effects of a single dose of atypical antipsychotics in healthy volunteers compared with placebo or haloperidol, Dec, 778

 Effectiveness and cost of atypical versus typical antipsychotic treatment in a nationwide cohort of patients with schizophrenia in Germany, Oct, 602

 Identifying potential adverse effects by patients’ ratings: A proof-of-concept study of a novel approach (brief report), Dec, 828

 Peripheral edema associated with risperidone oral solution: A case report and a review of the literature (letter), Feb, 128

Extrapyramidal syndrome (EPS)

 Adverse effects of second-generation antipsychotics in children and adolescents: A Bayesian meta-analysis, June, 309

 Hypomania associated with adjunctive aripiprazole in an elder female with recurrent major depressive disorder: Dose-related phenomenon? (letter), Dec, 836

F

Fagerström Test

 Effects of naltrexone on smoking cessation outcomes and weight gain in nicotine-dependent men and women, Oct, 630

Fasting glucose

 Dysregulation of adipocytokines related to second-generation antipsychotics in normal fasting glucose patients with schizophrenia (brief report), June, 390

 Excessive insulin secretion in Japanese schizophrenic patients treated with antipsychotics despite normal fasting glucose levels, Dec, 750

 The relationship between serum uric acid concentration and metabolic syndrome in patients with schizophrenia or schizoaffective disorder, Oct, 585

Fexofenadine

 Different effects of the selective serotonin reuptake inhibitors fluvoxamine, paroxetine, and sertraline on the pharmacokinetics of fexofenadine in healthy volunteers, April, 195

 Ketoconazole-associated preferential increase in dopamine D2 receptor occupancy in striatum compared to pituitary in vivo: Role for drug transporters? (brief report), Feb, 110

Fibromyalgia (FM)

 Add-on treatment of quetiapine for fibromyalgia (brief report), Oct, 684

 An exploratory, open trial of fluoxetine treatment of juvenile fibromyalgia (letter), April, 293

Fibromyalgia Impact Questionnaire (FIQ)

 Add-on treatment of quetiapine for fibromyalgia (brief report), Oct, 684

Finasteride (FIN)

 Finasteride attenuates pathological gambling in patients with Parkinson disease (letter), June, 424

First-episode psychosis (FEP)

 Case manager- and patient-rated alliance as a predictor of medication adherence in first-episode psychosis, Aug, 465

First-episode schizophrenia (FES)

 Akathisia and suicidal ideation in first-episode schizophrenia (brief report), Oct, 694

Floppy infant syndrome

 Neonatal complications after maternal concomitant use of SSRI and other central nervous system active drugs during the second or third trimester of pregnancy, Oct, 608

Fluoxetine

 An exploratory, open trial of fluoxetine treatment of juvenile fibromyalgia (letter), April, 293

 Antidepressant agents and suicide death among US department of veterans affairs patients in depression treatment, June, 346

 High venlafaxine serum levels after prior fluoxetine medication (letter), April, 295

 Symptomatic treatment of interferon-a-induced depression in hepatitis C: A systematic review (review article), Aug, 531

 The declining use of reboxetine in years 2000 to 2006: A pharmacoepidemiological comparative study (letter), April, 303

Fluphenazine

 Acute laryngeal dystonia associated with aripiprazole (letter), Dec, 837

 Prevalence of concomitant oral antipsychotic drug use among patients treated with long-acting, intramuscular, antipsychotic medications, June, 323

Fluvoxamine

 A randomized, double-blind, placebo-controlled trial of fluvoxamine in patients with schizophrenia: A preliminary study, Oct, 593

 Different effects of the selective serotonin reuptake inhibitors fluvoxamine, paroxetine, and sertraline on the pharmacokinetics of fexofenadine in healthy volunteers, April, 195

 Duloxetine-Associated Tardive dyskinesia resolved with fluvoxamine (letter), Oct, 723

Fluvoxamine add-on therapy

 A randomized, double-blind, placebo-controlled trial of fluvoxamine in patients with schizophrenia: A preliminary study, Oct, 593

Focal brain lesions

 Successful treatment of musical hallucinations with the acetylcholinesterase inhibitor donepezil, June, 422

Folate

 Risk factors associated with metabolic syndrome in bipolar and schizophrenia subjects treated with antipsychotics: The role of folate pharmacogenetics (brief report), April, 261

French Pharmacovigilance Database (FPVD)

 Drugs associated with restless legs syndrome: A case/noncase study in the French pharmacovigilance database (brief report), Dec, 824

Functional magnetic resonance imaging (fMRI)

 The impact of acamprosate on cue reactivity in alcohol dependent individuals: A functional magnetic resonance imaging study, Oct, 661

G

γ-glutamyltransferase (GGT)

 Add-on treatment of quetiapine for fibromyalgia (brief report), Oct, 684

GABA

 The psychopharmacology of aggressive behavior: A translational approach (review article), Feb, 83

Gabapentin

 Behavioral adverse effects of antiepileptic drugs in epilepsy (review article), June, 362

Galactorrhea

 Long-term effect of haloperidol, olanzapine, and risperidone on plasma prolactin levels in patients with first-episode psychosis (brief report), Dec, 804

Galantamine

 Do local meteorological conditions influence skin irritation caused by transdermal rivastigmine? A retroprospective, pilot study (brief report), June, 412

Gallstone

 Selective serotonin reuptake inhibitors and the risk of acute pancreatitis: A Swedish population-based case-control study, June, 336

Gamma-aminobutyric acid

 Pregabalin misuse-related issues; intake of large dosages, drug-smoking allegations, and possible association with myositis two case reports (letter), Dec, 839

Gastrointestinal disturbances

 Suspected and confirmed fatalities associated with mephedrone (4-methylmethcathinone, “meow meow”) in the United Kingdom (brief report), Oct, 710

Gastrointestinal hemorrhage

 Antidepressant use and the risk of upper gastrointestinal bleeding in psychiatric patients, Aug, 518

General linear model (GLM)

 N-acetylcysteine add-on treatment in refractory obsessive-compulsive disorder: A randomized, double-blind, placebo-controlled trial, Dec, 797

Generalized anxiety disorder (GAD)

 Restoration of functionality in postpartum depressed mothers (letter), Oct, 729

Genes

 Association study of 27 annotated genes for clozapine pharmacogenetics: Validation of preexisting studies and identification of a new candidate gene, ABCB1, for treatment response, Aug, 441

Genetic testing

 Evidence-based medicine versus personalized medicine: Are they enemies? (guest editorial), April, 153

Genetics

 The anticonvulsant levetiracetam potentiates alcohol consumption in non-treatment seeking alcohol abusers (brief report), April, 269

Geriatric depression scale (GDS)

 Effects of drug burden index on cognitive function in older men (brief report), April, 273

 Sedative load among community-dwelling people aged 75 years or older: Association with balance and mobility, April, 218

 Treatment of late-life major depressive disorder with selective serotonin reuptake inhibitors improves the multidimensional prognostic index (letter), Oct, 726

Germany

 Effectiveness and cost of atypical versus typical antipsychotic treatment in a nationwide cohort of patients with schizophrenia in Germany, Oct, 602

GI hemorrhage

 Antidepressant use and the risk of upper gastrointestinal bleeding in psychiatric patients, Aug, 518

Gilles de la Tourette disorder

 A randomized, double-blind study of 30 versus 20 mg dexmethylphenidate extended-release in children with attention-deficit/hyperactivity disorder: Late-day symptom control, Oct, 637

Global Assessment of Functioning (GAF) scores

 Enhanced ziprasidone combination therapy effectiveness in obese compared to nonobese patients with bipolar disorder, Dec, 814

Global Assessment of Functioning scale

 Tetrabenazine augmentation in treatment-resistant schizophrenia: A 12-week, double-blind, placebo-controlled trial (brief report), Feb, 95

Global Clinical Judgments (Consensus) Scale (GCJCS)

 The psychopharmacology of aggressive behavior: A translational approach (review article), April, 237

Glucose tolerance

 Excessive insulin secretion in Japanese schizophrenic patients treated with antipsychotics despite normal fasting glucose levels, Dec, 750

Glutamate

 Comment on “a multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia” by Kinon et al (letter), April, 291

 High-dose baclofen for treatment-resistant alcohol dependence (brief report), April, 266

 Randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder (brief report), Aug, 551

 The psychopharmacology of aggressive behavior: A translational approach (review article), Feb, 83, April, 237

Gray matter (GM)

 Caudate gray matter volume in obsessive-compulsive disorder is influenced by adverse childhood experiences and ongoing drug treatment (brief report), Aug, 544

Grimby Scale

 Sedative load among community-dwelling people aged 75 years or older: Association with balance and mobility, April, 218

Gynecomastia

 Long-term effect of haloperidol, olanzapine, and risperidone on plasma prolactin levels in patients with first-episode psychosis (brief report), Dec, 804

H

Haloperidol (HPD)

 A naturalistic study of intramuscular haloperidol versus intramuscular olanzapine for the management of acute agitation, June, 317

 Acute laryngeal dystonia associated with aripiprazole (letter), Dec, 837

 Akathisia and suicidal ideation in first-episode schizophrenia (brief report), Oct, 694

 Association study of 27 annotated genes for clozapine pharmacogenetics: Validation of preexisting studies and identification of a new candidate gene, ABCB1, for treatment response, Aug, 441

 Cognitive effects of a single dose of atypical antipsychotics in healthy volunteers compared with placebo or haloperidol, Dec, 778

 Electroconvulsive therapy and clozapine in adolescents with schizophrenia spectrum disorders: Is it a safe and effective combination?, Dec, 756

 Long-term effect of haloperidol, olanzapine, and risperidone on plasma prolactin levels in patients with first-episode psychosis (brief report), Dec, 804

 Metabolic effects of paliperidone extended release versus oral olanzapine in patients with schizophrenia: A prospective, randomized, controlled trial, Aug, 449

 Parkinsonism in elderly users of haloperidol (brief report), Oct, 688

 Tardive laryngeal dystonia associated with aripiprazole monotherapy (letter), April, 297

HAM-D17. See 17-item Hamilton Depression Rating Scale (HAM-D17)

Hamilton Anxiety Rating Scale (HARS)

 Add-on treatment of quetiapine for fibromyalgia (brief report), Oct, 684

 Agomelatine versus venlafaxine XR in the treatment of anhedonia in major depressive disorder, Aug, 487

Hamilton Anxiety Scale (HAM-A)

 A randomized, naturalistic, parallel-group study for the long-term treatment of panic disorder with clonazepam or paroxetine (brief report), Feb, 120

 Asenapine as adjunctive treatment for acute mania associated with bipolar disorder: Results of a 12-week core study and 40-week extension, Feb, 46

17-item Hamilton Depression Rating Scale (HAM-D-17)

 A randomized controlled pilot study of acamprosate added to escitalopram in adults with major depressive disorder and alcohol use disorder, Dec, 787

 Add-on treatment of quetiapine for fibromyalgia (brief report), Oct, 684

 Agomelatine versus venlafaxine XR in the treatment of anhedonia in major depressive disorder, Aug, 487

 Akathisia and suicidal ideation in first-episode schizophrenia (brief report), Oct, 694

 Combination of antidepressants in the treatment of major depressive disorder: A systematic review and meta-analysis (brief report), April, 278

 Comparison of academic and nonacademic sites in multi-center clinical trials, Feb, 65

 Early switch strategy in patients with major depressive disorder, Aug, 479

 Enhanced ziprasidone combination therapy effectiveness in obese compared to nonobese patients with bipolar disorder, Dec, 814

 Multicenter study on the clinical effectiveness, pharmacokinetics, and pharmacogenetics of mirtazapine in depression, Oct, 622

 Omega-3 fatty acid augmentation of citalopram treatment for patients with major depressive disorder, Feb, 61

 Randomized trials published in Chinese or Western journals: Comparative empirical analysis, June, 354

 Randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder (brief report), Aug, 551

 Symptomatic treatment of interferon-a-induced depression in hepatitis C: A systematic review (review article), Aug, 531

 The effectiveness and safety of adjunctive aripiprazole in Taiwanese patients with antidepressant-refractory major depressive disorder: A prospective, open-label trial, Feb, 56

 Treating depression after initial treatment failure: Directly comparing switch and augmenting strategies in STAR*D (brief report), Feb, 114

 Treatment of late-life major depressive disorder with selective serotonin reuptake inhibitors improves the multidimensional prognostic index (letter), Oct, 726

 Treatment with mirtazapine and venlafaxine increases noradrenaline excretion in depressed patients (letter), Aug, 574

 Two 6-week, randomized, double-blind, placebo-controlled studies of ziprasidone in outpatients with bipolar I depression, Aug, 470

Handedness

 Caudate gray matter volume in obsessive-compulsive disorder is influenced by adverse childhood experiences and ongoing drug treatment (brief report), Aug, 544

Hazard ratios (HRs)

 Antidepressant use and the risk of upper gastrointestinal bleeding in psychiatric patients, Aug, 518

 Follow-up study of a pharmacovigilance signal: No evidence of increased risk with risperidone of pituitary tumor with mass effect, Dec, 743

Head trauma

 Status epilepticus associated with the administration of long-acting methylphenidate in a 7-year-old girl (letter), April, 300

Headache

 An exploratory, open trial of fluoxetine treatment of juvenile fibromyalgia (letter), April, 293

Healthy subjects

 Adverse events in healthy subjects exposed to single and multiple doses of LY2140023 monohydrate: pooled results from 10 phase 1 studies, June, 408

Hebephrenic (disorganized) schizophrenia

 Predictors of clozapine response in patients with treatment-refractory schizophrenia (brief report), Oct, 678

Hematological toxicity

 Valproic acid treatment is associated with altered leukocyte subset development (brief report), Dec, 832

Hepatitis C virus (HCV)

 Symptomatic treatment of interferon-a-induced depression in hepatitis C: A systematic review (review article), Aug, 531

Heterogeneity

 Eicosapentaenoic acid interventions in schizophrenia: Meta-analysis of randomized, placebo-controlled studies, April, 179

 Evidence-based medicine versus personalized medicine: Are they enemies? (guest editorial), April, 153

High-density lipoprotein (HDL)

 Add-on treatment of quetiapine for fibromyalgia (brief report), Oct, 684

 Excessive insulin secretion in Japanese schizophrenic patients treated with antipsychotics despite normal fasting glucose levels, Dec, 750

 Metabolic effects of paliperidone extended release versus oral olanzapine in patients with schizophrenia: A prospective, randomized, controlled trial, Aug, 449

 The sustained effects of aripiprazole-augmented clozapine treatment on the psychotic symptoms and metabolic profiles of patients with refractory schizophrenia (letter), April, 282

 The relationship between serum uric acid concentration and metabolic syndrome in patients with schizophrenia or schizoaffective disorder, Oct, 585

High-performance liquid chromatography (HPLC)

 Reduced methadone clearance during aromatase inhibition, Aug, 511

Hillside Akathisia Scale (HAS)

 Akathisia and suicidal ideation in first-episode schizophrenia (brief report), Oct, 694

Hirsutism

 Long-term effect of haloperidol, olanzapine, and risperidone on plasma prolactin levels in patients with first-episode psychosis (brief report), Dec, 804

Histone deacetylase inhibitor (HDACI)

 Valproic acid treatment is associated with altered leukocyte subset development (brief report), Dec, 832

Homeostasis model assessment of insulin resistance (HOMA-IR)

 Excessive insulin secretion in Japanese schizophrenic patients treated with antipsychotics despite normal fasting glucose levels, Dec, 750

 Metabolic effects of paliperidone extended release versus oral olanzapine in patients with schizophrenia: A prospective, randomized, controlled trial, Aug, 449

Homovanillic acid (HVA)

 Effects of aripiprazole and the Taq1A polymorphism in the dopamine D2 receptor gene on the clinical response and plasma monoamine metabolites level during the acute phase of schizophrenia (brief report), Feb, 106

24-hour Holter ECG recording

 Increased risk of antipsychotic-related qt prolongation during nighttime: A 24-hour Holter electrocardiogram recording study, Feb, 18

5-HT transporter

 The case for basic research on the psychopharmacology of aggression (guest editorial), Feb, 1

 The psychopharmacology of aggressive behavior: A translational approach (review article), Feb, 83

5HT-2

 A case of quetiapine XR and divalproex-associated neutropenia followed by successful use of ziprasidone, June, 417

HTR1B

 No significant association between genetic variants in 7 candidate genes and response to ethylphenidate treatment in adult patients with ADHD (brief report), Dec, 820

HTR2C

 Association between HTR2C polymorphisms and obessity in patients without antipsychotic drugs (letter), Oct, 715

Human placenta

 Reduced methadone clearance during aromatase inhibition, Aug, 511

5-hydroxytryptamine (5-HT)1A receptors

 Cognitive effects of a single dose of atypical antipsychotics in healthy volunteers compared with placebo or haloperidol, Dec, 778

 The sustained effects of aripiprazole-augmented clozapine treatment on the psychotic symptoms and metabolic profiles of patients with refractory schizophrenia (letter), April, 282

Hyperactivity

 Does atomoxetine improve executive function, inhibitory control, and hyperactivity?: Results from a placebo-controlled trial using quantitative measurement technology, Oct, 653

Hyperactivity disorder (ADHD)

 A case of severe hyperthermia after administration of methylphenidate (letter), April, 299

 No significant association between genetic variants in 7 candidate genes and response to ethylphenidate treatment in adult patients with ADHD (brief report), Dec, 820

 Sapophagia (compulsive soap eating) and attention-deficit/ hyperactivity disorder in a child responsive to clonidine (letter), April, 291

Hyperhomocysteinemia

 Risk factors associated with metabolic syndrome in bipolar and schizophrenia subjects treated with antipsychotics: The role of folate pharmacogenetics (brief report), April, 261

Hyperkinesias

 Peripheral edema associated with risperidone oral solution: A case report and a review of the literature (letter), Feb, 128

Hyperlipidemia

 Excessive insulin secretion in Japanese schizophrenic patients treated with antipsychotics despite normal fasting glucose levels, Dec, 750

Hyperosmolar hyperglycemic syndrome (HHS)

 Olanzapine-related life-threatening hyperosmolar hyperglycemic syndrome: A case report (letter), Feb, 130

Hyperprolactinemia

 Atypical antipsychotics and pituitary tumors (guest editorial), Dec, 741

Hypertension

 Effectiveness of a cognitive behavioral weight management intervention in obese patients with psychotic disorders compared to patients with nonpsychotic disorders or no psychiatric disorders, Aug, 458

 The relationship between serum uric acid concentration and metabolic syndrome in patients with schizophrenia or schizoaffective disorder, Oct, 585

Hyperthermia

 A case of severe hyperthermia after administration of methylphenidate (letter), April, 299

Hyperuricemia

 The relationship between serum uric acid concentration and metabolic syndrome in patients with schizophrenia or schizoaffective disorder, Oct, 585

Hypnotics

 A method to assess the dissipation of the effects of residual hypnotics (brief report), Oct, 704

 Multicenter study on the clinical effectiveness, pharmacokinetics, and pharmacogenetics of mirtazapine in depression, Oct, 622

 Sedative load among community-dwelling people aged 75 years or older: Association with balance and mobility, April, 218

Hypoglycemia

 Neonatal complications after maternal concomitant use of SSRI and other central nervous system active drugs during the second or third trimester of pregnancy, Oct, 608

Hyponatremia

 Impact of hyponatremia on resource utilization in state psychiatric hospitals (letter), Aug, 580

 Psychotropic medication use hyponatremia and falls (letter), Aug, 582

Hypopituitarism

 Atypical antipsychotics and pituitary tumors (guest editorial), Dec, 741

Hypothalamic-pituitary-adrenocortical axis

 Olanzapine-related life-threatening hyperosmolar hyperglycemic syndrome: A case report (letter), Feb, 130

I

IM second-generation antipsychotics (IM SGAs)

 A naturalistic study of intramuscular haloperidol versus intramuscular olanzapine for the management of acute agitation, June, 317

Imipramine

 A randomized controlled pilot study of acamprosate added to escitalopram in adults with major depressive disorder and alcohol use disorder, Dec, 787

 Atomoxetine for encopresis in 2 children with attention-deficit/hyperactivity disorder (letter), April, 302

Immunotherapy

 Symptomatic treatment of interferon-a-induced depression in hepatitis C: A systematic review (review article), Aug, 531

Impaired fasting glucose (IFG)

 Dysregulation of adipocytokines related to second-generation antipsychotics in normal fasting glucose patients with schizophrenia (brief report), June, 390

 Excessive insulin secretion in Japanese schizophrenic patients treated with antipsychotics despite normal fasting glucose levels, Dec, 750

Impotence

 Long-term effect of haloperidol, olanzapine, and risperidone on plasma prolactin levels in patients with first-episode psychosis (brief report), Dec, 804

Impulse-control disorders (ICDs)

 Finasteride attenuates pathological gambling in patients with Parkinson disease (letter), June, 424

Impulsivity

 Does atomoxetine improve executive function, inhibitory control, and hyperactivity?: Results from a placebo-controlled trial using quantitative measurement technology, Oct, 653

 Open-label treatment with olanzapine for patients with borderline personality disorder (brief report), June, 398

Inattention

 Does atomoxetine improve executive function, inhibitory control, and hyperactivity?: Results from a placebo-controlled trial using quantitative measurement technology, Oct, 653

Incidence rate ratio (IRR)

 Treatment with duloxetine in adults and the incidence of cardiovascular events, Feb, 23

Infants

 Neonatal complications after maternal concomitant use of SSRI and other central nervous system active drugs during the second or third trimester of pregnancy, Oct, 608

Infertility

 Long-term effect of haloperidol, olanzapine, and risperidone on plasma prolactin levels in patients with first-episode psychosis (brief report), Dec, 804

Information bias

 Parkinsonism in elderly users of haloperidol (brief report), Oct, 688

Inhibitory control

 Does atomoxetine improve executive function, inhibitory control, and hyperactivity?: Results from a placebo-controlled trial using quantitative measurement technology, Oct, 653

Insomnia

 A method to assess the dissipation of the effects of residual hypnotics (brief report), Oct, 704

Instrumental activities of daily living (IADL) scale

 Treatment of late-life major depressive disorder with selective serotonin reuptake inhibitors improves the multidimensional prognostic index (letter), Oct, 726

Insulin resistance (IR)

 Metabolic effects of paliperidone extended release versus oral olanzapine in patients with schizophrenia: A prospective, randomized, controlled trial, Aug, 449

 Olanzapine-related life-threatening hyperosmolar hyperglycemic syndrome: A case report (letter), Feb, 130

Insulin secretion

 Excessive insulin secretion in Japanese schizophrenic patients treated with antipsychotics despite normal fasting glucose levels, Dec, 750

Interactive voice response (IVR)

 Two 6-week, randomized, double-blind, placebo-controlled studies of ziprasidone in outpatients with bipolar I depression, Aug, 470

Interferon-a (IFN- a)

 Symptomatic treatment of interferon-a-induced depression in hepatitis C: A systematic review (review article), Aug, 531

International Suicide Prevention Trial Scale for Suicidal Thinking (ISST)

 Asenapine as adjunctive treatment for acute mania associated with bipolar disorder: Results of a 12-week core study and 40-week extension, Feb, 46

Intramuscular (IM) regimens

 A naturalistic study of intramuscular haloperidol versus intramuscular olanzapine for the management of acute agitation, June, 317

Intrauterine growth

 Neonatal outcomes after late-gestation exposure to selective serotonin reuptake inhibitors, Oct, 615

Intraventricular hemorrhage

 Neonatal complications after maternal concomitant use of SSRI and other central nervous system active drugs during the second or third trimester of pregnancy, Oct, 608

Irritable bowel syndrome

 An exploratory, open trial of fluoxetine treatment of juvenile fibromyalgia (letter), April, 293

Ischemic heart disease (IHD)

 Treatment with duloxetine in adults and the incidence of cardiovascular events, Feb, 23

Ischemic stroke

 Normobaric hyperoxia treatment of schizophrenia, Aug, 525

J

Juvenile fibromyalgia (JFM)

 An exploratory, open trial of fluoxetine treatment of juvenile fibromyalgia (letter), April, 293

K

Ketoconazole

 Ketoconazole-associated preferential increase in dopamine D2 receptor occupancy in striatum compared to pituitary in vivo: Role for drug transporters? (brief report), Feb, 110

Kreek-McHugh-Schluger-Kellogg (KMSK) scale

 The anticonvulsant levetiracetam potentiates alcohol consumption in non-treatment seeking alcohol abusers (brief report), April, 269

Kruskal-Wallis test

 Omega-3 fatty acid treatment, with or without cytidine, fails to show therapeutic properties in bipolar disorder (brief report), Oct, 699

L

L-Threo-dihydroxyphenylserine

 Dopamine dysregulation syndrome including mania related to coadministration of droxidopa (letter), June, 428

Lamotrigine

 Behavioral adverse effects of antiepileptic drugs in epilepsy (review article), June, 362

Laryngeal dystonia

 Acute laryngeal dystonia associated with aripiprazole (letter), Dec, 837

Laser iridotomy (LI)

 Short-term exposure to antidepressant drugs and risk of acute angle-closure glaucoma among older adults (brief report), June, 403

Late-day control

 A randomized, double-blind study of 30 versus 20 mg dexmethylphenidate extended-release in children with attention-deficit/hyperactivity disorder: Late-day symptom control, Oct, 637

Late-gestation

 Neonatal outcomes after late-gestation exposure to selective serotonin reuptake inhibitors, Oct, 615

Late-life depression (LLD)

 Treatment of late-life major depressive disorder with selective serotonin reuptake inhibitors improves the multidimensional prognostic index (letter), Oct, 726

Leptin

 Dysregulation of adipocytokines related to second-generation antipsychotics in normal fasting glucose patients with schizophrenia (brief report), June, 390

 Trajectories of agouti-related protein and leptin levels during antipsychotic-associated weight gain in patients with schizophrenia, Dec, 767

Letrozole

 Reduced methadone clearance during aromatase inhibition, Aug, 511

Levetiracetam

 Behavioral adverse effects of antiepileptic drugs in epilepsy (review article), June, 362

 Efficacy and safety of levetiracetam for the prevention of alcohol relapse in recently detoxified alcohol-dependent patients (brief report), Aug, 558

 The anticonvulsant levetiracetam potentiates alcohol consumption in non-treatment seeking alcohol abusers (brief report), April, 269

Likert scale

 Satisfaction with methadone as a medication: Psychometric properties of the Spanish version of the treatment satisfaction questionnaire for medication, Feb, 69

 Treating depression after initial treatment failure: Directly comparing switch and augmenting strategies in STAR*D (brief report), Feb, 114

Lipid peroxidation

 The relationship between serum uric acid concentration and metabolic syndrome in patients with schizophrenia or schizoaffective disorder, Oct, 585

Lithium

 Asenapine as adjunctive treatment for acute mania associated with bipolar disorder: Results of a 12-week core study and 40-week extension, Feb, 46

 Bupropion xl for the sustained treatment of trichotillomania (letter), April, 298

 Enhanced ziprasidone combination therapy effectiveness in obese compared to nonobese patients with bipolar disorder, Dec, 814

 Olanzapine-related life-threatening hyperosmolar hyperglycemic syndrome: A case report (letter), Feb, 130

 Purinergic system in the treatment of bipolar disorder (letter), Oct, 735

 The psychopharmacology of aggressive behavior: A translational approach (review article), April, 237

Lithium carbonate

 Neutropenia associated with the comedication of quetiapine and valproate in 2 elderly patients (letter), June, 416

Lofexidine

 Actigraphic measurements in opioid detoxification with methadone or buprenorphine, Feb, 75

Long-acting injectable (LAI)

 Prevalence of concomitant oral antipsychotic drug use among patients treated with long-acting, intramuscular, antipsychotic medications, June, 323

Lorazepam

 Short-term treatment of catatonia with amantadine in schizophrenia and schizoaffective disorder (letter), Aug, 569

Low birth weight

 Neonatal outcomes after late-gestation exposure to selective serotonin reuptake inhibitors, Oct, 615

 Pregnancy outcome after exposure to antidepressants and the role of maternal depression: results from the Norwegian mother and child cohort study, April, 186

Low self-esteem

 From disordered eating to addiction: The “food drug” in bulimia nervosa (review article), June, 376

Low-density lipoprotein (LDL)

 Excessive insulin secretion in Japanese schizophrenic patients treated with antipsychotics despite normal fasting glucose levels, Dec, 750

 The sustained effects of aripiprazole-augmented clozapine treatment on the psychotic symptoms and metabolic profiles of patients with refractory schizophrenia (letter), April, 282

Lozapine

 Low-dose clozapine exacerbates and then improves mood in a patient with schizophrenia and history of surgical removal of an intraventricular meningioma (letter), Dec, 835

Luteolin

 Unwanted interactions among psychotropic drugs and other treatments for autism spectrum disorders (guest editorial), Aug, 437

LY2140023 monohydrate

 Adverse events in healthy subjects exposed to single and multiple doses of LY2140023 monohydrate: pooled results from 10 phase 1 studies, June, 408

 Comment on “a multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia” by Kinon et al (letter), April, 291

 Reply to Dr seeman’s comments on “a multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia” (letter), April, 292

Lysergic acid diethylamide (LSD)

 Human abuse potential and cognitive effects of taranabant, a cannabinoid 1 receptor inverse agonist, Aug, 492

M

m-opioid receptors

 Effects of naltrexone on smoking cessation outcomes and weight gain in nicotine-dependent men and women, Oct, 630

 Pharmacokinetic-pharmacodynamic modeling of mood and withdrawal symptoms in relation to plasma concentrations of methadone in patients undergoing methadone maintenance treatment, Oct, 666

MADRS.SeeMontgomery-Åsberg Depression Rating Scale (MADRS)

Magnetic resonance imaging (MRI)

 Atypical antipsychotics and pituitary tumors (guest editorial), Dec, 741

 Caudate gray matter volume in obsessive-compulsive disorder is influenced by adverse childhood experiences and ongoing drug treatment (brief report), Aug, 544

Maintenance treatment (MMT)

 Satisfaction with methadone as a medication: Psychometric properties of the Spanish version of the treatment satisfaction questionnaire for medication, Feb, 69

Major depressive disorder (MDD)

 A randomized controlled pilot study of acamprosate added to escitalopram in adults with major depressive disorder and alcohol use disorder, Dec, 787

 Agomelatine versus venlafaxine XR in the treatment of anhedonia in major depressive disorder, Aug, 487

 An exploratory, open trial of fluoxetine treatment of juvenile fibromyalgia (letter), April, 293

 Combination of antidepressants in the treatment of major depressive disorder: A systematic review and meta-analysis (brief report), April, 278

 DRD3, but not BDNF, genotype affects treatment response to paroxetine in major depressive disorder (letter), Oct, 724

 Duloxetine-Associated Tardive dyskinesia resolved with fluvoxamine (letter), Oct, 723

 Early switch strategy in patients with major depressive disorder, Aug, 479

 Omega-3 fatty acid augmentation of citalopram treatment for patients with major depressive disorder, Feb, 61

 Randomized trials published in Chinese or Western journals: Comparative empirical analysis, June, 354

 Randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder (brief report), Aug, 551

 Restoration of functionality in postpartum depressed mothers (letter), Oct, 729

 The effectiveness and safety of adjunctive aripiprazole in Taiwanese patients with antidepressant-refractory major depressive disorder: A prospective, open-label trial, Feb, 56

 Treating depression after initial treatment failure: Directly comparing switch and augmenting strategies in STAR*D (brief report), Feb, 114

 Treatment of late-life major depressive disorder with selective serotonin reuptake inhibitors improves the multidimensional prognostic index (letter), Oct, 726

Mania

 Asenapine as adjunctive treatment for acute mania associated with bipolar disorder: Results of a 12-week core study and 40-week extension, Feb, 46

 Omega-3 fatty acid treatment, with or without cytidine, fails to show therapeutic properties in bipolar disorder (brief report), Oct, 699

MAOA promoter gene

 Different impacts of aquaporin 4 and MAOA allele variation among olanzapine, risperidone, and paliperidone in schizophrenia (brief report), June, 394

Marginal structural models (MSM)

 Antidepressant agents and suicide death among US department of veterans affairs patients in depression treatment, June, 346

Medial prefrontal cortex (MPFC)

 From disordered eating to addiction: The “food drug” in bulimia nervosa (review article), June, 376

Medical Birth Register (MBR)

 Neonatal complications after maternal concomitant use of SSRI and other central nervous system active drugs during the second or third trimester of pregnancy, Oct, 608

Medicare part D

 Medicare part D’s impact on antipsychotic drug use and costs among elderly patients without prior drug insurance, Feb, 3

Medication pattern

 Does the medication pattern reflect the CYP2D6 genotype in patients with diagnoses within the schizophrenic spectrum?, Feb, 100

Melancholia Scale

 Combination of antidepressants in the treatment of major depressive disorder: A systematic review and meta-analysis (brief report), April, 278

Melatonin

 A case of obsessive-compulsive disorder successfully treated with agomelatine monotherapy (letter), April, 289

 Ramelteon dose escalation in a patient with substance misuse (letter), Oct, 738

Memantine

 A randomized controlled pilot study of acamprosate added to escitalopram in adults with major depressive disorder and alcohol use disorder, Dec, 787

Membrane transporters

 Ketoconazole-associated preferential increase in dopamine D2 receptor occupancy in striatum compared to pituitary in vivo: Role for drug transporters? (brief report), Feb, 110

Meow meow

 Suspected and confirmed fatalities associated with mephedrone (4-methylmethcathinone, “meow meow”) in the United Kingdom (brief report), Oct, 710

Mephedrone

 Suspected and confirmed fatalities associated with mephedrone (4-methylmethcathinone, “meow meow”) in the United Kingdom (brief report), Oct, 710

Mephenesin

 Mephenesin dependence (letter), Oct, 736

Mesterolone

 Mania related to mesterolone in a previously mentally healthy person (letter), Oct, 734

Meta-analysis

 Adverse effects of second-generation antipsychotics in children and adolescents: A Bayesian meta-analysis, June, 309

 Randomized trials published in Chinese or Western journals: Comparative empirical analysis, June, 354

Metabolic syndrome

 Impact of switching or initiating antipsychotic treatment on body weight during a 6-month follow-up in a cohort of patients with schizophrenia (brief report), Oct, 672

 Risk factors associated with metabolic syndrome in bipolar and schizophrenia subjects treated with antipsychotics: The role of folate pharmacogenetics (brief report), April, 261

 The relationship between serum uric acid concentration and metabolic syndrome in patients with schizophrenia or schizoaffective disorder, Oct, 585

Methadone

 Actigraphic measurements in opioid detoxification with methadone or buprenorphine, Feb, 75

 Pharmacokinetic-pharmacodynamic modeling of mood and withdrawal symptoms in relation to plasma concentrations of methadone in patients undergoing methadone maintenance treatment, Oct, 666

 Reduced methadone clearance during aromatase inhibition, Aug, 511

 Satisfaction with methadone as a medication: Psychometric properties of the Spanish version of the treatment satisfaction questionnaire for medication, Feb, 69

Methadone maintenance program

 Characteristics of quetiapine misuse among clients of a community-based methadone maintenance program (letter), Oct, 721

 Pharmacokinetic-pharmacodynamic modeling of mood and withdrawal symptoms in relation to plasma concentrations of methadone in patients undergoing methadone maintenance treatment, Oct, 666

 Satisfaction with methadone as a medication: Psychometric properties of the Spanish version of the treatment satisfaction questionnaire for medication, Feb, 69

3,4-methylenedioxymethamphetamine (MDMA)

 A case of severe hyperthermia after administration of methylphenidate (letter), April, 299

Methylphenidate (MPH)

 No significant association between genetic variants in 7 candidate genes and response to ethylphenidate treatment in adult patients with ADHD (brief report), Dec, 820

 Olanzapine-related life-threatening hyperosmolar hyperglycemic syndrome: A case report (letter), Feb, 130

 Predictive factors for more than 3 years’ duration of central stimulant treatment in adult attention-deficit/hyperactivity disorder: A retrospective, naturalistic study, Oct, 645

 Status epilepticus associated with the administration of long-acting methylphenidate in a 7-year-old girl (letter), April, 300

Mianserin

 Mianserin for the treatment of sleep disorders in patients with dementia (letter), Aug, 576

 Olanzapine-related life-threatening hyperosmolar hyperglycemic syndrome: A case report (letter), Feb, 130

Microdialysis

 Dopamine dysregulation syndrome including mania related to coadministration of droxidopa (letter), June, 428

Migraine

 An exploratory, open trial of fluoxetine treatment of juvenile fibromyalgia (letter), April, 293

Mild cognitive impairment (MCI)

 Effects of drug burden index on cognitive function in older men (brief report), April, 273

Milnacipran

 Add-on treatment of quetiapine for fibromyalgia (brief report), Oct, 684

Mirror-image predictor model

 Predictors of clozapine response in patients with treatment-refractory schizophrenia (brief report), Oct, 678

Mirtazapine (MIR)

 A case of quetiapine XR and divalproex-associated neutropenia followed by successful use of ziprasidone, June, 417

 Antidepressant agents and suicide death among US department of veterans affairs patients in depression treatment, June, 346

 Mianserin for the treatment of sleep disorders in patients with dementia (letter), Aug, 576

 Multicenter study on the clinical effectiveness, pharmacokinetics, and pharmacogenetics of mirtazapine in depression, Oct, 622

 Reversal of SSRI-associated urinary retention with mirtazapine augmentation (letter), June, 434

 Symptomatic treatment of interferon-a-induced depression in hepatitis C: A systematic review (review article), Aug, 531

 Treatment with mirtazapine and venlafaxine increases noradrenaline excretion in depressed patients (letter), Aug, 574

Mixed model repeated-measures (MMRM)

 Dyskinesia symptoms during treatment with olanzapine or haloperidol (letter), June, 420

 Two 6-week, randomized, double-blind, placebo-controlled studies of ziprasidone in outpatients with bipolar I depression, Aug, 470

MK-0657

 Randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder (brief report), Aug, 551

Mobility limitation

 Sedative load among community-dwelling people aged 75 years or older: Association with balance and mobility, April, 218

Modafinil

 Symptomatic treatment of interferon-a-induced depression in hepatitis C: A systematic review (review article), Aug, 531

Monoamine oxidase A (MAO-A)

 Different impacts of aquaporin 4 and MAOA allele variation among olanzapine, risperidone, and paliperidone in schizophrenia (brief report), June, 394

 The case for basic research on the psychopharmacology of aggression (guest editorial), Feb, 1

 The psychopharmacology of aggressive behavior: A translational approach (review article), Feb, 83

Montgomery-Åsberg Depression Rating Scale (MADRS)

 A randomized, double-blind, placebo-controlled trial of fluvoxamine in patients with schizophrenia: A preliminary study, Oct, 593

 Application of external review for subject selection in a schizophrenia trial (letter), April, 285

 Asenapine as adjunctive treatment for acute mania associated with bipolar disorder: Results of a 12-week core study and 40-week extension, Feb, 46

 Combination of antidepressants in the treatment of major depressive disorder: A systematic review and meta-analysis (brief report), April, 278

 Comparison of academic and nonacademic sites in multi-center clinical trials, Feb, 65

 Omega-3 fatty acid augmentation of citalopram treatment for patients with major depressive disorder, Feb, 61

 Omega-3 fatty acid treatment, with or without cytidine, fails to show therapeutic properties in bipolar disorder (brief report), Oct, 699

 Randomized trials published in Chinese or Western journals: Comparative empirical analysis, June, 354

 Randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder (brief report), Aug, 551

 Restoration of functionality in postpartum depressed mothers (letter), Oct, 729

 The effectiveness and safety of adjunctive aripiprazole in Taiwanese patients with antidepressant-refractory major depressive disorder: A prospective, open-label trial, Feb, 56

 The sustained effects of aripiprazole-augmented clozapine treatment on the psychotic symptoms and metabolic profiles of patients with refractory schizophrenia (letter), April, 282

 Two 6-week, randomized, double-blind, placebo-controlled studies of ziprasidone in outpatients with bipolar I depression, Aug, 470

Mood disorder

 Aripiprazole for the treatment of Tourette syndrome: A case series of 100 patients (brief report), Aug, 548

Mood stabilizers

 All-cause mortality and medication risk factors in schizophrenia: A prospective cohort study, Feb, 31

 Omega-3 fatty acid treatment, with or without cytidine, fails to show therapeutic properties in bipolar disorder (brief report), Oct, 699

Morphine benzedrine group (MBG)

 Human abuse potential and cognitive effects of taranabant, a cannabinoid 1 receptor inverse agonist, Aug, 492

Mortality

 All-cause mortality and medication risk factors in schizophrenia: A prospective cohort study, Feb, 31

Motion-tracking (MT) device

 Does atomoxetine improve executive function, inhibitory control, and hyperactivity?: Results from a placebo-controlled trial using quantitative measurement technology, Oct, 653

Multidimensional Anxiety Scale

 An exploratory, open trial of fluoxetine treatment of juvenile fibromyalgia (letter), April, 293

Multidimensional prognostic index (MPI)

 Treatment of late-life major depressive disorder with selective serotonin reuptake inhibitors improves the multidimensional prognostic index (letter), Oct, 726

Multiple linear regression (MLR)

 Cognitive impairment in patients clinically recovered from central nervous system depressant drug overdose, Aug, 503

Multivariate analyses

 Impact of switching or initiating antipsychotic treatment on body weight during a 6-month follow-up in a cohort of patients with schizophrenia (brief report), Oct, 672

Multivariate regression models

 Effectiveness and cost of atypical versus typical antipsychotic treatment in a nationwide cohort of patients with schizophrenia in Germany, Oct, 602

Myeloid progenitors

 Valproic acid treatment is associated with altered leukocyte subset development (brief report), Dec, 832

N

N-methyl-D-aspartate (NMDA)

 Human abuse potential and cognitive effects of taranabant, a cannabinoid 1 receptor inverse agonist, Aug, 492

 The psychophar4macology of aggressive behavior: A translational approach (review article), Feb, 83

Naltrexone

 Effects of naltrexone on smoking cessation outcomes and weight gain in nicotine-dependent men and women, Oct, 630

Naranjo probability scale

 Pregabalin misuse-related issues; intake of large dosages, drug-smoking allegations, and possible association with myositis two case reports (letter), Dec, 839

National Cholesterol Education Program

 Metabolic effects of paliperidone extended release versus oral olanzapine in patients with schizophrenia: A prospective, randomized, controlled trial, Aug, 449

National death index (NDI)

 Treatment with duloxetine in adults and the incidence of cardiovascular events, Feb, 23

National Institute of Mental Health (NIMH)

 Randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder (brief report), Aug, 551

National Institutes of Health

 Randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder (brief report), Aug, 551

National programme on substance abuse deaths (np-SAD) database

 Suspected and confirmed fatalities associated with mephedrone (4-methylmethcathinone, “meow meow”) in the United Kingdom (brief report), Oct, 710

Nausea

 Aripiprazole for the treatment of Tourette syndrome: A case series of 100 patients (brief report), Aug, 548

 Effects of naltrexone on smoking cessation outcomes and weight gain in nicotine-dependent men and women, Oct, 630

 Peripheral edema associated with risperidone oral solution: A case report and a review of the literature (letter), Feb, 128

 Recurrence of panic attacks after brucellosis treatment-highly probable citalopram and rifampin drug interaction (letter), Dec, 842

4’-N-desmethyl olanzapine (DMO)

 Interindividual variation in olanzapine concentration influenced by UGT1A4 L48V polymorphism in serum and upstream FMO polymorphisms in cerebrospinal fluid (letter), April, 287

NE-100

 A randomized, double-blind, placebo-controlled trial of fluvoxamine in patients with schizophrenia: A preliminary study, Oct, 593

Nefazodone

 A randomized controlled pilot study of acamprosate added to escitalopram in adults with major depressive disorder and alcohol use disorder, Dec, 787

Negative Symptom Assessment Scale

 Asenapine versus olanzapine in people with persistent negative symptoms of schizophrenia, Feb, 36

Negative Symptom Assessment Scale (NSA-16) total score

 Asenapine versus olanzapine in people with persistent negative symptoms of schizophrenia, Feb, 36

Neonatal morbidity

 Neonatal complications after maternal concomitant use of SSRI and other central nervous system active drugs during the second or third trimester of pregnancy, Oct, 608

Neonatal outcomes

 Neonatal outcomes after late-gestation exposure to selective serotonin reuptake inhibitors, Oct, 615

Neonatal symptoms

 Neonatal complications after maternal concomitant use of SSRI and other central nervous system active drugs during the second or third trimester of pregnancy, Oct, 608

Neonatal withdrawal syndrome

 Neonatal outcomes after late-gestation exposure to selective serotonin reuptake inhibitors, Oct, 615

Neuroactive steroids

 The psychopharmacology of aggressive behavior: A translational approach (review article), Feb, 83

Neurocognitive

 Human abuse potential and cognitive effects of taranabant, a cannabinoid 1 receptor inverse agonist, Aug, 492

Neurodevelopmental disorders

 Status epilepticus associated with the administration of long-acting methylphenidate in a 7-year-old girl (letter), April, 300

Neuroleptic malignant syndrome

 Acute laryngeal dystonia associated with aripiprazole (letter), Dec, 837

Neuroleptics (NLs)

 Aripiprazole for the treatment of Tourette syndrome: A case series of 100 patients (brief report), Aug, 548

Neuropeptide Y (NPY)

 The case for basic research on the psychopharmacology of aggression (guest editorial), Feb, 1

 Trajectories of agouti-related protein and leptin levels during antipsychotic-associated weight gain in patients with schizophrenia, Dec, 767

Neurotransmission

 Aripiprazole for the treatment of Tourette syndrome: A case series of 100 patients (brief report), Aug, 548

Neurotransmitters

 The psychopharmacology of aggressive behavior: A translational approach (review article), April, 237

Neutropenia

 A case of quetiapine XR and divalproex-associated neutropenia followed by successful use of ziprasidone, June, 417

Neutrophils

 Valproic acid treatment is associated with altered leukocyte subset development (brief report), Dec, 832

Nicotine

 Human abuse potential and cognitive effects of taranabant, a cannabinoid 1 receptor inverse agonist, Aug, 492

Nicotine dependence

 Effects of naltrexone on smoking cessation outcomes and weight gain in nicotine-dependent men and women, Oct, 630

Nicotine replacement

 Effects of naltrexone on smoking cessation outcomes and weight gain in nicotine-dependent men and women, Oct, 630

Night Eating Symptom Scale

 Escitalopram for treatment of night eating syndrome: A 12-week, randomized, placebo-controlled trial, June, 341

Night eating syndrome

 Escitalopram for treatment of night eating syndrome: A 12-week, randomized, placebo-controlled trial, June, 341

Nitric oxide synthase

 The case for basic research on the psychopharmacology of aggression (guest editorial), Feb, 1

 The psychopharmacology of aggressive behavior: A translational approach (review article), Feb, 83

NLs. See Neuroleptics (NLs)

NMDA

 Randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder (brief report), Aug, 551

NNT.SeeNumber neededto treat (NNT)

Nonacademic

 Comparison of academic and nonacademic sites in multi-center clinical trials, Feb, 65

Noncompetitive glutamate N-methyl-D-aspartate (NMDA) receptor

 A randomized controlled pilot study of acamprosate added to escitalopram in adults with major depressive disorder and alcohol use disorder, Dec, 787

Nonresponsive obsessive-compulsive disorder (OCD)

 N-acetylcysteine add-on treatment in refractory obsessive-compulsive disorder: A randomized, double-blind, placebo-controlled trial, Dec, 797

Nonsteroidal anti-inflammatory drugs (NSAIDs)

 Antidepressant use and the risk of upper gastrointestinal bleeding in psychiatric patients, Aug, 518

 Symptomatic treatment of interferon-a-induced depression in hepatitis C: A systematic review (review article), Aug, 531

Noradrenaline (NA)

 Tranylcypromine and bupropion combination therapy in treatment-resistant major depression (letter), Aug, 572

Noradrenergic dysfunction

 Management of a risperidone-induced tardive Pisa syndrome: A case report, June, 418

Norclozapine

 Association study of 27 annotated genes for clozapine pharmacogenetics: Validation of preexisting studies and identification of a new candidate gene, ABCB1, for treatment response, Aug, 441

 Clozapine levels might be affected by excessive cola consumption (letter), Oct, 717

Norepinephrine (NE)

 Delayed, fatal cardiotoxicity associated with bupropion and citalopram overdose (letter), June, 431

 Evidence-based medicine versus personalized medicine: Are they enemies? (guest editorial), April, 153

 The psychopharmacology of aggressive behavior: A translational approach (review article), Feb, 83, April, 237

Norepinephrine transporter

 Add-on treatment of quetiapine for fibromyalgia (brief report), Oct, 684

Normal fasting glucose (NFG)

 Dysregulation of adipocytokines related to second-generation antipsychotics in normal fasting glucose patients with schizophrenia (brief report), June, 390

Normobaric hyperoxia

 Normobaric hyperoxia treatment of schizophrenia, Aug, 525

NR2B

 Randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder (brief report), Aug, 551

NSA-16

 Asenapine versus olanzapine in people with persistent negative symptoms of schizophrenia, Feb, 36

Number needed to harm (NNH)

 Antidepressant use and the risk of upper gastrointestinal bleeding in psychiatric patients, Aug, 518

Number neededto treat (NNT)

 Effectiveness of a cognitive behavioral weight management intervention in obese patients with psychotic disorders compared to patients with nonpsychotic disorders or no psychiatric disorders, Aug, 458

Nursing homes (NHs)

 Variation in antipsychotic treatment choice across US nursing homes, Feb, 11

O

Obesity

 Association between HTR2C polymorphisms and obessity in patients without antipsychotic drugs (letter), Oct, 715

 Effectiveness of a cognitive behavioral weight management intervention in obese patients with psychotic disorders compared to patients with nonpsychotic disorders or no psychiatric disorders, Aug, 458

 Enhanced ziprasidone combination therapy effectiveness in obese compared to nonobese patients with bipolar disorder, Dec, 814

 Human abuse potential and cognitive effects of taranabant, a cannabinoid 1 receptor inverse agonist, Aug, 492

Objective Opioid Withdrawal Scale (OOWS)

 Pharmacokinetic-pharmacodynamic modeling of mood and withdrawal symptoms in relation to plasma concentrations of methadone in patients undergoing methadone maintenance treatment, Oct, 666

Observational study

 Short-term exposure to antidepressant drugs and risk of acute angle-closure glaucoma among older adults (brief report), June, 403

Observed cases (OCs)

 Two 6-week, randomized, double-blind, placebo-controlled studies of ziprasidone in outpatients with bipolar I depression, Aug, 470

Obsessive-compulsive disorder (OCD)

 A case of obsessive-compulsive disorder successfully treated with agomelatine monotherapy (letter), April, 289

 Aripiprazole for the treatment of Tourette syndrome: A case series of 100 patients (brief report), Aug, 548

 Caudate gray matter volume in obsessive-compulsive disorder is influenced by adverse childhood experiences and ongoing drug treatment (brief report), Aug, 544

 N-acetylcysteine add-on treatment in refractory obsessive-compulsive disorder: A randomized, double-blind, placebo-controlled trial, Dec, 797

 Restoration of functionality in postpartum depressed mothers (letter), Oct, 729

Obsessive-Compulsive Drinking Scale

 A randomized controlled pilot study of acamprosate added to escitalopram in adults with major depressive disorder and alcohol use disorder, Dec, 787

 High-dose baclofen for treatment-resistant alcohol dependence (brief report), April, 266

OCD.See Obsessive-compulsive disorder (OCD); Obsessive-compulsive disorder (OCD)

OCs.SeeObserved cases (OCs)

Odds ratio (OR)

 Adverse effects of second-generation antipsychotics in children and adolescents: A Bayesian meta-analysis, June, 309

 Drugs associated with restless legs syndrome: A case/noncase study in the French pharmacovigilance database (brief report), Dec, 824

 Effects of drug burden index on cognitive function in older men (brief report), April, 273

 Optimizing the early prediction model for symptomatic remission with short-term treatment for schizophrenia, Dec, 773

 Selective serotonin reuptake inhibitors and the risk of acute pancreatitis: A Swedish population-based case-control study, June, 336

 The declining use of reboxetine in years 2000 to 2006: A pharmacoepidemiological comparative study (letter), April, 303

Olanzapine (OLZ)

 A naturalistic study of intramuscular haloperidol versus intramuscular olanzapine for the management of acute agitation, June, 317

 A randomized, placebo-controlled study of zonisamide to prevent olanzapine-associated weight gain, April, 165

 Adverse effects of second-generation antipsychotics in children and adolescents: A Bayesian meta-analysis, June, 309

 Asenapine versus olanzapine in people with persistent negative symptoms of schizophrenia, Feb, 36

 Comment on “a multicenter, in patient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia” by Kinon et al (letter), April, 291

 Different impacts of aquaporin 4 and MAOA allele variation among olanzapine, risperidone, and paliperidone in schizophrenia (brief report), June, 394

 Dysregulation of adipocytokines related to second-generation antipsychotics in normal fasting glucose patients with schizophrenia (brief report), June, 390

 Electroconvulsive therapy and clozapine in adolescents with schizophrenia spectrum disorders: Is it a safe and effective combination?, Dec, 756

 Impact of switching or initiating antipsychotic treatment on body weight during a 6-month follow-up in a cohort of patients with schizophrenia (brief report), Oct, 672

 Increased risk of antipsychotic-related qt prolongation during nighttime: A 24-hour Holter electrocardiogram recording study, Feb, 18

 Long-term effect of haloperidol, olanzapine, and risperidone on plasma prolactin levels in patients with first-episode psychosis (brief report), Dec, 804

 Metabolic effects of paliperidone extended release versus oral olanzapine in patients with schizophrenia: A prospective, randomized, controlled trial, Aug, 449

 Olanzapine-related life-threatening hyperosmolar hyperglycemic syndrome: A case report (letter), Feb, 130

 Open-label treatment with olanzapine for patients with borderline personality disorder (brief report), June, 398

 Tardive laryngeal dystonia associated with aripiprazole monotherapy (letter), April, 297

 The relationship between serum uric acid concentration and metabolic syndrome in patients with schizophrenia or schizoaffective disorder, Oct, 585

 Too good to be true? Aspirin and schizophrenia (editorial), Oct, 583

 Trajectories of agouti-related protein and leptin levels during antipsychotic-associated weight gain in patients with schizophrenia, Dec, 767

 Two 6-week, randomized, double-blind, placebo-controlled studies of ziprasidone in outpatients with bipolar I depression, Aug, 470

Older adults

 Effects of drug burden index on cognitive function in older men (brief report), April, 273

Omega-3 fatty acids (O3FA)

 Eicosapentaenoic acid interventions in schizophrenia: Meta-analysis of randomized, placebo-controlled studies, April, 179

 Omega-3 fatty acid augmentation of citalopram treatment for patients with major depressive disorder, Feb, 61

 Omega-3 fatty acid treatment, with or without cytidine, fails to show therapeutic properties in bipolar disorder (brief report), Oct, 699

 Too good to be true? Aspirin and schizophrenia (editorial), Oct, 583

Opiate abuse

 Predictive factors for more than 3 years’ duration of central stimulant treatment in adult attention-deficit/hyperactivity disorder: A retrospective, naturalistic study, Oct, 645

Opiate Dosage Adequacy Scale

 Satisfaction with methadone as a medication: Psychometric properties of the Spanish version of the treatment satisfaction questionnaire for medication, Feb, 69

Opioid dependence

 Actigraphic measurements in opioid detoxification with methadone or buprenorphine, Feb, 75

 Satisfaction with methadone as a medication: Psychometric properties of the Spanish version of the treatment satisfaction questionnaire for medication, Feb, 69

Opioid receptor antagonists

 Effects of naltrexone on smoking cessation outcomes and weight gain in nicotine-dependent men and women, Oct, 630

Opioids

 Cognitive impairment in patients clinically recovered from central nervous system depressant drug overdose, Aug, 503

Oral antipsychotics

 Prevalence of concomitant oral antipsychotic drug use among patients treated with long-acting, intramuscular, antipsychotic medications, June, 323

Oral glucose tolerance test (OGTT)

 Excessive insulin secretion in Japanese schizophrenic patients treated with antipsychotics despite normal fasting glucose levels, Dec, 750

Orlistat

 Human abuse potential and cognitive effects of taranabant, a cannabinoid 1 receptor inverse agonist, Aug, 492

Osmotic release oral system

 Status epilepticus associated with the administration of long-acting methylphenidate in a 7-year-old girl (letter), April, 300

Osmotic-controlled extended-release oral delivery system (OROS)

 Metabolic effects of paliperidone extended release versus oral olanzapine in patients with schizophrenia: A prospective, randomized, controlled trial, Aug, 449

Out-of-pocket costs

 Medicare part D’s impact on antipsychotic drug use and costs among elderly patients without prior drug insurance, Feb, 3

Oxcarbazepine

 Behavioral adverse effects of antiepileptic drugs in epilepsy (review article), June, 362

 Bupropion xl for the sustained treatment of trichotillomania (letter), April, 298

Oxidative stress

 The relationship between serum uric acid concentration and metabolic syndrome in patients with schizophrenia or schizoaffective disorder, Oct, 585

Oxygen

 Normobaric hyperoxia treatment of schizophrenia, Aug, 525

Oxygen generators

 Normobaric hyperoxia treatment of schizophrenia, Aug, 525

Oxygen saturation

 Human abuse potential and cognitive effects of taranabant, a cannabinoid 1 receptor inverse agonist, Aug, 492

P

p-chlorophenylalanine potentiates

 The psychopharmacology of aggressive behavior: A translational approach (review article), Feb, 83

P-glycoprotein

 Association study of 27 annotated genes for clozapine pharmacogenetics: Validation of preexisting studies and identification of a new candidate gene, ABCB1, for treatment response, Aug, 441

 Different effects of the selective serotonin reuptake inhibitors fluvoxamine, paroxetine, and sertraline on the pharmacokinetics of fexofenadine in healthy volunteers, April, 195

 Ketoconazole-associated preferential increase in dopamine D2 receptor occupancy in striatum compared to pituitary in vivo: Role for drug transporters? (brief report), Feb, 110

P-glycoprotein (P-gp)

 Ketoconazole-associated preferential increase in dopamine D2 receptor occupancy in striatum compared to pituitary in vivo: Role for drug transporters? (brief report), Feb, 110

P-glycoprotein substrate

 Different effects of the selective serotonin reuptake inhibitors fluvoxamine, paroxetine, and sertraline on the pharmacokinetics of fexofenadine in healthy volunteers, April, 195

P450 (CYP450)

 Hypomania associated with adjunctive aripiprazole in an elder female with recurrent major depressive disorder: Dose-related phenomenon? (letter), Dec, 836

 Recurrence of panic attacks after brucellosis treatment-highly probable citalopram and rifampin drug interaction (letter), Dec, 842

Paliperidone

 Acute renal failure after paliperidone overdose: A case report (letter), Feb, 128

 Catatonia and encephalopathy associated with paliperidone palmitate (letter), April, 284

 Different impacts of aquaporin 4 and MAOA allele variation among olanzapine, risperidone, and paliperidone in schizophrenia (brief report), June, 394

Paliperidone ER

 Metabolic effects of paliperidone extended release versus oral olanzapine in patients with schizophrenia: A prospective, randomized, controlled trial, Aug, 449

Panic attacks (PAs)

 A randomized, naturalistic, parallel-group study for the long-term treatment of panic disorder with clonazepam or paroxetine (brief report), Feb, 120

Panic disorder (PD)

 A randomized, naturalistic, parallel-group study for the long-term treatment of panic disorder with clonazepam or paroxetine (brief report), Feb, 120

 An exploratory, open trial of fluoxetine treatment of juvenile fibromyalgia (letter), April, 293

PANSS.SeePositive and Negative Syndrome Scale (PANSS)

Pantoprazole

 Too good to be true? Aspirin and schizophrenia (editorial), Oct, 583

Parkinson disease (PD)

 Dopamine dysregulation syndrome including mania related to coadministration of droxidopa (letter), June, 428

 Finasteride attenuates pathological gambling in patients with Parkinson disease (letter), June, 424

 Tetrabenazine augmentation in treatment-resistant schizophrenia: A 12-week, double-blind, placebo-controlled trial (brief report), Feb, 95

Paroxetine

 A randomized, naturalistic, parallel-group study for the long-term treatment of panic disorder with clonazepam or paroxetine (brief report), Feb, 120

 Antidepressant agents and suicide death among US department of veterans affairs patients in depression treatment, June, 346

 Different effects of the selective serotonin reuptake inhibitors fluvoxamine, paroxetine, and sertraline on the pharmacokinetics of fexofenadine in healthy volunteers, April, 195

 Symptomatic treatment of interferon-a-induced depression in hepatitis C: A systematic review (review article), Aug, 531

 The declining use of reboxetine in years 2000 to 2006: A pharmacoepidemiological comparative study (letter), April, 303

Paroxetine hydrochloride

 Olanzapine-related life-threatening hyperosmolar hyperglycemic syndrome: A case report (letter), Feb, 130

Pathological gambling (PG)

 Finasteride attenuates pathological gambling in patients with Parkinson disease (letter), June, 424

Patient’s Global Improvement Scale (PGI)

 Omega-3 fatty acid augmentation of citalopram treatment for patients with major depressive disorder, Feb, 61

Pattern recognition memory

 A randomized, double-blind, placebo-controlled trial of fluvoxamine in patients with schizophrenia: A preliminary study, Oct, 593

PCR.SeePolymerase chain reaction (PCR)

Pearson correlation analysis

 Pharmacokinetic-pharmacodynamic modeling of mood and withdrawal symptoms in relation to plasma concentrations of methadone in patients undergoing methadone maintenance treatment, Oct, 666

Pedagogical and psychological services (PPSs)

 Predictive factors for more than 3 years’ duration of central stimulant treatment in adult attention-deficit/hyperactivity disorder: A retrospective, naturalistic study, Oct, 645

People and/or Property Scale

 The psychopharmacology of aggressive behavior: A translational approach (review article), April, 237

Peptic ulcer

Antidepressant use and the risk of upper gastrointestinal bleeding in psychiatric patients, Aug, 518

Per-protocol population (PPP)

 Does atomoxetine improve executive function, inhibitory control, and hyperactivity?: Results from a placebo-controlled trial using quantitative measurement technology, Oct, 653

Perceived Stress Scale

 The impact of acamprosate on cue reactivity in alcohol dependent individuals: A functional magnetic resonance imaging study, Oct, 661

Percentage of optimal birth weight (POBW)

 Neonatal outcomes after late-gestation exposure to selective serotonin reuptake inhibitors, Oct, 615

Perforation

 Antidepressant use and the risk of upper gastrointestinal bleeding in psychiatric patients, Aug, 518

Peripheral pharmacokinetic hypothesis

 Parkinsonism in elderly users of haloperidol (brief report), Oct, 688

Perphenazine

 Electroconvulsive therapy and clozapine in adolescents with schizophrenia spectrum disorders: Is it a safe and effective combination?, Dec, 756

Persistent negative symptoms

 Asenapine versus olanzapine in people with persistent negative symptoms of schizophrenia, Feb, 36

Personalized medicine (PM)

 Evidence-based medicine versus personalized medicine: Are they enemies? (guest editorial), April, 153

Pet1

 The case for basic research on the psychopharmacology of aggression (guest editorial), Feb, 1

Pharmacodynamics

 Association study of 27 annotated genes for clozapine pharmacogenetics: Validation of preexisting studies and identification of a new candidate gene, ABCB1, for treatment response, Aug, 441

 Pharmacokinetic-pharmacodynamic modeling of mood and withdrawal symptoms in relation to plasma concentrations of methadone in patients undergoing methadone maintenance treatment, Oct, 666

 Randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder (brief report), Aug, 551

Pharmacoepidemiology

 Follow-up study of a pharmacovigilance signal: No evidence of increased risk with risperidone of pituitary tumor with mass effect, Dec, 743

 Selective serotonin reuptake inhibitors and the risk of acute pancreatitis: A Swedish population-based case-control study, June, 336

 Treatment with duloxetine in adults and the incidence of cardiovascular events, Feb, 23

Pharmacogenetics

 Association study of 27 annotated genes for clozapine pharmacogenetics: Validation of preexisting studies and identification of a new candidate gene, ABCB1, for treatment response, Aug, 441

 Multicenter study on the clinical effectiveness, pharmacokinetics, and pharmacogenetics of mirtazapine in depression, Oct, 622

 No significant association between genetic variants in 7 candidate genes and response to ethylphenidate treatment in adult patients with ADHD (brief report), Dec, 820

Pharmacokinetic interaction

 Reduced methadone clearance during aromatase inhibition, Aug, 511

Pharmacokinetics

 Association study of 27 annotated genes for clozapine pharmacogenetics: Validation of preexisting studies and identification of a new candidate gene, ABCB1, for treatment response, Aug, 441

 Different effects of the selective serotonin reuptake inhibitors fluvoxamine, paroxetine, and sertraline on the pharmacokinetics of fexofenadine in healthy volunteers, April, 195

 Multicenter study on the clinical effectiveness, pharmacokinetics, and pharmacogenetics of mirtazapine in depression, Oct, 622

 Pharmacokinetic-pharmacodynamic modeling of mood and withdrawal symptoms in relation to plasma concentrations of methadone in patients undergoing methadone maintenance treatment, Oct, 666

 Randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder (brief report), Aug, 551

Pharmacological agents

 A randomized, double-blind, placebo-controlled trial of fluvoxamine in patients with schizophrenia: A preliminary study, Oct, 593

Pharmacology

 Case manager- and patient-rated alliance as a predictor of medication adherence in first-episode psychosis, Aug, 465

Pharmacotherapies

Effects of naltrexone on smoking cessation outcomes and weight gain in nicotine-dependent men and women, Oct, 630

Pharmacovigilance

 Antidepressant use and the risk of upper gastrointestinal bleeding in psychiatric patients, Aug, 518

 Drugs associated with restless legs syndrome: A case/noncase study in the French pharmacovigilance database (brief report), Dec, 824

 Follow-up study of a pharmacovigilance signal: No evidence of increased risk with risperidone of pituitary tumor with mass effect, Dec, 743

Phenobarbital

 Behavioral adverse effects of antiepileptic drugs in epilepsy (review article), June, 362

Phenolic amines

 Unwanted interactions among psychotropic drugs and other treatments for autism spectrum disorders (guest editorial), Aug, 437

Phentermine

 Human abuse potential and cognitive effects of taranabant, a cannabinoid 1 receptor inverse agonist, Aug, 492

Phenytoin (PHT)

 Behavioral adverse effects of antiepileptic drugs in epilepsy (review article), June, 362

 The cytochrome P-450 2C9/2C19 but not the ABCB1 genetic polymorphism may be associated with the liver cytochrome 3A4 induction by phenytoin (letter), June, 429

 The psychopharmacology of aggressive behavior: A translational approach (review article), April, 237

 Valproic acid treatment is associated with altered leukocyte subset development (brief report), Dec, 832

Pimozide

 Aripiprazole for the treatment of Tourette syndrome: A case series of 100 patients (brief report), Aug, 548

Pisa syndrome

 Management of a risperidone-induced tardive Pisa syndrome: A case report, June, 418

Pituitary adenomas

 Follow-up study of a pharmacovigilance signal: No evidence of increased risk with risperidone of pituitary tumor with mass effect, Dec, 743

Pituitary tumor

 Follow-up study of a pharmacovigilance signal: No evidence of increased risk with risperidone of pituitary tumor with mass effect, Dec, 743

PK/PD modeling

 Pharmacokinetic-pharmacodynamic modeling of mood and withdrawal symptoms in relation to plasma concentrations of methadone in patients undergoing methadone maintenance treatment, Oct, 666

pKa

 Too good to be true? Aspirin and schizophrenia (editorial), Oct, 583

Placebo (PBO)

 A method to assess the dissipation of the effects of residual hypnotics (brief report), Oct, 704

 A randomized, double-blind study of 30 versus 20 mg dexmethylphenidate extended-release in children with attention-deficit/hyperactivity disorder: Late-day symptom control, Oct, 637

 Adverse events in healthy subjects exposed to single and multiple doses of LY2140023 monohydrate: pooled results from 10 phase 1 studies, June, 408

 Aripiprazole for the treatment of Tourette syndrome: A case series of 100 patients (brief report), Aug, 548

 Does atomoxetine improve executive function, inhibitory control, and hyperactivity?: Results from a placebo-controlled trial using quantitative measurement technology, Oct, 653

 Effects of naltrexone on smoking cessation outcomes and weight gain in nicotine-dependent men and women, Oct, 630

 Reply to Dr seeman’s comments on “a multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia” (letter), April, 292

 The impact of acamprosate on cue reactivity in alcohol dependent individuals: A functional magnetic resonance imaging study, Oct, 661

 Two 6-week, randomized, double-blind, placebo-controlled studies of ziprasidone in outpatients with bipolar I depression, Aug, 470

Placebo response

 Two 6-week, randomized, double-blind, placebo-controlled studies of ziprasidone in outpatients with bipolar I depression, Aug, 470

Placebo-controlled study

 Eicosapentaenoic acid interventions in schizophrenia: Meta-analysis of randomized, placebo-controlled studies, April, 179

Placebo-controlled trials (RCTs)

 The effectiveness and safety of adjunctive aripiprazole in Taiwanese patients with antidepressant-refractory major depressive disorder: A prospective, open-label trial, Feb, 56

Plasma concentration

 Parkinsonism in elderly users of haloperidol (brief report), Oct, 688

Plasma glucose levels (FPG)

 Excessive insulin secretion in Japanese schizophrenic patients treated with antipsychotics despite normal fasting glucose levels, Dec, 750

Plasma leptin

 Trajectories of agouti-related protein and leptin levels during antipsychotic-associated weight gain in patients with schizophrenia, Dec, 767

Plasma letrozole

 Reduced methadone clearance during aromatase inhibition, Aug, 511

Plasma protein binding

 Pharmacokinetic-pharmacodynamic modeling of mood and withdrawal symptoms in relation to plasma concentrations of methadone in patients undergoing methadone maintenance treatment, Oct, 666

Plasma tryptophan

 Modulation of central serotonin affects emotional information processing in impulsive aggressive personality disorder, June, 329

Poisson regression model

 Effectiveness and cost of atypical versus typical antipsychotic treatment in a nationwide cohort of patients with schizophrenia in Germany, Oct, 602

Polymerase chain reaction (PCR)

 Association study of 27 annotated genes for clozapine pharmacogenetics: Validation of preexisting studies and identification of a new candidate gene, ABCB1, for treatment response, Aug, 441

Polypharmacy

 Neonatal complications after maternal concomitant use of SSRI and other central nervous system active drugs during the second or third trimester of pregnancy, Oct, 608

Polyphenols

 Unwanted interactions among psychotropic drugs and other treatments for autism spectrum disorders (guest editorial), Aug, 437

Polysomnography recording

 A method to assess the dissipation of the effects of residual hypnotics (brief report), Oct, 704

Polysynaptic interneurons

 Mephenesin dependence (letter), Oct, 736

Positive And Negative Syndrome Scale (PANSS)

 A randomized, double-blind, placebo-controlled trial of fluvoxamine in patients with schizophrenia: A preliminary study, Oct, 593

 A randomized, placebo-controlled study of zonisamide to prevent olanzapine-associated weight gain, April, 165

 Akathisia and suicidal ideation in first-episode schizophrenia (brief report), Oct, 694

 Asenapine versus olanzapine in people with persistent negative symptoms of schizophrenia, Feb, 36

 Augmenting clozapine with sertindole: Double-blind, randomized, placebo-controlled study, April, 173

 Comment on “a multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia” by Kinon et al (letter), April, 291

 Different impacts of aquaporin 4 and MAOA allele variation among olanzapine, risperidone, and paliperidone in schizophrenia (brief report), June, 394

 Dopaminergic genes influence early response to atypical antipsychotics in patients with first presentation of psychosis (letter), Aug, 566

 Effects of aripiprazole and the Taq1A polymorphism in the dopamine D2 receptor gene on the clinical response and plasma monoamine metabolites level during the acute phase of schizophrenia (brief report), Feb, 106

 Eicosapentaenoic acid interventions in schizophrenia: Meta-analysis of randomized, placebo-controlled studies, April, 179

 Electroconvulsive therapy and clozapine in adolescents with schizophrenia spectrum disorders: Is it a safe and effective combination?, Dec, 756

 Metabolic effects of paliperidone extended release versus oral olanzapine in patients with schizophrenia: A prospective, randomized, controlled trial, Aug, 449

 Normobaric hyperoxia treatment of schizophrenia, Aug, 525

 Optimizing the early prediction model for symptomatic remission with short-term treatment for schizophrenia, Dec, 773

 Reply to Dr seeman’s comments on “a multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia” (letter), April, 292

 The psychopharmacology of aggressive behavior: A translational approach (review article), April, 237

 Too good to be true? Aspirin and schizophrenia (editorial), Oct, 583

Positive and Negative Syndrome Scale and Clinical Global Impression

 Electroconvulsive therapy and clozapine in adolescents with schizophrenia spectrum disorders: Is it a safe and effective combination?, Dec, 756

Positive Symptom Total Scale

 Polymorphisms in serotonergic genes and psychopathological traits in eating disorders (letter), June, 426

Positron emission tomography

 A randomized, double-blind, placebo-controlled trial of fluvoxamine in patients with schizophrenia: A preliminary study, Oct, 593

Positron emission tomography (PET)

 Ketoconazole-associated preferential increase in dopamine D2 receptor occupancy in striatum compared to pituitary in vivo: Role for drug transporters? (brief report), Feb, 110

Post Hoc Analyses

 A method to assess the dissipation of the effects of residual hypnotics (brief report), Oct, 704

Posterior cingulate cortex

 The impact of acamprosate on cue reactivity in alcohol dependent individuals: A functional magnetic resonance imaging study, Oct, 661

Postgraduate year (PGY)

 US psychiatric residents’ treatment of patients with bipolar disorder, April, 231

Postpartum depression (PPD)

 Restoration of functionality in postpartum depressed mothers (letter), Oct, 729

Posttraumatic stress disorder

 An exploratory, open trial of fluoxetine treatment of juvenile fibromyalgia (letter), April, 293

 Caudate gray matter volume in obsessive-compulsive disorder is influenced by adverse childhood experiences and ongoing drug treatment (brief report), Aug, 544

Postural balance

 Sedative load among community-dwelling people aged 75 years or older: Association with balance and mobility, April, 218

PPSs.SeePedagogical and psychological services (PPSs)

Practice patterns

 US psychiatric residents’ treatment of patients with bipolar disorder, April, 231

Preclozapine period

 Predictors of clozapine response in patients with treatment-refractory schizophrenia (brief report), Oct, 678

Prefrontal cortex (PFC)

 The psychopharmacology of aggressive behavior: A translational approach (review article), Feb, 83

Pregabalin

 Add-on treatment of quetiapine for fibromyalgia (brief report), Oct, 684

 Behavioral adverse effects of antiepileptic drugs in epilepsy (review article), June, 362

 Pregabalin misuse-related issues; intake of large dosages, drug-smoking allegations, and possible association with myositis two case reports (letter), Dec, 839

 Pregabalin-associated increase of clozapine serum levels (letter), Feb, 127

Pregnancy

 Neonatal outcomes after late-gestation exposure to selective serotonin reuptake inhibitors, Oct, 615

 Pregnancy outcome after exposure to antidepressants and the role of maternal depression: results from the Norwegian mother and child cohort study, April, 186

Prescription patterns

 Common use of antipsychotic polypharmacy in older Asian patients with schizophrenia (2001–2009) (brief report), Dec, 809

Preterm birth

 Neonatal complications after maternal concomitant use of SSRI and other central nervous system active drugs during the second or third trimester of pregnancy, Oct, 608

 Neonatal outcomes after late-gestation exposure to selective serotonin reuptake inhibitors, Oct, 615

 Pregnancy outcome after exposure to antidepressants and the role of maternal depression: results from the Norwegian mother and child cohort study, April, 186

Prevention

 Efficacy and safety of levetiracetam for the prevention of alcohol relapse in recently detoxified alcohol-dependent patients (brief report), Aug, 558

Primidone

 Behavioral adverse effects of antiepileptic drugs in epilepsy (review article), June, 362

Principal component (PC)

 Computational prediction of state anxiety in Asian patients with cancer susceptible to chemotherapy-induced nausea and vomiting, April, 207

Principal component (PC) analysis

 Computational prediction of state anxiety in Asian patients with cancer susceptible to chemotherapy-induced nausea and vomiting, April, 207

Principal variables

 Computational prediction of state anxiety in Asian patients with cancer susceptible to chemotherapy-induced nausea and vomiting, April, 207

Profile of Mood Scale (POMS)

 Pharmacokinetic-pharmacodynamic modeling of mood and withdrawal symptoms in relation to plasma concentrations of methadone in patients undergoing methadone maintenance treatment, Oct, 666

Prolactin (PRL)

 Atypical antipsychotics and pituitary tumors (guest editorial), Dec, 741

 Long-term effect of haloperidol, olanzapine, and risperidone on plasma prolactin levels in patients with first-episode psychosis (brief report), Dec, 804

Promoter

 Association study of 27 annotated genes for clozapine pharmacogenetics: Validation of preexisting studies and identification of a new candidate gene, ABCB1, for treatment response, Aug, 441

Propensity score

 Treating depression after initial treatment failure: Directly comparing switch and augmenting strategies in STAR*D (brief report), Feb, 114

Propranolol

 Akathisia and suicidal ideation in first-episode schizophrenia (brief report), Oct, 694

Prostatic hypertrophy

 Reversal of SSRI-associated urinary retention with mirtazapine augmentation (letter), June, 434

Proton pump inhibitors

 Antidepressant use and the risk of upper gastrointestinal bleeding in psychiatric patients, Aug, 518

Psychiatric disorders

 Antidepressant use and the risk of upper gastrointestinal bleeding in psychiatric patients, Aug, 518

 Successful treatment of musical hallucinations with the acetylcholinesterase inhibitor donepezil, June, 422

Psychiatric hospitalization

 Predictors of clozapine response in patients with treatment-refractory schizophrenia (brief report), Oct, 678

Psychiatric illness

 Ketoconazole-associated preferential increase in dopamine D2 receptor occupancy in striatum compared to pituitary in vivo: Role for drug transporters? (brief report), Feb, 110

 Neonatal outcomes after late-gestation exposure to selective serotonin reuptake inhibitors, Oct, 615

Psychiatric inpatient treatment

 The impact of acamprosate on cue reactivity in alcohol dependent individuals: A functional magnetic resonance imaging study, Oct, 661

Psychiatric pharmacotherapy

 High venlafaxine serum levels after prior fluoxetine medication (letter), April, 295

Psychoactive agents

 Olanzapine-related life-threatening hyperosmolar hyperglycemic syndrome: A case report (letter), Feb, 130

Psychoactive substances

 Suspected and confirmed fatalities associated with mephedrone (4-methylmethcathinone, “meow meow”) in the United Kingdom (brief report), Oct, 710

Psychogeriatric patients

 Common use of antipsychotic polypharmacy in older Asian patients with schizophrenia (2001–2009) (brief report), Dec, 809

Psychometric analyses

 Satisfaction with methadone as a medication: Psychometric properties of the Spanish version of the treatment satisfaction questionnaire for medication, Feb, 69

Psychomotor retardation

 Tetrabenazine augmentation in treatment-resistant schizophrenia: A 12-week, double-blind, placebo-controlled trial (brief report), Feb, 95

Psychopathology

 Akathisia and suicidal ideation in first-episode schizophrenia (brief report), Oct, 694

 Dyskinesia symptoms during treatment with olanzapine or haloperidol (letter), June, 420

Psychopharmacologic treatment

 Bupropion xl for the sustained treatment of trichotillomania (letter), April, 298

Psychopharmacology

 Bupropion xl for the sustained treatment of trichotillomania (letter), April, 298

 Identifying potential adverse effects by patients’ ratings: A proof-of-concept study of a novel approach (brief report), Dec, 828

 The case for basic research on the psychopharmacology of aggression (guest editorial), Feb, 1

 The psychopharmacology of aggressive behavior: A translational approach (review article), Feb, 83, April, 237

Psychopharmacotherapy

 Tranylcypromine and bupropion combination therapy in treatment-resistant major depression (letter), Aug, 572

Psychosis

 Effectiveness of a cognitive behavioral weight management intervention in obese patients with psychotic disorders compared to patients with nonpsychotic disorders or no psychiatric disorders, Aug, 458

 Eicosapentaenoic acid interventions in schizophrenia: Meta-analysis of randomized, placebo-controlled studies, April, 179

 Electroconvulsive therapy and clozapine in adolescents with schizophrenia spectrum disorders: Is it a safe and effective combination?, Dec, 756

Psychosocial predictors

 Effectiveness of a cognitive behavioral weight management intervention in obese patients with psychotic disorders compared to patients with nonpsychotic disorders or no psychiatric disorders, Aug, 458

Psychostimulants

 A randomized, double-blind study of 30 versus 20 mg dexmethylphenidate extended-release in children with attention-deficit/hyperactivity disorder: Late-day symptom control, Oct, 637

 Does atomoxetine improve executive function, inhibitory control, and hyperactivity?: Results from a placebo-controlled trial using quantitative measurement technology, Oct, 653

 Symptomatic treatment of interferon-a-induced depression in hepatitis C: A systematic review (review article), Aug, 531

Psychotherapeutic interventions

 The impact of acamprosate on cue reactivity in alcohol dependent individuals: A functional magnetic resonance imaging study, Oct, 661

Psychotherapy

 Symptomatic treatment of interferon-a-induced depression in hepatitis C: A systematic review (review article), Aug, 531

Psychotic disorders

 Effectiveness of a cognitive behavioral weight management intervention in obese patients with psychotic disorders compared to patients with nonpsychotic disorders or no psychiatric disorders, Aug, 458

Psychotic exacerbation

 Effectiveness and cost of atypical versus typical antipsychotic treatment in a nationwide cohort of patients with schizophrenia in Germany, Oct, 602

Psychotic spectrum disorders (PSDs)

 Effectiveness of a cognitive behavioral weight management intervention in obese patients with psychotic disorders compared to patients with nonpsychotic disorders or no psychiatric disorders, Aug, 458

Psychotic symptoms

 Eicosapentaenoic acid interventions in schizophrenia: Meta-analysis of randomized, placebo-controlled studies, April, 179

Psychotropic medications

 Omega-3 fatty acid treatment, with or without cytidine, fails to show therapeutic properties in bipolar disorder (brief report), Oct, 699

PubMed

 Symptomatic treatment of interferon-a-induced depression in hepatitis C: A systematic review (review article), Aug, 531

PUFA

 Eicosapentaenoic acid interventions in schizophrenia: Meta-analysis of randomized, placebo-controlled studies, April, 179

Pulmonary disease

 Normobaric hyperoxia treatment of schizophrenia, Aug, 525

Pulmonary infections

 Evidence-based medicine versus personalized medicine: Are they enemies? (guest editorial), April, 153

Pulse rate

 Tetrabenazine augmentation in treatment-resistant schizophrenia: A 12-week, double-blind, placebo-controlled trial (brief report), Feb, 95

Purinergic system

 Purinergic system in the treatment of bipolar disorder (letter), Oct, 735

Q

Q statistic

 Eicosapentaenoic acid interventions in schizophrenia: Meta-analysis of randomized, placebo-controlled studies, April, 179

QLS.SeeQuality of Life Scale (QLS)

QT interval

 Reduced methadone clearance during aromatase inhibition, Aug, 511

QT syndrome

 A randomized, double-blind study of 30 versus 20 mg dexmethylphenidate extended-release in children with attention-deficit/hyperactivity disorder: Late-day symptom control, Oct, 637

QTc prolongation

 Augmenting clozapine with sertindole: Double-blind, randomized, placebo-controlled study, April, 173

Quality

 Randomized trials published in Chinese or Western journals: Comparative empirical analysis, June, 354

Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q)

 Asenapine as adjunctive treatment for acute mania associated with bipolar disorder: Results of a 12-week core study and 40-week extension, Feb, 46

Quality of Life Scale (QLS)

 A randomized, double-blind, placebo-controlled trial of fluvoxamine in patients with schizophrenia: A preliminary study, Oct, 593

 Asenapine versus olanzapine in people with persistent negative symptoms of schizophrenia, Feb, 36

Quantitative measurement

 Does atomoxetine improve executive function, inhibitory control, and hyperactivity?: Results from a placebo-controlled trial using quantitative measurement technology, Oct, 653

Quercetin

 Unwanted interactions among psychotropic drugs and other treatments for autism spectrum disorders (guest editorial), Aug, 437

Questionnaire

 Early switch strategy in patients with major depressive disorder, Aug, 479

Quetiapine (QEP)

 Actigraphic measurements in opioid detoxification with methadone or buprenorphine, Feb, 75

 Add-on treatment of quetiapine for fibromyalgia (brief report), Oct, 684

 Adverse effects of second-generation antipsychotics in children and adolescents: A Bayesian meta-analysis, June, 309

 Characteristics of quetiapine misuse among clients of a community-based methadone maintenance program (letter), Oct, 721

 Dyskinesia symptoms during treatment with olanzapine or haloperidol (letter), June, 420

 Dysregulation of adipocytokines related to second-generation antipsychotics in normal fasting glucose patients with schizophrenia (brief report), June, 390

 Electroconvulsive therapy and clozapine in adolescents with schizophrenia spectrum disorders: Is it a safe and effective combination?, Dec, 756

 Follow-up study of a pharmacovigilance signal: No evidence of increased risk with risperidone of pituitary tumor with mass effect, Dec, 743

 Neutropenia associated with the comedication of quetiapine and valproate in 2 elderly patients (letter), June, 416

 Tardive laryngeal dystonia associated with aripiprazole monotherapy (letter), April, 297

Quit rates

 Effects of naltrexone on smoking cessation outcomes and weight gain in nicotine-dependent men and women, Oct, 630

R

Rabbit Syndrome (RS)

 Rabbit syndrome following discontinuation of paliperidone in a patient with schizoaffective disorder (letter), Oct, 720

Racemic methadone hydrochloride

 Reduced methadone clearance during aromatase inhibition, Aug, 511

Racemic MPH

 A randomized, double-blind study of 30 versus 20 mg dexmethylphenidate extended-release in children with attention-deficit/hyperactivity disorder: Late-day symptom control, Oct, 637

Ramelteon

 Ramelteon dose escalation in a patient with substance misuse (letter), Oct, 738

Randomized

 Eicosapentaenoic acid interventions in schizophrenia: Meta-analysis of randomized, placebo-controlled studies, April, 179

Randomized clinical trials (RCTs)

 Evidence-based medicine versus personalized medicine: Are they enemies? (guest editorial), April, 153

Randomized controlled trial (RCT)

 Add-on treatment of quetiapine for fibromyalgia (brief report), Oct, 684

 All-cause mortality and medication risk factors in schizophrenia: A prospective cohort study, Feb, 31

 Antidepressant agents and suicide death among US department of veterans affairs patients in depression treatment, June, 346

 Early switch strategy in patients with major depressive disorder, Aug, 479

 Escitalopram for treatment of night eating syndrome: A 12-week, randomized, placebo-controlled trial, June, 341

 N-acetylcysteine add-on treatment in refractory obsessive-compulsive disorder: A randomized, double-blind, placebo-controlled trial, Dec, 797

Rated charts (RCs)

 A naturalistic study of intramuscular haloperidol versus intramuscular olanzapine for the management of acute agitation, June, 317

Rating of Aggression

 The psychopharmacology of aggressive behavior: A translational approach (review article), April, 237

Readiness to Discharge Questionnaire (RDQ)

 Asenapine as adjunctive treatment for acute mania associated with bipolar disorder: Results of a 12-week core study and 40-week extension, Feb, 46

Reboxetine

 A randomized, placebo-controlled study of zonisamide to prevent olanzapine-associated weight gain, April, 165

 The declining use of reboxetine in years 2000 to 2006: A pharmacoepidemiological comparative study (letter), April, 303

Receiver operating characteristic (ROC)

 Optimizing the early prediction model for symptomatic remission with short-term treatment for schizophrenia, Dec, 773

Rehospitalization

 Effectiveness and cost of atypical versus typical antipsychotic treatment in a nationwide cohort of patients with schizophrenia in Germany, Oct, 602

Reisberg Global Deterioration Scale

 Parkinsonism in elderly users of haloperidol (brief report), Oct, 688

Relapse

 Efficacy and safety of levetiracetam for the prevention of alcohol relapse in recently detoxified alcohol-dependent patients (brief report), Aug, 558

Relative risk (RR)

 Combination of antidepressants in the treatment of major depressive disorder: A systematic review and meta-analysis (brief report), April, 278

REM sleep behavior disorder (RBD)

 Agomelatine may improve REM sleep behavior disorder symptoms (letter), Oct, 732

Residency education

 US psychiatric residents’ treatment of patients with bipolar disorder, April, 231

Residual sedation

 A method to assess the dissipation of the effects of residual hypnotics (brief report), Oct, 704

Respiratory diagnoses

 Neonatal complications after maternal concomitant use of SSRI and other central nervous system active drugs during the second or third trimester of pregnancy, Oct, 608

 Neonatal outcomes after late-gestation exposure to selective serotonin reuptake inhibitors, Oct, 615

Restless legs syndrome (RLS)

 Drugs associated with restless legs syndrome: A case/noncase study in the French pharmacovigilance database (brief report), Dec, 824

Retrosplenial cortex

 The impact of acamprosate on cue reactivity in alcohol dependent individuals: A functional magnetic resonance imaging study, Oct, 661

Reward bulimia nervosa (BN)

 From disordered eating to addiction: The “food drug” in bulimia nervosa (review article), June, 376

Riboflavin

 The anticonvulsant levetiracetam potentiates alcohol consumption in non-treatment seeking alcohol abusers (brief report), April, 269

Rifampin

 Recurrence of panic attacks after brucellosis treatment-highly probable citalopram and rifampin drug interaction (letter), Dec, 842

Risperidone

 Adverse effects of second-generation antipsychotics in children and adolescents: A Bayesian meta-analysis, June, 309

 Akathisia and suicidal ideation in first-episode schizophrenia (brief report), Oct, 694

 Atypical antipsychotics and pituitary tumors (guest editorial), Dec, 741

 Catatonia and encephalopathy associated with paliperidone palmitate (letter), April, 284

 Cognitive effects of a single dose of atypical antipsychotics in healthy volunteers compared with placebo or haloperidol, Dec, 778

 Different impacts of aquaporin 4 and MAOA allele variation among olanzapine, risperidone, and paliperidone in schizophrenia (brief report), June, 394

 Dyskinesia symptoms during treatment with olanzapine or haloperidol (letter), June, 420

 Dysregulation of adipocytokines related to second-generation antipsychotics in normal fasting glucose patients with schizophrenia (brief report), June, 390

 Follow-up study of a pharmacovigilance signal: No evidence of increased risk with risperidone of pituitary tumor with mass effect, Dec, 743

 Improvement in intractable tardive dystonia in bipolar disorder after aripiprazole treatment: A case report (letter), Aug, 563

 Increased risk of antipsychotic-related qt prolongation during nighttime: A 24-hour Holter electrocardiogram recording study, Feb, 18

 Ketoconazole-associated preferential increase in dopamine D2 receptor occupancy in striatum compared to pituitary in vivo: Role for drug transporters? (brief report), Feb, 110

 Long-term effect of haloperidol, olanzapine, and risperidone on plasma prolactin levels in patients with first-episode psychosis (brief report), Dec, 804

 Metabolic effects of paliperidone extended release versus oral olanzapine in patients with schizophrenia: A prospective, randomized, controlled trial, Aug, 449

 Peripheral edema associated with risperidone oral solution: A case report and a review of the literature (letter), Feb, 128

 Prevalence of concomitant oral antipsychotic drug use among patients treated with long-acting, intramuscular, antipsychotic medications, June, 323

 Too good to be true? Aspirin and schizophrenia (editorial), Oct, 583

 Unwanted interactions among psychotropic drugs and other treatments for autism spectrum disorders (guest editorial), Aug, 437

Rivastigmine

 Do local meteorological conditions influence skin irritation caused by transdermal rivastigmine? A retroprospective, pilot study (brief report), June, 412

Ropinirole

 Ropinirole as an effective adjunctive treatment for clozapine-resistant negative symptoms in simple schizophrenia (letter), Oct, 719

S

Salute to our reviewers,See February 2013 issue

Schizoaffective disorder

 Rabbit syndrome following discontinuation of paliperidone in a patient with schizoaffective disorder (letter), Oct, 720

 Two 6-week, randomized, double-blind, placebo-controlled studies of ziprasidone in outpatients with bipolar I depression, Aug, 470

Schizophrenia

 A randomized, double-blind, placebo-controlled trial of fluvoxamine in patients with schizophrenia: A preliminary study, Oct, 593

 Acute renal failure after paliperidone overdose: A case report (letter), Feb, 128

 All-cause mortality and medication risk factors in schizophrenia: A prospective cohort study, Feb, 31

 Asenapine versus olanzapine in people with persistent negative symptoms of schizophrenia, Feb, 36

 Association study of 27 annotated genes for clozapine pharmacogenetics: Validation of preexisting studies and identification of a new candidate gene, ABCB1, for treatment response, Aug, 441

 Augmenting clozapine with sertindole: Double-blind, randomized, placebo-controlled study, April, 173

 Case manager- and patient-rated alliance as a predictor of medication adherence in first-episode psychosis, Aug, 465

 Cognitive effects of a single dose of atypical antipsychotics in healthy volunteers compared with placebo or haloperidol, Dec, 778

 Comment on “a multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia” by Kinon et al (letter), April, 291

 Common use of antipsychotic polypharmacy in older Asian patients with schizophrenia (2001–2009) (brief report), Dec, 809

 Does the medication pattern reflect the CYP2D6 genotype in patients with diagnoses within the schizophrenic spectrum?, Feb, 100

 Effectiveness and cost of atypical versus typical antipsychotic treatment in a nationwide cohort of patients with schizophrenia in Germany, Oct, 602

 Effectiveness of a cognitive behavioral weight management intervention in obese patients with psychotic disorders compared to patients with nonpsychotic disorders or no psychiatric disorders, Aug, 458

 Effects of aripiprazole and the Taq1A polymorphism in the dopamine D2 receptor gene on the clinical response and plasma monoamine metabolites level during the acute phase of schizophrenia (brief report), Feb, 106

 Eicosapentaenoic acid interventions in schizophrenia: Meta-analysis of randomized, placebo-controlled studies, April, 179

 Electroconvulsive therapy and clozapine in adolescents with schizophrenia spectrum disorders: Is it a safe and effective combination?, Dec, 756

 Excessive insulin secretion in Japanese schizophrenic patients treated with antipsychotics despite normal fasting glucose levels, Dec, 750

 Human abuse potential and cognitive effects of taranabant, a cannabinoid 1 receptor inverse agonist, Aug, 492

 Hypomania associated with adjunctive aripiprazole in an elder female with recurrent major depressive disorder: Dose-related phenomenon? (letter), Dec, 836

 Impact of switching or initiating antipsychotic treatment on body weight during a 6-month follow-up in a cohort of patients with schizophrenia (brief report), Oct, 672

 Increased risk of antipsychotic-related qt prolongation during nighttime: A 24-hour Holter electrocardiogram recording study, Feb, 18

 Is psychiatry ignoring suicide? The case for clozapine (guest editorial), June, 307

 Low-dose clozapine exacerbates and then improves mood in a patient with schizophrenia and history of surgical removal of an intraventricular meningioma (letter), Dec, 835

 Metabolic effects of paliperidone extended release versus oral olanzapine in patients with schizophrenia: A prospective, randomized, controlled trial, Aug, 449

 Normobaric hyperoxia treatment of schizophrenia, Aug, 525

 Optimizing the early prediction model for symptomatic remission with short-term treatment for schizophrenia, Dec, 773

 Predictors of clozapine response in patients with treatment-refractory schizophrenia (brief report), Oct, 678

 Pregabalin-associated increase of clozapine serum levels (letter), Feb, 127

 Prevalence of concomitant oral antipsychotic drug use among patients treated with long-acting, intramuscular, antipsychotic medications, June, 323

 Reply to Dr seeman’s comments on “a multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia” (letter), April, 292

 Risk factors associated with metabolic syndrome in bipolar and schizophrenia subjects treated with antipsychotics: The role of folate pharmacogenetics (brief report), April, 261

 Ropinirole as an effective adjunctive treatment for clozapine-resistant negative symptoms in simple schizophrenia (letter), Oct, 719

 Short-term treatment of catatonia with amantadine in schizophrenia and schizoaffective disorder (letter), Aug, 569

 Tetrabenazine augmentation in treatment-resistant schizophrenia: A 12-week, double-blind, placebo-controlled trial (brief report), Feb, 95

 The relationship between serum uric acid concentration and metabolic syndrome in patients with schizophrenia or schizoaffective disorder, Oct, 585

 The sustained effects of aripiprazole-augmented clozapine treatment on the psychotic symptoms and metabolic profiles of patients with refractory schizophrenia (letter), April, 282

 Too good to be true? Aspirin and schizophrenia (editorial), Oct, 583

 Trajectories of agouti-related protein and leptin levels during antipsychotic-associated weight gain in patients with schizophrenia, Dec, 767

Schizophrenia mortality

 All-cause mortality and medication risk factors in schizophrenia: A prospective cohort study, Feb, 31

Schuirmann test

 Metabolic effects of paliperidone extended release versus oral olanzapine in patients with schizophrenia: A prospective, randomized, controlled trial, Aug, 449

Second-generation antipsychotics (SGA)

 Adverse effects of second-generation antipsychotics in children and adolescents: A Bayesian meta-analysis, June, 309

 All-cause mortality and medication risk factors in schizophrenia: A prospective cohort study, Feb, 31

 Does the medication pattern reflect the CYP2D6 genotype in patients with diagnoses within the schizophrenic spectrum?, Feb, 100

 Dysregulation of adipocytokines related to second-generation antipsychotics in normal fasting glucose patients with schizophrenia (brief report), June, 390

 Trajectories of agouti-related protein and leptin levels during antipsychotic-associated weight gain in patients with schizophrenia, Dec, 767

Sedatives

 Aripiprazole for the treatment of Tourette syndrome: A case series of 100 patients (brief report), Aug, 548

 Characteristics of quetiapine misuse among clients of a community-based methadone maintenance program (letter), Oct, 721

 Sedative load among community-dwelling people aged 75 years or older: Association with balance and mobility, April, 218

 Tetrabenazine augmentation in treatment-resistant schizophrenia: A 12-week, double-blind, placebo-controlled trial (brief report), Feb, 95

Seizure

 Status epilepticus associated with the administration of long-acting methylphenidate in a 7-year-old girl (letter), April, 300

Selective serotonin reuptake inhibitor (SSRI)

 A randomized, naturalistic, parallel-group study for the long-term treatment of panic disorder with clonazepam or paroxetine (brief report), Feb, 120

 Add-on treatment of quetiapine for fibromyalgia (brief report), Oct, 684

 Antidepressant agents and suicide death among US department of veterans affairs patients in depression treatment, June, 346

 Antidepressant use and the risk of upper gastrointestinal bleeding in psychiatric patients, Aug, 518

 Bupropion xl for the sustained treatment of trichotillomania (letter), April, 298

 Combination of antidepressants in the treatment of major depressive disorder: A systematic review and meta-analysis (brief report), April, 278

 Different effects of the selective serotonin reuptake inhibitors fluvoxamine, paroxetine, and sertraline on the pharmacokinetics of fexofenadine in healthy volunteers, April, 195

 Early switch strategy in patients with major depressive disorder, Aug, 479

 Escitalopram for treatment of night eating syndrome: A 12-week, randomized, placebo-controlled trial, June, 341

 Evidence-based medicine versus personalized medicine: Are they enemies? (guest editorial), April, 153

 High venlafaxine serum levels after prior fluoxetine medication (letter), April, 295

 Neonatal complications after maternal concomitant use of SSRI and other central nervous system active drugs during the second or third trimester of pregnancy, Oct, 608

 Neonatal outcomes after late-gestation exposure to selective serotonin reuptake inhibitors, Oct, 615

 Pregnancy outcome after exposure to antidepressants and the role of maternal depression: results from the Norwegian mother and child cohort study, April, 186

 Randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder (brief report), Aug, 551

 Reversal of SSRI-associated urinary retention with mirtazapine augmentation (letter), June, 434

 Selective serotonin reuptake inhibitors and the risk of acute pancreatitis: A Swedish population-based case-control study, June, 336

 Short-term exposure to antidepressant drugs and risk of acute angle-closure glaucoma among older adults (brief report), June, 403

 Symptomatic treatment of interferon-a-induced depression in hepatitis C: A systematic review (review article), Aug, 531

 The psychopharmacology of aggressive behavior: A translational approach (review article), April, 237

 Treatment of late-life major depressive disorder with selective serotonin reuptake inhibitors improves the multidimensional prognostic index (letter), Oct, 726

 Treatment with duloxetine in adults and the incidence of cardiovascular events, Feb, 23

 Unwanted interactions among psychotropic drugs and other treatments for autism spectrum disorders (guest editorial), Aug, 437

Serotonin

 Delayed, fatal cardiotoxicity associated with bupropion and citalopram overdose (letter), June, 431

 Evidence-based medicine versus personalized medicine: Are they enemies? (guest editorial), April, 153

 High-dose baclofen for treatment-resistant alcohol dependence (brief report), April, 266

 Modulation of central serotonin affects emotional information processing in impulsive aggressive personality disorder, June, 329

 No significant association between genetic variants in 7 candidate genes and response to ethylphenidate treatment in adult patients with ADHD (brief report), Dec, 820

 The case for basic research on the psychopharmacology of aggression (guest editorial), Feb, 1

 The psychopharmacology of aggressive behavior: A translational approach (review article), Feb, 83, April, 237

Serotonin noradrenaline reuptake inhibitors

 Cognitive impairment in patients clinically recovered from central nervous system depressant drug overdose, Aug, 503

Serotonin-norepinephrine reuptake inhibitor (SNRI)

 Agomelatine versus venlafaxine XR in the treatment of anhedonia in major depressive disorder, Aug, 487

 Serotonin-norepinephrine euptake inhibitor treatment for tinnitus and depression (letter), Oct, 729

 Treatment with duloxetine in adults and the incidence of cardiovascular events, Feb, 23

Sertindole

 Augmenting clozapine with sertindole: Double-blind, randomized, placebo-controlled study, April, 173

Sertraline

 A randomized controlled pilot study of acamprosate added to escitalopram in adults with major depressive disorder and alcohol use disorder, Dec, 787

 Antidepressant agents and suicide death among US department of veterans affairs patients in depression treatment, June, 346

 Different effects of the selective serotonin reuptake inhibitors fluvoxamine, paroxetine, and sertraline on the pharmacokinetics of fexofenadine in healthy volunteers, April, 195

 Symptomatic treatment of interferon-a-induced depression in hepatitis C: A systematic review (review article), Aug, 531

Serum insulin

 Excessive insulin secretion in Japanese schizophrenic patients treated with antipsychotics despite normal fasting glucose levels, Dec, 750

Severity measurement

 Effectiveness and cost of atypical versus typical antipsychotic treatment in a nationwide cohort of patients with schizophrenia in Germany, Oct, 602

Severity of Dependence Scale (SDS)

 Actigraphic measurements in opioid detoxification with methadone or buprenorphine, Feb, 75

Sexual abuse

 From disordered eating to addiction: The “food drug” in bulimia nervosa (review article), June, 376

Short Opioid Withdrawal Scale (SOWS)

 Actigraphic measurements in opioid detoxification with methadone or buprenorphine, Feb, 75

Sibutramine

 A randomized, placebo-controlled study of zonisamide to prevent olanzapine-associated weight gain, April, 165

Side effects

 Do local meteorological conditions influence skin irritation caused by transdermal rivastigmine? A retroprospective, pilot study (brief report), June, 412

 Identifying potential adverse effects by patients’ ratings: A proof-of-concept study of a novel approach (brief report), Dec, 828

Simpson-Angus Scale (SAS)

 Asenapine as adjunctive treatment for acute mania associated with bipolar disorder: Results of a 12-week core study and 40-week extension, Feb, 46

 Cognitive effects of a single dose of atypical antipsychotics in healthy volunteers compared with placebo or haloperidol, Dec, 778

 Parkinsonism in elderly users of haloperidol (brief report), Oct, 688

 Short-term treatment of catatonia with amantadine in schizophrenia and schizoaffective disorder (letter), Aug, 569

 Tetrabenazine augmentation in treatment-resistant schizophrenia: A 12-week, double-blind, placebo-controlled trial (brief report), Feb, 95

 Two 6-week, randomized, double-blind, placebo-controlled studies of ziprasidone in outpatients with bipolar I depression, Aug, 470

Single nucleotide polymorphisms (SNPs)

 Association study of 27 annotated genes for clozapine pharmacogenetics: Validation of preexisting studies and identification of a new candidate gene, ABCB1, for treatment response, Aug, 441

SKAMP-Attention

 A randomized, double-blind study of 30 versus 20 mg dexmethylphenidate extended-release in children with attention-deficit/hyperactivity disorder: Late-day symptom control, Oct, 637

Sleep

 Add-on treatment of quetiapine for fibromyalgia (brief report), Oct, 684

 Effectiveness of a cognitive behavioral weight management intervention in obese patients with psychotic disorders compared to patients with nonpsychotic disorders or no psychiatric disorders, Aug, 458

Sleep-related movement disorders

 Drugs associated with restless legs syndrome: A case/noncase study in the French pharmacovigilance database (brief report), Dec, 824

Smoking

 Effects of naltrexone on smoking cessation outcomes and weight gain in nicotine-dependent men and women, Oct, 630

 Multicenter study on the clinical effectiveness, pharmacokinetics, and pharmacogenetics of mirtazapine in depression, Oct, 622

 Neonatal outcomes after late-gestation exposure to selective serotonin reuptake inhibitors, Oct, 615

 Parkinsonism in elderly users of haloperidol (brief report), Oct, 688

 Selective serotonin reuptake inhibitors and the risk of acute pancreatitis: A Swedish population-based case-control study, June, 336

Social interaction

 Effects of large doses of arachidonic acid added to docosahexaenoic acid on social impairment in individuals with autism spectrum disorders: A double-blind, placebo-controlled, randomized trial, April, 200

Social phobia

 An exploratory, open trial of fluoxetine treatment of juvenile fibromyalgia (letter), April, 293

Sparteine

 Evidence-based medicine versus personalized medicine: Are they enemies? (guest editorial), April, 153

Spatial recognition memory

 A randomized, double-blind, placebo-controlled trial of fluvoxamine in patients with schizophrenia: A preliminary study, Oct, 593

Spheroidal Oral Drug Absorption System (SODAS) technology

 A randomized, double-blind study of 30 versus 20 mg dexmethylphenidate extended-release in children with attention-deficit/hyperactivity disorder: Late-day symptom control, Oct, 637

Statistical parametric mapping software

 Caudate gray matter volume in obsessive-compulsive disorder is influenced by adverse childhood experiences and ongoing drug treatment (brief report), Aug, 544

Steroidogenesis

 Reduced methadone clearance during aromatase inhibition, Aug, 511

Stroke

 Effectiveness of a cognitive behavioral weight management intervention in obese patients with psychotic disorders compared to patients with nonpsychotic disorders or no psychiatric disorders, Aug, 458

Subject selection

 Comparison of academic and nonacademic sites in multi-center clinical trials, Feb, 65

Subjective Opioid Withdrawal Scale (SOWS)

 Pharmacokinetic-pharmacodynamic modeling of mood and withdrawal symptoms in relation to plasma concentrations of methadone in patients undergoing methadone maintenance treatment, Oct, 666

Suboptimal response

 Predictors of clozapine response in patients with treatment-refractory schizophrenia (brief report), Oct, 678

Substance abuse

 Akathisia and suicidal ideation in first-episode schizophrenia (brief report), Oct, 694

 From disordered eating to addiction: The “food drug” in bulimia nervosa (review article), June, 376

Substance use disorder (SUD)

 A naturalistic study of intramuscular haloperidol versus intramuscular olanzapine for the management of acute agitation, June, 317

 Case manager- and patient-rated alliance as a predictor of medication adherence in first-episode psychosis, Aug, 465

 Predictive factors for more than 3 years’ duration of central stimulant treatment in adult attention-deficit/hyperactivity disorder: A retrospective, naturalistic study, Oct, 645

Sudden cardiac death

 Increased risk of antipsychotic-related qt prolongation during nighttime: A 24-hour Holter electrocardiogram recording study, Feb, 18

Suicidal ideation

 Akathisia and suicidal ideation in first-episode schizophrenia (brief report), Oct, 694

Suicide

 Antidepressant agents and suicide death among US department of veterans affairs patients in depression treatment, June, 346

 Is psychiatry ignoring suicide? The case for clozapine (guest editorial), June, 307

Sulpiride

 Aripiprazole for the treatment of Tourette syndrome: A case series of 100 patients (brief report), Aug, 548

Sustained virologic response (SVR)

 Symptomatic treatment of interferon-a-induced depression in hepatitis C: A systematic review (review article), Aug, 531

Swanson, Kotkin, Agler, M-Flynn, and Pelham (SKAMP)

 A randomized, double-blind study of 30 versus 20 mg dexmethylphenidate extended-release in children with attention-deficit/hyperactivity disorder: Late-day symptom control, Oct, 637

Swedish Prescribed Drug Register (PDR)

 Neonatal complications after maternal concomitant use of SSRI and other central nervous system active drugs during the second or third trimester of pregnancy, Oct, 608

Symptom assessment

 Identifying potential adverse effects by patients’ ratings: A proof-of-concept study of a novel approach (brief report), Dec, 828

Systemic steroids

 Antidepressant use and the risk of upper gastrointestinal bleeding in psychiatric patients, Aug, 518

T

Tandem mass spectrometry

 Reduced methadone clearance during aromatase inhibition, Aug, 511

Taq1A polymorphism

 Effects of aripiprazole and the Taq1A polymorphism in the dopamine D2 receptor gene on the clinical response and plasma monoamine metabolites level during the acute phase of schizophrenia (brief report), Feb, 106

Taranabant

 Human abuse potential and cognitive effects of taranabant, a cannabinoid 1 receptor inverse agonist, Aug, 492

Tardive dyskinesia (TD)

 Duloxetine-Associated Tardive dyskinesia resolved with fluvoxamine (letter), Oct, 723

 Dyskinesia symptoms during treatment with olanzapine or haloperidol (letter), June, 420

 Rabbit syndrome following discontinuation of paliperidone in a patient with schizoaffective disorder (letter), Oct, 720

 Tetrabenazine augmentation in treatment-resistant schizophrenia: A 12-week, double-blind, placebo-controlled trial (brief report), Feb, 95

Tardive dystonia (TDt)

 Improvement in intractable tardive dystonia in bipolar disorder after aripiprazole treatment: A case report (letter), Aug, 563

 Tardive laryngeal dystonia associated with aripiprazole monotherapy (letter), April, 297

Testosterone augmentation regimens

 Reduced methadone clearance during aromatase inhibition, Aug, 511

Tetrabenazine (TBZ)

 Tetrabenazine augmentation in treatment-resistant schizophrenia: A 12-week, double-blind, placebo-controlled trial (brief report), Feb, 95

Therapeutic alliance

 Case manager- and patient-rated alliance as a predictor of medication adherence in first-episode psychosis, Aug, 465

Thioridazine

 Excessive insulin secretion in Japanese schizophrenic patients treated with antipsychotics despite normal fasting glucose levels, Dec, 750

Tiagabine

 Behavioral adverse effects of antiepileptic drugs in epilepsy (review article), June, 362

Tiapride

 Aripiprazole for the treatment of Tourette syndrome: A case series of 100 patients (brief report), Aug, 548

Tics

 Aripiprazole for the treatment of Tourette syndrome: A case series of 100 patients (brief report), Aug, 548

Tinnitus

 Serotonin-norepinephrine euptake inhibitor treatment for tinnitus and depression (letter), Oct, 729

Topiramate

 Behavioral adverse effects of antiepileptic drugs in epilepsy (review article), June, 362

Tourette syndrome (TS)

 Aripiprazole for the treatment of Tourette syndrome: A case series of 100 patients (brief report), Aug, 548

TPH2

 No significant association between genetic variants in 7 candidate genes and response to ethylphenidate treatment in adult patients with ADHD (brief report), Dec, 820

 The case for basic research on the psychopharmacology of aggression (guest editorial), Feb, 1

Trail-Making Test (TMT)

 Cognitive effects of a single dose of atypical antipsychotics in healthy volunteers compared with placebo or haloperidol, Dec, 778

 Cognitive impairment in patients clinically recovered from central nervous system depressant drug overdose, Aug, 503

 Effects of drug burden index on cognitive function in older men (brief report), April, 273

Transdermal matrix patch

 Do local meteorological conditions influence skin irritation caused by transdermal rivastigmine? A retroprospective, pilot study (brief report), June, 412

Translational medicine

 The psychopharmacology of aggressive behavior: A translational approach (review article), Feb, 83, April, 237

Tranylcypromine

 Tranylcypromine and bupropion combination therapy in treatment-resistant major depression (letter), Aug, 572

Trazodone

 Mianserin for the treatment of sleep disorders in patients with dementia (letter), Aug, 576

Treatment

 Efficacy and safety of levetiracetam for the prevention of alcohol relapse in recently detoxified alcohol-dependent patients (brief report), Aug, 558

 Enhanced ziprasidone combination therapy effectiveness in obese compared to nonobese patients with bipolar disorder, Dec, 814

 Normobaric hyperoxia treatment of schizophrenia, Aug, 525

 Omega-3 fatty acid augmentation of citalopram treatment for patients with major depressive disorder, Feb, 61

 Randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder (brief report), Aug, 551

 Symptomatic treatment of interferon-a-induced depression in hepatitis C: A systematic review (review article), Aug, 531

 The anticonvulsant levetiracetam potentiates alcohol consumption in non-treatment seeking alcohol abusers (brief report), April, 269

 Variation in antipsychotic treatment choice across US nursing homes, Feb, 11

Treatment optimization

 Early switch strategy in patients with major depressive disorder, Aug, 479

Treatment resistance

 Ketoconazole-associated preferential increase in dopamine D2 receptor occupancy in striatum compared to pituitary in vivo: Role for drug transporters? (brief report), Feb, 110

 Predictors of clozapine response in patients with treatment-refractory schizophrenia (brief report), Oct, 678

 Treating depression after initial treatment failure: Directly comparing switch and augmenting strategies in STAR*D (brief report), Feb, 114

Treatment Satisfaction Questionnaire for Medication (TSQM)

 Satisfaction with methadone as a medication: Psychometric properties of the Spanish version of the treatment satisfaction questionnaire for medication, Feb, 69

Treatment-emergent adverse events (TEAEs)

 Adverse events in healthy subjects exposed to single and multiple doses of LY2140023 monohydrate: pooled results from 10 phase 1 studies, June, 408

Treatment-resistant schizophrenia

 Tetrabenazine augmentation in treatment-resistant schizophrenia: A 12-week, double-blind, placebo-controlled trial (brief report), Feb, 95

Trichotillomania

 Bupropion xl for the sustained treatment of trichotillomania (letter), April, 298

Tricyclic antidepressants (TCA)

 Atomoxetine for encopresis in 2 children with attention-deficit/hyperactivity disorder (letter), April, 302

 Evidence-based medicine versus personalized medicine: Are they enemies? (guest editorial), April, 153

 Short-term exposure to antidepressant drugs and risk of acute angle-closure glaucoma among older adults (brief report), June, 403

 Treatment with duloxetine in adults and the incidence of cardiovascular events, Feb, 23

Trifluoperazine

 Electroconvulsive therapy and clozapine in adolescents with schizophrenia spectrum disorders: Is it a safe and effective combination?, Dec, 756

Triglyceride

 Metabolic effects of paliperidone extended release versus oral olanzapine in patients with schizophrenia: A prospective, randomized, controlled trial, Aug, 449

 The relationship between serum uric acid concentration and metabolic syndrome in patients with schizophrenia or schizoaffective disorder, Oct, 585

Triptorelin

 Treatment with triptorelin in mentally disordered sex offenders (letter), Oct, 739

Tumor necrosis factor a Dysregulation of adipocytokines related to second-generation antipsychotics in normal fasting glucose patients with schizophrenia (brief report), June, 390

Type 2 diabetes

 The relationship between serum uric acid concentration and metabolic syndrome in patients with schizophrenia or schizoaffective disorder, Oct, 585

U

Udvalg for Klinske UndersEgelser (UKU) scale

 Long-term effect of haloperidol, olanzapine, and risperidone on plasma prolactin levels in patients with first-episode psychosis (brief report), Dec, 804

 Tetrabenazine augmentation in treatment-resistant schizophrenia: A 12-week, double-blind, placebo-controlled trial (brief report), Feb, 95

Ultrarapid metabolizers (UMs)

 Multicenter study on the clinical effectiveness, pharmacokinetics, and pharmacogenetics of mirtazapine in depression, Oct, 622

University Hospital Medical Information Network (UMIN, Tokyo, Japan)

 A randomized, double-blind, placebo-controlled trial of fluvoxamine in patients with schizophrenia: A preliminary study, Oct, 593

Upper gastrointestinal bleeding (UGIB)

 Antidepressant use and the risk of upper gastrointestinal bleeding in psychiatric patients, Aug, 518

Uric acid (UA)

 Purinergic system in the treatment of bipolar disorder (letter), Oct, 735

 The relationship between serum uric acid concentration and metabolic syndrome in patients with schizophrenia or schizoaffective disorder, Oct, 585

Urinary retention

 Reversal of SSRI-associated urinary retention with mirtazapine augmentation (letter), June, 434

Urine drug screen (UDS)

 A naturalistic study of intramuscular haloperidol versus intramuscular olanzapine for the management of acute agitation, June, 317

 Actigraphic measurements in opioid detoxification with methadone or buprenorphine, Feb, 75

Utrecht Patient Oriented Database (UPOD)

 Valproic acid treatment is associated with altered leukocyte subset development (brief report), Dec, 832

V

Valproate

 Asenapine as adjunctive treatment for acute mania associated with bipolar disorder: Results of a 12-week core study and 40-week extension, Feb, 46

 Enhanced ziprasidone combination therapy effectiveness in obese compared to nonobese patients with bipolar disorder, Dec, 814

Valproic acid (VPA)

 Actigraphic measurements in opioid detoxification with methadone or buprenorphine, Feb, 75

 Valproic acid treatment is associated with altered leukocyte subset development (brief report), Dec, 832

Vasopressin V1 antagonist

 The case for basic research on the psychopharmacology of aggression (guest editorial), Feb, 1

Venlafaxine

 Agomelatine versus venlafaxine XR in the treatment of anhedonia in major depressive disorder, Aug, 487

 Antidepressant agents and suicide death among US department of veterans affairs patients in depression treatment, June, 346

 High venlafaxine serum levels after prior fluoxetine medication (letter), April, 295

 Treatment with duloxetine in adults and the incidence of cardiovascular events, Feb, 23

 Treatment with mirtazapine and venlafaxine increases noradrenaline excretion in depressed patients (letter), Aug, 574

Verona Service Satisfaction Scale for methadone treatment (VSSS-MT)

 Satisfaction with methadone as a medication: Psychometric properties of the Spanish version of the treatment satisfaction questionnaire for medication, Feb, 69

Veterans

 Antidepressant agents and suicide death among US department of veterans affairs patients in depression treatment, June, 346

Vigabatrin

 Behavioral adverse effects of antiepileptic drugs in epilepsy (review article), June, 362

Visual analog scale (VAS)

 Early switch strategy in patients with major depressive disorder, Aug, 479

 Human abuse potential and cognitive effects of taranabant, a cannabinoid 1 receptor inverse agonist, Aug, 492

 Modulation of central serotonin affects emotional information processing in impulsive aggressive personality disorder, June, 329

Visuomotor skills

 Cognitive impairment in patients clinically recovered from central nervous system depressant drug overdose, Aug, 503

Volunteers

 Cognitive effects of a single dose of atypical antipsychotics in healthy volunteers compared with placebo or haloperidol, Dec, 778

W

Wechsler Intelligence Scale

 Effects of large doses of arachidonic acid added to docosahexaenoic acid on social impairment in individuals with autism spectrum disorders: A double-blind, placebo-controlled, randomized trial, April, 200

 Predictive factors for more than 3 years’ duration of central stimulant treatment in adult attention-deficit/hyperactivity disorder: A retrospective, naturalistic study, Oct, 645

Weekly Ratings of Evening and Morning Behavior (WREMB)

 Does atomoxetine improve executive function, inhibitory control, and hyperactivity?: Results from a placebo-controlled trial using quantitative measurement technology, Oct, 653

Weight gain

 A randomized, placebo-controlled study of zonisamide to prevent olanzapine-associated weight gain, April, 165

 Effects of naltrexone on smoking cessation outcomes and weight gain in nicotine-dependent men and women, Oct, 630

 Impact of switching or initiating antipsychotic treatment on body weight during a 6-month follow-up in a cohort of patients with schizophrenia (brief report), Oct, 672

 Trajectories of agouti-related protein and leptin levels during antipsychotic-associated weight gain in patients with schizophrenia, Dec, 767

Weight management program

 Effectiveness of a cognitive behavioral weight management intervention in obese patients with psychotic disorders compared to patients with nonpsychotic disorders or no psychiatric disorders, Aug, 458

White blood cell (WBC)

 A case of quetiapine XR and divalproex-associated neutropenia followed by successful use of ziprasidone, June, 417

Word fluency

 Cognitive effects of a single dose of atypical antipsychotics in healthy volunteers compared with placebo or haloperidol, Dec, 778

Working alliance inventory (WAI)

 Case manager- and patient-rated alliance as a predictor of medication adherence in first-episodepsychosis, Aug, 465

Working memory

 Cognitive impairment in patients clinically recovered from central nervous system depressant drug overdose, Aug, 503

X

Xanodyne

 Reduced methadone clearance during aromatase inhibition, Aug, 511

Y

Yale Global Tic Severity Scale (YGTSS)

 Aripiprazole for the treatment of Tourette syndrome: A case series of 100 patients (brief report), Aug, 548

Yale-Brown Obsessive Compulsive Scale (Y-BOCS)

 Application of external review for subject selection in a schizophrenia trial (letter), April, 285

 Caudate gray matter volume in obsessive-compulsive disorder is influenced by adverse childhood experiences and ongoing drug treatment (brief report), Aug, 544

 Finasteride attenuates pathological gambling in patients with Parkinson disease (letter), June, 424

 N-acetylcysteine add-on treatment in refractory obsessive-compulsive disorder: A randomized, double-blind, placebo-controlled trial, Dec, 797

 The sustained effects of aripiprazole-augmented clozapine treatment on the psychotic symptoms and metabolic profiles of patients with refractory schizophrenia (letter), April, 282

Young Mania Rating Scale (YMRS)

 A randomized, placebo-controlled study of zonisamide to prevent olanzapine-associated weight gain, April, 165

 Asenapine as adjunctive treatment for acute mania associated with bipolar disorder: Results of a 12-week core study and 40-week extension, Feb, 46

 Omega-3 fatty acid treatment, with or without cytidine, fails to show therapeutic properties in bipolar disorder (brief report), Oct, 699

 The psychopharmacology of aggressive behavior: A translational approach (review article), April, 237

 Two 6-week, randomized, double-blind, placebo-controlled studies of ziprasidone in outpatients with bipolar I depression, Aug, 470

Z

Zanarini Rating Scale

 Open-label treatment with olanzapine for patients with borderline personality disorder (brief report), June, 398

Ziprasidone

 A case of quetiapine XR and divalproex-associated neutropenia followed by successful use of ziprasidone, June, 417

 Adverse effects of second-generation antipsychotics in children and adolescents: A Bayesian meta-analysis, June, 309

 Enhanced ziprasidone combination therapy effectiveness in obese compared to nonobese patients with bipolar disorder, Dec, 814

 Impact of switching or initiating antipsychotic treatment on body weight during a 6-month follow-up in a cohort of patients with schizophrenia (brief report), Oct, 672

 Metabolic effects of paliperidone extended release versus oral olanzapine in patients with schizophrenia: A prospective, randomized, controlled trial, Aug, 449

 The psychopharmacology of aggressive behavior: A translational approach (review article), April, 237

 Trajectories of agouti-related protein and leptin levels during antipsychotic-associated weight gain in patients with schizophrenia, Dec, 767

 Two 6-week, randomized, double-blind, placebo-controlled studies of ziprasidone in outpatients with bipolar I depression, Aug, 470

Zolpidem

 Multicenter study on the clinical effectiveness, pharmacokinetics, and pharmacogenetics of mirtazapine in depression, Oct, 622

Zonisamide

 A randomized, placebo-controlled study of zonisamide to prevent olanzapine-associated weight gain, April, 165

 Behavioral adverse effects of antiepileptic drugs in epilepsy (review article), June, 362

Zopiclone

 A method to assess the dissipation of the effects of residual hypnotics (brief report), Oct, 704

 Multicenter study on the clinical effectiveness, pharmacokinetics, and pharmacogenetics of mirtazapine in depression, Oct, 622

© 2012 Lippincott Williams & Wilkins, Inc.